CLINICAL DIAGNOSTIC WHOLE EXOME SEQUENCING FOR INFANTS   IN INTENSIVE CARE SETTINGS: OUTCOMES ANALYSIS   AND ECONOMIC EVALUATION by SMITH, HADLEY STEVENS
The Texas Medical Center Library 
DigitalCommons@TMC 
UT School of Public Health Dissertations (Open 
Access) School of Public Health 
Summer 5-2019 
CLINICAL DIAGNOSTIC WHOLE EXOME SEQUENCING FOR 
INFANTS IN INTENSIVE CARE SETTINGS: OUTCOMES ANALYSIS 
AND ECONOMIC EVALUATION 
HADLEY STEVENS SMITH 
UTHealth School of Public Health 
Follow this and additional works at: https://digitalcommons.library.tmc.edu/uthsph_dissertsopen 
 Part of the Community Psychology Commons, Health Psychology Commons, and the Public Health 
Commons 
Recommended Citation 
SMITH, HADLEY STEVENS, "CLINICAL DIAGNOSTIC WHOLE EXOME SEQUENCING FOR INFANTS IN 
INTENSIVE CARE SETTINGS: OUTCOMES ANALYSIS AND ECONOMIC EVALUATION" (2019). UT School of 
Public Health Dissertations (Open Access). 106. 
https://digitalcommons.library.tmc.edu/uthsph_dissertsopen/106 
This is brought to you for free and open access by the 
School of Public Health at DigitalCommons@TMC. It has 
been accepted for inclusion in UT School of Public Health 
Dissertations (Open Access) by an authorized 
administrator of DigitalCommons@TMC. For more 
information, please contact nha.huynh@library.tmc.edu. 
 
  
 
CLINICAL DIAGNOSTIC WHOLE EXOME SEQUENCING FOR INFANTS  
IN INTENSIVE CARE SETTINGS: OUTCOMES ANALYSIS  
AND ECONOMIC EVALUATION 
 
by 
 
HADLEY STEVENS SMITH, MPSA, BS 
 
 
APPROVED: 
 
 
 
 
J. MICHAEL SWINT, PHD 
 
 
 
SEEMA R. LALANI, MD 
 
 
 
MARCIA C. DE OLIVEIRA OTTO, PHD  
 
 
 
HEIDI V. RUSSELL, MD, PHD 
 
 
 
JOSE-MIGUEL YAMAL, PHD 
 
 
 
DEAN, THE UNIVERSITY OF TEXAS 
SCHOOL OF PUBLIC HEALTH 
 
  
 
Copyright 
by 
Hadley Stevens Smith, PhD, MPSA, BS 
2019 
 
 
 
 
  
 
  
 
CLINICAL DIAGNOSTIC WHOLE EXOME SEQUENCING FOR INFANTS  
IN INTENSIVE CARE SETTINGS: OUTCOMES ANALYSIS  
AND ECONOMIC EVALUATION 
 
 
by 
 
HADLEY STEVENS SMITH 
BS, Texas A&M University, 2015 
MPSA, Texas A&M University, 2015 
 
 
Presented to the Faculty of The University of Texas 
School of Public Health 
in Partial Fulfillment 
of the Requirements 
for the Degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
 
THE UNIVERSITY OF TEXAS  
SCHOOL OF PUBLIC HEALTH 
Houston, Texas 
May, 2019 
  
 
  
 
ACKNOWLEDGEMENTS 
I am grateful for the encouragement and learning opportunities provided by 
colleagues in the Center for Medical Ethics and Health Policy and the Department of 
Molecular and Human Genetics at Baylor College of Medicine. This work was 
performed with appreciated support from the Department of Molecular and Human 
Genetics. I especially thank Drs. Brendan Lee and Amy McGuire for extension of 
countless opportunities, Dr. Mike Swint and members of my committee for teaching 
and mentorship, and Jill Oliver Robinson for thoughtful comments on manuscript 
drafts. 
  
 
  
 
CLINICAL DIAGNOSTIC WHOLE EXOME SEQUENCING FOR INFANTS  
IN INTENSIVE CARE SETTINGS: OUTCOMES ANALYSIS 
 
AND ECONOMIC EVALUATION 
 
 
Hadley Stevens Smith, PhD, MPSA 
The University of Texas  
School of Public Health, 2019 
 
 
Dissertation Chair: J. Michael Swint, PhD 
 
Whole exome sequencing (ES) is an extensive form of genetic testing and 
increasingly used as a diagnostic tool. Clinical uptake of genome-scale sequencing 
occurred without clear guidelines for application or robust information regarding 
potential impact on patient health outcomes or cost of care. For infants in intensive 
care with suspected genetic conditions, ES can be especially powerful to identify a 
specific diagnosis and inform crucial decisions about medical care. However, little is 
known about the cost-effectiveness of ES compared to other diagnostic strategies. 
This project first assessed the literature on pediatric clinical ES. Then, using 
electronic medical record, diagnostic laboratory, and hospital cost data, we analyzed 
and compared outcomes and costs of care for patients with suspected genetic 
etiologies admitted to intensive care within the first year of life in two patient cohorts: 
those who had ES (ES, n=368) and did not have ES (No-ES, n=368) as part of a 
diagnostic workup at a large children’s hospital. Molecular diagnostic yield (25.8% 
No-ES, 27.7% ES; p=0.56) and 1-year survival (84.8% No-ES, 80.2% ES; p=0.10) 
were similar between cohorts, while ES patients had higher total cost, diagnostic 
 
  
 
investigation cost, and genetic test cost during the index admission and for the year 
after the date of first inpatient genetics consultation (all p<0.01). ES demonstrated 
important diagnostic utility for patients with monogenic disease, yet other genetic 
tests, especially chromosomal microarray, remain important given the burden of 
chromosomal abnormalities in this population. As clinically applied over the first 5 
years, ES does not appear to be a cost-effective diagnostic tool for the broad 
population of newborns and infants with suspected genetic disease compared to 
standard diagnostic tests such as chromosomal microarray analysis and 
panel/single gene testing. Further work is needed to develop outcome measures to 
capture utility of ES results – both diagnostic and non-diagnostic – for clinicians, 
patients, and patients’ families, and to specify clinical guidelines for appropriate ES 
application.
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INTRODUCTION 
Completion of the Human Genome Project in 2003 marked a major 
accomplishment in the field of biological research. It fostered an ambitious goal 
within the scientific and medical community to translate genetic knowledge from the 
research setting to the clinical setting and use an individual patient’s genetic makeup 
to guide medical decision-making.1 Rapid reductions in the cost of sequencing, 
along with identification of clinically relevant gene variants though accumulation of 
sequence information, have made genome-scale sequencing increasingly relevant 
for patient care. In clinical practice, whole exome sequencing (ES) has been 
successfully applied as a diagnostic tool.2,3  
ES is a powerful test because it can identify a molecular-level diagnosis 
based on a broad picture of a patient’s most clinically relevant genetic sequence 
information. Using next-generation sequencing techniques, ES simultaneously 
analyzes the deoxyribonucleic acid (DNA) sequence of the exons in each gene, 
collectively referred to as the exome. The exome is the subset of the genome that 
codes for protein products and is most well-understood.4 ES can potentially replace 
a wide range of other diagnostic tests and may both reduce the time required to 
establish a diagnosis and increase the probability that a specific diagnosis is made 
in a particular patient.  
ES is especially useful for individuals with rare diseases or diseases that are 
difficult or impossible to diagnose with other diagnostic modalities.5 Care providers 
can order ES from a clinical genetic laboratory in three different forms: sequencing 
of the patient only (proband ES), sequencing of the patient and both biological 
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parents (trio ES) and sequencing of the patient and both parents with a reduced 
turnaround time (critical trio ES).  
While clinical uptake of genomic sequencing is increasing, there is very little 
evidence on the impact of ES on patient health outcomes or the cost-effectiveness 
of using ES as a diagnostic test compared to other diagnostic strategies. Moreover, 
specific and measurable patient outcomes following clinical genomic sequencing 
(cGS) have not yet been systematically explored or defined. Measurement and 
analysis of the effectiveness of ES to achieve relevant and specific health outcomes 
can provide important evidence of clinical utility. Moreover, effectiveness data is a 
necessary precursory step to economic evaluation. Generation of an evidence base 
to help understand where and how ES fits into medical care is essential to guide 
practical and efficient technology translation from the laboratory bench to the patient 
bedside. In turn, evaluation of bedside use – and the development of appropriate 
methods for conducting such evaluations – is an increasingly important topic for 
health services research. 
 
Study Aims 
This research addressed the following overarching question: What is the 
impact of exome sequencing (ES) as a clinical diagnostic tool for critically ill infants 
with suspected genetic conditions? To investigate this question, three sub-questions 
were asked: (1) What is currently known about the effectiveness and cost-
effectiveness of clinical genomic sequencing (cGS)?; (2) How do relevant and 
measurable outcomes for infants in intensive care settings compare between 
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patients who did and did not have ES?; and (3) How does cost of care compare 
between patients who did and did not have ES, and what is the cost-effectiveness of 
ES for diagnosis of infants in intensive care compared to usual diagnostic care? 
Research aims were developed to investigate each sub-question in turn. Motivations 
for each aim of this research, the aims, and the specific objectives to achieve each 
aim are listed below. 
 
Motivation 1: A comprehensive review of publications reporting on cGS has not yet 
been published. cGS use has not been summarized by clinical setting or patient 
type, and reported outcomes such as diagnostic yield of these tools has not yet been 
synthesized across studies. Knowledge of how cGS has been applied in practice to 
date can inform uptake and direct further research.  
 
Aim 1. Synthesize the available clinical and economic evidence from the literature 
on genomic sequencing as a clinical diagnostic tool in pediatric patient populations 
Objectives: 
a. Perform a scoping review of published peer-reviewed literature on the 
use of genome sequencing (GS) and exome sequencing (ES) in 
clinical practice for pediatric patients (0–18 years of age) 
b. Summarize disease areas, and associated molecular diagnostic yield, 
in which diagnostic cGS has been used, and identify commonalities 
and differences in what has been reported 
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c. Identify and describe categories of reported sources of clinical utility of 
cGS and medical management changes following results, as well as 
how these categories were defined and operationally measured 
d. Summarize the level of evidence in the literature on effectiveness and 
cost-effectiveness from a health services research perspective 
 
Motivation 2: Identification of an appropriate patient population, comparison 
population, and outcome measures to use as endpoints in health economic analyses 
has been identified as a major hurdle for value assessments of cGS. A robust, 
comparative analysis of the effectiveness of ES to achieve specific outcomes is 
lacking. Construction of an appropriate cohort of comparison group patients and 
determination of important and feasibly measurable outcomes are crucial elements 
of study design to assess the value of cGS. 
 
Aim 2. Identify and describe a population of undiagnosed infants with suspected 
genetic etiology in intensive care settings, define and measure relevant clinical 
outcomes, and compare outcomes for patients who did and did not have ES. 
 Objectives: 
a. Provide an overview of practical challenges associated with outcome 
measurement in cGS 
b. Describe methods for identification of the patient population and 
procedures used for matching patients who had ES to patients who did 
not have ES based on clinically relevant features 
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c. Provide descriptive statistics on demographics and clinical features of 
patients included in the study sample 
d. Identify relevant outcomes, conduct retrospective electronic medical 
record review to compile data on candidate outcome measures, and 
describe how outcomes were measured  
e. Perform statistical analyses to compare outcomes between cohorts of 
patients who did and did not have ES and other relevant subgroups 
 
Motivation 3: There is very little evidence on the cost-effectiveness of clinical 
diagnostic ES for infants in intensive care settings. Evidence from economic 
evaluation is needed to inform the clinical use of the test and payers’ medical 
coverage policy. 
 
Aim 3. Compare cost of care for patients who did and did not have ES as part of a 
diagnostic workup and calculate incremental cost-effectiveness of ES, compared to 
a diagnostic pathway that does not include ES, for critically ill infants less than 1 
year of life with a suspected genetic etiology at Texas Children’s Hospital  
 Objectives: 
a. Analyze costs for cohorts of patients who did and did not have ES over 
the index admission and one year following the initial genetics 
consultation for categories of total cost, hospital billing code, diagnostic 
pathway, and genetic tests.  
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b. Compare costs and outcomes over the time horizon of the index 
admission and one year following the initial genetics consultation using 
the hospital perspective. Primary outcomes by which to measure 
effectiveness include molecular diagnostic yield and survival. 
c. Calculate incremental cost-effectiveness ratios (ICERs) for ES for 
relevant outcome measures 
 
BACKGROUND 
Whole exome sequencing (ES) demonstrated proof of concept to diagnose a 
patient in the research setting in 2009.6 ES became commercially available as a 
clinical test in 2011, meaning that a clinician could order it from a diagnostic 
laboratory. It generally utilizes a blood sample to generate the deoxyribonucleic acid 
(DNA) sequence of the patient’s exome – a word used to collectively refer to the 
approximately 180,000 exons, the portion of the genome that encodes instructions 
for making protein products that is made up of about 30 million base pairs, or 1-2% 
of the total genome sequence.6 
ES was first available as a test for the proband (i.e., the patient for whom the 
genetic investigation is being performed). Two additional forms of ES, trio ES 
introduced in October 2014 and critical trio ES introduced in April 2015, require 
blood or saliva samples from both biological parents of the proband. Parental 
sequence information increases the ability of medical geneticists to differentiate 
between inherited sequence variants and de novo mutations in the child.7 For 
example, a sequence variant detected in the patient is less likely to be causal of 
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disease presentation if it was inherited from a healthy parent. The proband’s DNA 
sequence is compared to a reference sequence and the sequence of both parents, 
and sequence variants are interpreted alongside clinical phenotype, variant 
databases, and disease gene literature.  
Critical trio ES was developed for use in critically ill patients and has a two to 
three week turnaround time, compared to eight to ten weeks for return of results 
from proband-only and trio ES. Reduced turnaround time is important when the 
results of the test are needed to guide urgent medical management decisions. 
Definitive knowledge of the genetic basis of disease within a short timeframe may be 
especially influential in the neonatal intensive care unit (NICU) and pediatric 
intensive care unit (PICU).  
Establishment of a molecular diagnosis can inform critical medical decisions 
that impact health outcomes, and time to diagnosis can impact the availability or 
effectiveness of clinical intervention.3,8-10 A correct molecular diagnosis can guide 
the initiation or discontinuation of therapy, medication, or diet. It can also inform the 
need for further testing, prognosis, anticipatory care, and whether palliative care 
initiation or withdrawal of support is appropriate.3,10 Length of hospital stay may also 
be directly or indirectly affected by quicker result reporting. Therefore, in high-cost, 
high-intensity care settings such as the NICU and PICU, turnaround time of a 
diagnostic test can potentially affect both costs and outcomes.  
Quantification of the effect of incorporating ES into a diagnostic pathway is 
needed to inform both clinical policy and health care payer policy. A diagnostic 
workup for infants with a suspected genetic etiology may include many diagnostic 
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modalities (e.g., imaging, metabolite screening, targeted genetic testing), which we 
refer to as usual diagnostic care. There are no clearly delineated diagnostic 
pathways for the heterogeneous population of NICU patients. The diagnostic 
pathway may include only usual diagnostic care or one of the three ES forms. 
Patient outcomes following alternative strategies for diagnosis and the cost per 
measure of effect can be calculated and compared to quantify the value of clinical 
diagnostic ES.  
This project provided a practical approach to outcome measurement and 
incorporated those outcome measures into a full economic evaluation of ES for 
infants in intensive care settings. It specifically evaluated clinical uptake and 
application of ES as a diagnostic tool. As such, it did not include analysis of other 
genomic applications, such as pharmacogenetic testing, tumor genotyping, prenatal 
genetic testing, or direct-to-consumer genetic tests. 
 
Conceptual Framework 
This study can be positioned within conceptual models of technology 
translation from laboratory science to clinical application, commonly referred to as 
“bench to bedside.” The Office of Public Health Genomics at the Centers for Disease 
Control and Prevention was the first to apply a translation research framework to the 
field of genetic medicine.11,12 The framework takes a public health perspective and 
emphasizes the need for multidisciplinary research in genetics. Beyond basic 
science research, there are four stages of translation research associated with 
connecting advances in basic science genetics to patient care and ultimately 
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population health. The feedback loop between stages of translational research is 
depicted in Figure 1. As characterized by Khoury, Gwinn, Yoon, Dowling, Moore, 
Bradley 12 the stages of research are as follows: 
T0 – Basic science research 
T1 – Development of basic science research into an application, a product 
such as a genetic test, for use in the clinical setting 
T2 – Assessment of a genomic application in clinical practice and 
development of evidence-based practice guidelines for its use 
T3 – Analysis of the clinical implementation of a genomic application 
according to evidence-based practice guidelines through delivery, 
dissemination, and diffusion research 
T4 – Evaluation of the population health impact of a genomic application 
through outcomes research 
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Figure 1. Translation of genomic research to clinical and public health applications 
 
Adapted from: Figure 1 in 11Khoury MJ, Gwinn M, Bowen SM, Dotson DW. Beyond base pairs to 
bedside: a population perspective on how genomics can improve health. American Journal of Public 
Health. 2012;102(1):34-37. 
 
 
The crux of T2 stage research is to determine the impact of a genomic 
application on patient health and the associated value. Results of such analyses are 
then used to inform development of evidence-based practice guidelines. Thus, 
economic evaluations used to determine the value of a test or intervention are 
situated in the continuum of translation of genetic research at the T2 stage. 
Full economic evaluations of a health care intervention consider both the 
costs and health outcomes of two or more strategies.13 Cost-effectiveness analysis 
(CEA) is a framework used to compare the cost of alternative courses of action with 
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associated health outcomes, which are measured in natural units. A CEA can inform 
decision-makers about the value of a genomic application and provide evidence for 
consideration in practice guideline development. There are defined criteria for CEAs 
conducted in the realm of health and medicine, and Table 1 displays a checklist of 
items that should be considered and reported in a formal CEA. 
 
Table 1. Cost-Effectiveness Analysis Framework – A Checklist of Necessary Components 
Well-defined question in answerable form 
Comprehensive description of the competing alternatives 
Effectiveness of the service established 
All important and relevant costs and consequences for each alternative identified 
Costs and consequences measured accurately in appropriate physical units 
Costs and consequences valued credibly 
Costs and consequences adjusted for differential timing 
Incremental analysis of costs and consequences of alternatives 
Allowance made for uncertainty in the estimates of costs and consequences 
Presentation and discussion of study results includes all issues of concern to users 
Adapted from Box 3.1, p. 28 of 13  
 
Literature Review 
Whole Exome Sequencing in Clinical Practice 
Provision of medical care based on a patient’s genetic sequence information 
has been an ambitious goal of the scientific and medical community since the idea of 
the Human Genome Project was first conceived. The ability to relate basic science 
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research in the field of genetics to patient care requires development of genomic 
applications that are useful in the clinical setting. Translation of genomic 
technologies from the research setting to the clinical setting is a hallmark of the 
beginning of a new era of clinical care – the era of genomic medicine – exemplified 
by clinical diagnostic ES.1 Ultimately, the intent of genomic medicine is to improve 
the health of individual patients by tailoring therapy to their specific genetic makeup.  
A combination of advances in genetic basic science and development of 
corresponding clinical applications have created the conditions for translation of 
genomic sequencing into the patient care setting. The rapid decline of technical 
costs of DNA sequencing, development of faster next-generation sequencing (NGS) 
technologies, and increased understanding of molecular biology of disease have 
made genetic sequencing increasingly relevant to medical practice. Unlike whole 
genome sequencing (WGS) which sequences the more than three billion bases in 
the entire human genome, only the exome is sequenced in ES. Because ES 
involves sequencing fewer chemical bases, it also costs less to perform than WGS. 
The cost to sequence an exome is now near $1,000 – the benchmark cost at which 
scientists have long held that the sequencing of every patient is justified.14 The 
exome is the protein-coding region of the genome, meaning that it contains 
information required to make the “material” end products of genetic sequence 
information. Although the exome only constitutes less than two percent of the entire 
genome, it is where approximately 85% of disease-causing mutations lie and is the 
most well-understood portion.4,15 Therefore, the most clinically meaningful sequence 
information, with the greatest potential for medical actionability based on findings, is 
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obtained through ES. At reasonably attainable costs and accompanied by a greater 
understanding of the genetic basis of disease (due largely to accumulation of 
sequence information itself as more patients are sequenced, leading to discovery of 
new disease-causing genes), ES is anticipated to have widespread application to 
clinical diagnosis in the future. 
As a result of the volume of information ES provides, it may be used to 
diagnose any number of conditions across multiple disease categories. ES has a 
broad scope as a diagnostic tool because it simultaneously analyzes all of the 
coding variation in a human genome, even in areas that are not yet well understood 
clinically. This makes it particularly powerful in the context of rare diseases, and 
results from ES are a major source of information on rare disease-related gene 
variation.16 ES can provide insight that would not be possible using more targeted 
genetic tests, such as single gene or gene-panel tests that only provide information 
on specific coding regions. ES conveys information on pathogenic genetic variants 
that may occur anywhere in the exome, including in genes for which single gene 
tests do not exist or a clinician may not know to order.17 It is especially useful for 
individuals with rare diseases or diseases that are difficult or impossible to diagnose 
using other diagnostic modalities such as imaging, biopsies, cerebrospinal fluid 
examination, and electromyography or even other types of genetic testing such as 
chromosomal microarray and targeted single or gene panel tests.4 
ES has demonstrated molecular diagnostic proof-of-concept and clinical utility 
to impact the course of patient care in clinical practice.2,7,17-27 Most studies are on 
pediatric populations with undiagnosed disease with suspected genetic etiology, 
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particularly patients with neurodevelopmental disabilities or some other neurologic 
phenotype. Obtaining sequence information for parent-child trios often results in a 
higher diagnostic yield (i.e., larger proportion of patients diagnosed out of all patients 
sequenced).2,28 The reported molecular diagnostic yield ranges from approximately 
25% to 58%. Results of ES have reportedly influenced changes in drug therapy, 
surgery decisions, understanding of inheritance pattern, palliative care initiation, and 
understanding of risk for future pregnancies (i.e., risk for potential future siblings of 
the proband to also be affected by an inherited disorder). 
The potential for ES to impact patient care has received special attention in 
the neonatal intensive care unit (NICU) setting, where it may be distinctly valuable 
as a diagnostic tool. ES is helpful in diagnosing congenital malformations, especially 
for newborns in which the clinical presentation is atypical or the phenotype is not yet 
fully developed, which hinders the ability of clinicians to make a clinical 
diagnosis.10,29 Although ES may reduce the length and cost of the diagnostic 
odyssey in patient populations for which other forms of testing do not yield a 
diagnosis, the time required to generate the data and format a clinical report can 
limit the utility of non-rapid ES diagnostic test for critically ill patients. Turnaround 
time can be crucial in the NICU and PICU, where time to diagnosis and 
establishment of a molecular diagnosis can inform critical medical decisions.  
In addition to ES, other forms of next-generation sequencing are being 
applied in the NICU, including WGS and rapid, expanded panel sequencing.9,30-32 
WGS has demonstrated proof-of-concept for diagnosis in the NICU.10,33 Research-
based rapid trio WGS in the level 4 NICU and PICU at Children’s Mercy Hospital 
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provided diagnosis for 20 of 35 (57%) acutely ill infants less than four months of age 
with suspected genetic disease. Standard genetic testing failed to identify 18 of the 
20 diagnoses. Studies of this patient population suggest that WGS can increase 28 
day mortality while decreasing one year mortality, most likely through its impact on 
the decision of whether to withdraw life support.10,23 Of the molecular diagnoses, 
20% led to a positive clinical impact and 30% led to the initiation of palliative care.23 
 
Methodology and Measurement Challenges in Economic Evaluations of 
Clinical Genomic Sequencing 
Very little is known about the cost-effectiveness of cGS. The need for robust 
evidence from economic evaluations has been widely recognized, and implementing 
institutions often identify the need for cost-effectiveness information when describing 
their initial applications of clinical ES.17,19,20,22,34 Further study and more robust 
evidence are considered requisite by some institutions before cGS is incorporated 
into routine clinical care plans.23 Most peer-reviewed literature on applications of ES 
is written from a clinical genetics perspective. These studies usually have a small 
sample size (typically 40 or fewer) of heterogeneous patients from a single 
institution. Molecular diagnostic yield is a commonly reported outcome measure, 
which is usually presented as a raw calculation and does not account for the 
influence of a multitude of factors by which it may be affected.35 If any change in 
clinical management is discussed, it is typically reported in the style of a case report 
or case series. Most studies are retrospective and do not include a comparison 
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group. However, one recent prospective analysis of diagnostic ES suggests that it is 
cost-effective, and potentially even cost-saving as a first-line test.36  
Outcomes research and economic evaluations of cGS are sparse because 
they face a host of methodological issues. There is no consensus among health 
economists as to what the methodological approach should be, and there is a 
question as to whether traditional economic evaluation approaches are applicable to 
genetic services or whether new methodology must be developed.37,38 In a review of 
published discussions of methodological challenges surrounding the economic 
evaluation of genomic services, Buchanan, Wordsworth, and Schuh39 summarized 
the specific challenges as development of methods to incorporate effectiveness 
data, costing of sequencing platforms, and measurement of health outcomes. The 
Institute of Medicine’s Roundtable on Translating Genomic-Based Research for 
Health identified four categories of challenges that surround the economic evaluation 
of genomic medicine: (1) incongruent disciplinary perspectives and language 
barriers between economists and geneticists; (2) insufficient outcomes evidence and 
lack of standardized thresholds for evidence and willingness to pay; (3) dynamic 
nature of genome data and inability of traditional economic assessments to keep 
pace; (4) need for development of methods to incorporate personal utility.38 
Costing of genomic sequencing procedures presents a unique set of 
challenges. The appropriate unit of analysis for costs is the testing service, which 
includes the cost of medical geneticists’ effort involved in interpretation of results and 
pre- and post-test genetic counseling, plus lab costs such as chemical reagents 
required for sequencing, bioinformatics pipeline development, data storage, and 
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quality assurance/quality control practices.40-42 Moreover, the cost of ES and 
placement in the diagnostic pathway, which is determined by provider behavior, 
impacts the cost per diagnosis. Parameter values change quickly as a result of 
relatively rapid changes in basic science in genomics and clinical practice in the field 
of genomics.40 
Outcome measurement has been identified as a major challenge in 
evaluating clinical genetic services and providing evidence of medical benefit to 
payers.12,38,43-46 Because genomic testing has created a new paradigm for clinical 
diagnosis, it does not conform to the established method of comparing a new test to 
the existing gold standard.47 In a systematic literature review of 342 health 
technology assessments and economic evaluations of genetic testing technologies, 
the majority (62%) of reviewed studies were CEAs, and 75% of the CEAs used 
intermediate outcome measures such as the number of cases detected.48 An 
intermediate measure is not traditionally regarded as an appropriate endpoint in a 
CEA. Ideally, such analyses of alternative interventions compare final health 
consequences, measured in natural units such as life-years gained.13 In the case of 
genetic testing where information is the immediate outcome, arriving at a final health 
outcome measure is methodologically challenging and may not be pragmatic 
because it requires systematically measuring not only immediate changes in medical 
management but also impacts on health over a long term.49 However, establishment 
of a molecular diagnosis may be regarded as an appropriate endpoint because it 
can have some value in and of itself, apart from its potential effects on care 
rendered. Moreover, for conditions without available treatment, the value of a 
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diagnostic test may be determined by its ability to correctly identify the underlying 
cause of disease.50 The objectives of decision-makers and stakeholders for whom 
the analysis is performed determine whether a molecular diagnosis is an acceptable 
outcome measure.13 The clinical utility for any specific molecular diagnosis is 
partially determined by current availability of treatment options, and thus may 
change over time as new therapeutics become available.  
Measurement of effectiveness and the concept of utility in the realm of genetic 
medicine have been widely discussed. Two main perspectives on the concept of 
clinical utility have emerged. Narrowly defined, clinical utility is the impact of a test 
on medical management of the patient. A more broad definition of clinical utility 
encompasses other aspects of genetic tests for the patient and family, and the 
relevant factors depend upon which stakeholders’ perspective the analysis is 
conducted from.  
Under the first view, clinical utility of a test or service is determined strictly by its 
impact on health outcomes of the patient via guidance of a change in medical 
management. In the context of ES, results from the test may inform clinical decisions 
that have direct implications for the patient; multiple scenarios have been 
documented in practice.20-22,26,51,52 ES may lead the provider to initiate a change in 
management or treatment plan, such as initiation or discontinuation of medications, 
therapy or other diagnostic tests. Results may also guide anticipatory or palliative 
care. Additionally, knowledge of sequence information may avert a potentially 
harmful misdiagnosis. Establishment of a molecular diagnosis enables providers to 
make a more accurate prognosis. For patients with certain molecular diagnoses, 
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genotype information may make them eligible for clinical trials of a relevant 
therapeutic.21,25 
Under the second view, clinical utility depends upon the stakeholder’s 
perspective from which the analysis is conducted. For example, third-party payers 
are interested in test results providing an accurate, timely diagnosis that impacts 
clinical management or ends the “diagnostic odyssey” – the prolonged search for the 
cause of illness which often involves numerous forms of invasive testing, multiple 
specialist visits, and can last for years. Establishment of a molecular diagnosis via 
ES may lessen the duration, expense, and invasiveness of the diagnostic 
odyssey.20,25,52-54 From a healthcare payer perspective, the ability of ES to shorten 
the diagnostic odyssey is key because paying for one test early in the diagnostic 
pathway might potentially avoid charges for multiple unsuccessful tests and 
consultations later on, and it can also replace multiple specific tests. Thus, a receipt 
of a diagnosis is a relevant endpoint.   
Genetic sequence information obtained through ES can also have impacts that 
extend beyond the patient to other members of the family. ES results can inform 
reproductive risk assessment and reproductive options for the proband, but they can 
also aid in family planning decisions for the parents of the proband. Results may 
also guide disease screening for family members, especially if the genetic 
information leads to a change in the presumed inheritance pattern of the condition 
that implicates disease risk in a family member.21 Families might value information 
for career and residential planning.55 Receipt of a diagnosis may have value in and 
of itself, even if the diagnosis does not affect health outcomes directly.46 In addition 
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to providing information useful for planning in various aspects of familial life and the 
possibility to engage in disease support groups, ending the diagnostic odyssey can 
relieve the family of a significant psychological and financial burden that comes with 
continued searching for the cause of a child’s illness.56,57 
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) 
working group, established by the Office of Public Health Genomics of the Centers 
for Disease Control and Prevention, has stated that “hard” clinical outcomes 
conventionally used in evaluation of diagnostic tests should be considered alongside 
“soft” (i.e., behavioral) outcomes when evaluating genomic technologies.46 This is 
based on the notion that genomic sequencing involves many more aspects of the 
patient’s life – and the lives of family members – than just their health state. 
Capturing such broad effects is not possible with outcome measures commonly 
used in economic evaluations, such as quality-adjusted life years (QALYs), which do 
not incorporate non-health related outcomes. Thus, most economic evaluations of 
genetic testing have been CEAs rather than cost-utility analyses because 
appropriate metrics for utility in the genomic arena have not yet been developed.37 In 
addition, measurement of psychological effects requires longitudinal assessment, 
which is difficult in practice. Such psychological effects may be important, however, 
especially when assessing the value of newborn genetic sequencing. The BabySeq 
project, a randomized controlled trial of newborn genomic sequencing funded by the 
National Institutes of Health, is evaluating psychological impacts on the family as 
well as clinical and economic outcomes.58,59 
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The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) 
Working Group (EWG), an independent panel supported by the CDC’s National 
Office of Public Health Genomics, specified the components of evaluation of a 
genetic test. Known as the ACCE criteria, the factors for consideration are analytic 
validity, clinical validity, clinical utility, and ethical social, and legal implications.60 
Analytic validity is defined as the ability of the test to accurately and reliably measure 
the genotype of interest in the lab, which includes analytic sensitivity, specificity, and 
reliability. Clinical validity is defined as the ability of the test to accurately and reliably 
predict the clinically defined disorder or phenotype of interest, which includes clinical 
sensitivity and specificity (that incorporate analytic sensitivity and specificity), 
positive and negative predictive values considering characteristics of the population 
of interest, and the molecular attributes of the genotype. Clinical utility of the test is 
defined as its effect on measurable clinical outcomes and usefulness in guiding 
decisions about patient care management compared with current management 
without genetic testing. When the EWG employs this criteria to assess outcomes of 
genetic tests, the outcomes of interest are tailored to each clinical scenario for which 
the use of the test is being evaluated.46  
The EGAPP definition of clinical utility as an impact on medical management 
emphasizes that a critical piece of information required to assess the value of a 
genetic test is how it influences the medical decision-making process. The role of 
physician behavior in patient health outcomes is also necessary to consider. Once 
the results of a diagnostic test are returned, a change in clinical practice (e.g., 
initiation of a treatment change, ordering of other tests, withdrawal of support) 
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precedes a change in patient outcomes (e.g., survival, quality of life, disease 
progression, response to therapy). As formulated by Peabody and colleagues,61 
physician behavior lies along the causal pathway to patient outcomes. 
Due to many of these methodological challenges, there is a lack of robust 
economic evaluations of cGS, and the cost-effectiveness of different forms of ES 
compared to other diagnostic strategies has not been performed. A systematic 
review of health economic evidence on genome sequencing found that the few 
studies published through May 2013 are merely cost calculations, and that poor 
methodology limits the accuracy of the findings.62 Most studies aim to describe 
genetic findings; they do not formally assess costs. Calculations of per-sample costs 
are usually incomplete because they do not include the substantial indirect costs 
associated with genetic testing such as genetic counseling, clinical geneticist 
consultations, bioinformatics pipeline and protocol development, variant validation 
tests, and overhead.42 
Such gaps in evidence highlight the need for multidisciplinary research in 
genomic medicine. From a public health perspective, in order to quantify the full 
value of genomic sequencing procedures, assessments must be performed at each 
stage of the translation process. A more robust evidence base is necessary to 
ensure appropriate applications of genomic medicine that ultimately improve 
population health. Currently, T2 stage evaluations of promising applications such as 
diagnostics are particularly deficient and needed.11 Absence of an evidence base 
hinders the development of practice guidelines and appropriate uptake of genomic 
services. As of 2007, it was estimated that three percent or less of research 
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published in the area of genomics focuses on evaluation of a genomic application 
after it is in use (T2-T4 research), and T2 research in human genetics has been 
called “inconsistent and nonsystematic.”63,64 Systematically assessing data from 
individual medical centers that have implemented particular genetic applications in 
isolation can help develop a foundation for best practices.1 Such assessments can 
guide efficient uptake and use of services in other institutions. 
Although provider behavior is an essential element of implementation, research 
on how ES results inform medical decision making has received even less attention 
than costs. In intensive care settings, decisions with especially high stakes may be 
made on the basis of ES results (i.e., the decision to withdraw support). Care 
decisions involve multiple stakeholders. Clinical judgment of providers plays a 
crucial role, but respect for autonomy requires that parents of critically ill infants be 
informed of test results and allowed to participate.65 More attention has been 
devoted to parental decision support tools to help parents decide whether to have 
their child’s exome sequenced than to the parent’s involvement in medical decision 
making once results are received.66 Survey data suggest that parents are interested 
in the possibility of whole genome sequencing of newborns (integrated with current 
newborn screening program).67 However, this might not apply in the context of an 
intensive care setting where medical decisions are imminent. 
 
Lack of Robust Economic Evidence 
There are several limitations of work to date on evaluations of genomic 
sequencing procedures. There is virtually no evidence from large-scale randomized 
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controlled clinical trials. Nearly all studies are retrospective, apart from one recent 
prospective parallel study of ES on 40 critically ill infants.26 Even well-designed 
retrospective studies to date are based on a small sample size; for example, 35 
families met inclusion criteria for the NICU study by Willig and colleagues.23 A 
randomized controlled trial of rapid WGS in NICUs is in the design stages, and a 
cost-effectiveness analysis is planned to take place alongside the trial.68 However, in 
order to harness information from cGS that has already been performed and 
because randomized controlled trials will not always be appropriate or pragmatic, 
approaches for comparative effectiveness research that utilizes existing records 
should be developed.64 
Patient heterogeneity within the sample is a substantial analytic hurdle for both 
prospective and retrospective study designs. Most studies to date include all patients 
(or families) who underwent genetic testing in the analysis, leading to a diverse array 
of molecular causes of disease within patients studied. Cost-effectiveness may be 
different for different clinical scenarios. The clinical settings or patient groups in 
which genomic diagnostics have the highest clinical utility are not yet known. 
Determination of these factors has been designated as an important research 
focus.64 Knowledge of particular situations in which ES is cost-effective can inform 
efficient clinical use and payer policy. 
Heterogeneity also exists in provider behavior. While little is known about uptake 
of cGS among physicians, there is some evidence of a “silo” approach, which 
describes implementation being driven by a particular individual or department within 
an institution.1,27 The decision of a physician to order ES may be influenced by 
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availability, departmental standards, peers, or individual research interests. Lack of 
established practice guidelines on cGS makes choice of comparators difficult 
because each provider may order sequencing based on different criteria or at a 
different point in the diagnostic pathway, and cost-effectiveness is always dependent 
upon the clinical context. Most CEAs of genetic testing use decision analytic 
modelling to incorporate available evidence. However, the appropriateness of 
parameter values used to perform the analysis has been questioned.48,69 
Epidemiologic studies from which parameters are taken is often not properly 
considered, and uncertainty in the parameter values is often not properly accounted 
for through sensitivity analysis. 
Absence of robust economic evidence has created a barrier to clinical ES in 
some circumstances. Although costs of next generation sequencing procedures 
have substantially decreased, they remain unaffordable for many patients. Out-of-
pocket costs are one of the largest practical barriers to translation of ES technology 
from bench to bedside. Indeed, insurance coverage has been referred to as the 
“fourth hurdle” in technology translation from basic science to clinical use.70 ES 
charges can range between $4,500 and $9,000. Even in cases of partial coverage, 
the mean out-of-pocket expense for patients involved in one study was $1,082.13 
(range $279—$2,500), and some patients who were referred for ES and approved 
by clinical review boards decided not to undergo testing after coverage denial.34 
Clinical geneticists have expressed concern about insurance coverage and the 
lengthy insurance approval process.71 Burdensome administrative requirements or 
denial of coverage is a potential barrier to patient access to cGSs.  
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Private payers have been reluctant to cover sequencing procedures largely 
because they regard the technology as unproven. Insurers require more data on 
clinical utility and cost-effectiveness before they will consider genomic sequencing 
as anything other than “experimental” or “investigational.” Lack of robust evidence 
on clinical utility has been cited as a major barrier to convincing payers to cover the 
service.1,61 Little or no evidence exists in the form typically required for coverage of a 
new technology or service – namely proof of analytic validity, clinical validity, and 
clinical utility, formal health technology assessments, and practice guidelines – for all 
of the reasons related to practical and methodological challenges discussed 
above.72,73 From a payer perspective, Sabatini and colleagues demonstrated that 
whether use of ES was cost-saving or cost-increasing depended upon clinical 
features of the patient population, the cost of the test, and where it was incorporated 
in the diagnostic pathway.74 Development of practice guidelines is thus an important 
component of an evidence-based use and coverage feedback loop.  
 
Public Health Significance 
Ability to more quickly and precisely diagnose genetic disorders and provide 
appropriate diagnosis-based care can substantially impact public health. 
Collectively, rare and genetic-based diseases are associated with substantial 
disease burden and societal cost.75,76 Congenital malformations and chromosomal 
abnormalities are the leading cause of death for children under one year of age in 
the United States.77 Genetic disease diagnoses account disproportionately for 
neonatal and pediatric hospital admissions and are consistently associated with 
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higher total charges and longer length of inpatient stay.78-80 In 2012, admissions 
associated with a suspected genetic disease diagnosis accounted for an estimated 
$14–$57 billion, representing 11–46% of total charges for all inpatient admissions of 
patients 0 – 20 years of age.76 Based on national estimates, up to 14% of inpatient 
pediatric admissions are associated with genetic disease, at a mean cost of up to 
$77,000 higher for neonatal admissions and up to $17,000 for pediatric admissions, 
compared to patients who did not have a genetic disease diagnosis.76  
Tools of precision medicine relate to public health through application of 
diagnostics such as clinical genomic sequencing (cGS) to subpopulations who stand 
to benefit the most from them, such as critically ill newborns and infants.81 Use of 
genomic technology and data-driven approaches to provide care for a defined group 
of patients has been conceptualized as a “precision public health” approach.82 cGS 
can potentially lead to more efficient diagnosis and effective treatment, with the 
anticipated impact of reduced diagnostic odyssey extent, improved outcomes, and 
associated cost-savings for the health care system. 
This project contributes to the field by synthesizing the evidence to date on 
diagnostic cGS application for pediatric populations and associated outcomes and 
costs. Further, this study provided a practical example of methods for defining and 
matching cohorts of patients to perform comparative analysis. It resulted in creation 
of a unique dataset on patients receiving care at a large children’s hospital over a 
period of more than 5 years that merged information from multiple sources, including 
extensive electronic medical record review. This study quantified the relative 
effectiveness and cost-effectiveness of exome sequencing (ES) as a diagnostic 
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compared to standard diagnostic care for infants in intensive care. It provided insight 
into the relative performance of various genetic diagnostic tools in a broadly defined 
patient population with suspected genetic disease. Results can inform clinical policy 
and help guide evidence-based precision medicine in neonatology and pediatrics. In 
turn, findings may impact patient access to cGS via health care payer medical policy 
development, institutional uptake, and public research investment in translational 
genomics. 
 
METHODS 
The goal of this research was to generate evidence regarding the use of ES 
as a clinical diagnostic tool. It examined and synthesized published academic 
literature to provide a scoping overview of available evidence on clinical use of ES. It 
also provided a practical example of electronic medical record review for outcomes 
research on a genomic application. Outcomes were described and compared based 
on use of ES in the diagnostic pathway, clinical setting, and relevant patient 
characteristics. Cost-effectiveness of diagnostic strategies – no ES versus ES 
testing (proband-only, trio, and critical trio) – for infants in an intensive care setting 
was estimated by comparing costs of diagnostic pathways and relevant outcome 
measures. 
Data came from Texas Children’s Hospital (TCH) electronic medical records 
(EMR) and administrative databases and Baylor Miraca Genetics Laboratories (BG) 
ES result reports. All ES orders from TCH were performed at BG. Each research aim 
was designed to contribute information regarding the health impact and value of 
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genomic sequencing as a clinical diagnostic tool for infants in an intensive care 
setting. This Methods section provides details on the methods used to achieve each 
aim. 
 
Study Design 
Aim 1 
A scoping review of published peer-reviewed literature was performed. 
Scoping reviews are intended to provide an overview of the nature of literature on a 
topic via structured searches and identify gaps in knowledge. Fewer restrictions for 
inclusion are placed on patient population, intervention, outcome, and study design 
than in systematic reviews. The review was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines,83 
adapted for use in a scoping review as appropriate. CGS is defined to include WGS 
and ES. Sequencing may have been performed for the proband (i.e., patient) only or 
alongside parents or other family members (duo or trio), in a non-rapid or a rapid 
manner with reduced turnaround time. Sequencing was considered clinical rather 
than research for the purpose of this review if the report’s stated goal was to make a 
diagnosis or otherwise impact medical management of the patient(s). In contrast, if 
the objective was gene discovery or disease mechanism elucidation, the sequencing 
was considered research.  
A search strategy was designed with the assistance of a librarian from the 
Texas Medical Center library. PubMed, Embase, and Cochrane Library were 
searched. The PubMed search included the following Medical Subject Headings 
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(MeSH) terms: Genome; Exome; Sequence Analysis, DNA; Adolescent; Child; 
Infant; Diagnostic Techniques and Procedures; Clinical Decision-Making; Diagnosis, 
Differential. Items identified through database searches were imported into the web 
application Rayyan (Doha, Qatar) for title and abstract screening.84 Title and abstract 
of each record were screened by two independent reviewers, and conflicts were 
resolved through consensus. Citations selected for full-text review were imported 
into EndNote (Clarivate Analytics, Boston, Massachusetts), and full-text articles were 
obtained. A full-text review form was completed for each article to determine whether 
inclusion/exclusion criteria were met. One author reviewed each full-text article, and 
a second reviewer reviewed a randomly selected 10% of the full-text articles. 
Articles that met the following pre-determined criteria were included: (1) peer-
reviewed original research article; (2) published between January 2009 and June 
2017 (with an updated search performed in November 2017); (3) proband (if a case 
report) or the majority of probands (if more than 5 probands in study) less than 19 
years of age at the time of sequencing; (4) described/evaluated the clinical 
application of a CGS for diagnostic purposes. Studies of patients who had a clinical 
diagnosis of a condition with known genetic heterogeneity, and thereby not 
determined to have a “specific” diagnosis, were included. Studies of patients 
enrolled in a research protocol performing CGS for a clinical purpose were included 
regardless of how costs of sequencing were covered, as the aim of sequencing was 
considered more important than the funding arrangement. No restrictions were 
placed on study design; clinical reports (individual cases and case series), 
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intervention studies (any methodology), and economic evaluations (any 
methodology) were included. 
Publications with a primary aim of genetic research were excluded as were 
publications on population-based screening, tumor genotyping, mitochondrial 
genome sequencing only (without the nuclear genome), pharmacogenetic testing, 
disease carrier testing, prenatal genetic testing, and targeted exome sequencing 
(e.g., “clinical exome” or “Mendeliome”) panels of thousands genes known to be 
associated with single-gene disorders. While targeted exomes may be considered 
more similar to a whole exome than targeted panel, multiple permutations of such 
tests exist. Because there is inconsistency in covered genes, publications on 
targeted tests were excluded for comparability of results and feasibility of this review. 
Reports on patients who were sequenced post-mortem and those that indicated the 
initiation of sequencing but not results were also excluded.  
 
Aims 2 and 3 
This was a retrospective cohort study in which ES was the exposure factor. 
Two patient cohorts were defined; patients who had ES as part of a diagnostic 
workup (ES cohort) were matched based on clinical characteristics and phenotypic 
presentation to patients who did not (No-ES cohort).  
Data on admission characteristics, demographics, phenotypic presentation, 
clinical outcomes, ES order and result return, and ES uptake by attending clinician 
was collected through retrospective EMR review. Establishment of a molecular 
diagnosis and survival were the primary outcomes of interest. A retrospective 
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approach was optimal in order to utilize information on the large number of patients 
who had already had ES, ensure follow-up time of at least one year over which to 
measure outcomes, and enable comparison of multiple outcomes.  
 
Study Setting 
Aim 1 
This study was performed in the Department of Molecular and Human 
Genetics at Baylor College of Medicine. 
 
Aims 2 and 3 
 This study was performed in the Department of Molecular and Human 
Genetics at Baylor College of Medicine. Clinical care was provided at Texas 
Children’s Hospital (TCH) and genomic sequencing was performed at Baylor Miraca 
Genetics Laboratories (BG), both located in Houston, TX. TCH is a not-for-profit 
health care organization with large acute critical care capacity. Each year, more than 
6,000 children are admitted to TCH ICUs, which have 116 intensive care beds. The 
TCH NICU is certified level IV, the highest level of care available for premature and 
critically ill newborns. BG is one of the foremost genetic testing laboratories in the 
US and was the first to describe ES’s application to clinical diagnosis.2,19 It is 
accredited by the College of American Pathologists (CAP) certified under the US 
Centers for Disease Control and Prevention Clinical Laboratory Improvement 
Amendments of 1988 (CLIA) to return clinical-grade results. BG offers proband-only, 
trio ES, and critical trio ES, all of which must be ordered by a clinical care provider. 
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Each ES report is reviewed by a laboratory director and signed out by a molecular 
geneticist.  
 
 
Study Subjects 
Aim 1 
Not Applicable. 
 
 
Aims 2 and 3 
The target population for this study is undiagnosed newborns infants in 
intensive care with suspected genetic etiology. Patients who had a consultation from 
the Genetics service during an intensive care unit inpatient stay at TCH within the 
first year of life were included. The study timeframe was December 1, 2011 (when 
the first ES order was placed for an infant at TCH, very soon after BG offered it as a 
clinical test) through June 30, 2017. A Genetics consultation documented in the 
medical record indicated a suspected genetic etiology in the patient. Figure 2 
illustrates the flow of patient selection. 
 
Included patients met the following criteria:  
• TCH intensive care inpatient admission within the first year of life 
• Inpatient genetics consultation documented in the medical record 
• Inpatient stay and genetics consultation occurred between December 1, 2011 
and June 30, 2017 
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ES-cohort patients met the following additional criteria: 
• Received ES (proband-only, trio, or critical trio) as part of the diagnostic 
pathway 
• ES ordered within the first year of life 
 
Among all included patients who met the above criteria, patients eligible for 
inclusion in the No-ES cohort were defined as patients who did not receive ES in the 
diagnostic pathway. They may have received other forms of genetic testing such as 
single gene or gene panel tests (e.g., cardiomyopathy panel, BluePrint panel, CHD7 
sequencing, Noonan panel, SMA panel), chromosomal microarray, and methylation 
studies. A clinician may have ordered ES for patients in the No-ES cohort without it 
being performed for reasons such as lack of parental consent or cancelation by lab 
due to insufficient blood sample. 
Two datasets were combined to define the patient population. The first 
dataset, obtained from the hospital, contained medical record numbers of all patients 
at TCH who (1) had an intensive care unit inpatient admission within the first year of 
life, and (2) had an order for inpatient consultation from the Genetics service. The 
second dataset, obtained from the diagnostic laboratory, contained ES report data 
for all patients who had ES (1) ordered from TCH, and (2) an ES order date less 
than 366 days from date of birth. All ES ordered at TCH is sent to BG. Datasets 
were merged on medical record number. Patients appearing in both datasets were 
preliminarily designated as the ES cohort; patients appearing only in the hospital 
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data were preliminarily designated as the No-ES cohort, subject to verification of 
inclusion criteria via EMR review. 
 
Figure 2. Study flow diagram 
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EMR review was then performed for all patients. We defined the index 
admission as the admission during which the initial Genetics consult was ordered. 
Patients for whom a consult order was placed but later canceled were not included. 
A consult order and a note from a member of the Genetics service (even if not 
electronically filed as a “consult”) indicated consultation. 
Patients in the ES cohort had one of 3 forms of ES: sequence analysis of only 
the patient (proband), a trio of patient and both parents (trio), or trio of patient and 
parents with expedited turnaround time (critical trio). Clinical ES became available in 
October 2011 in proband form. The trio test was introduced in October 2014 and 
critical trio in April 2015. 
To determine comparable cohorts of patients who did and did not have ES, we 
calculated a propensity score for each patient. This method allows adjustment for 
confounding when assessing multiple outcomes.85,86 The propensity score was used 
to represent multiple HPO terms and other relevant factors as a one-dimensional 
score.87 We generated a binary variable for each HPO identification (ID) number 
appearing in the data. HPO ID numbers were used instead of terms themselves to 
ensure synonymous terms did not appear as separate variables. Granularity was 
preserved; we did not use hierarchical processing to map to higher order terms 
(although in many cases, multiple levels of terms were generated). HPO term 
variables with count fewer than 10, meaning that the term was observed in fewer 
than 10 patients, were dropped, leaving 340 term variables. Based on clinician 
consensus, another 33 term variables were dropped because they related to 
transient clinical characteristics, such as fever or emesis, not relevant for making a 
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diagnosis. HPO terms were selected for inclusion in the propensity score model 
using a backward automated variable selection process (p-value for removal = 0.1). 
We calculated a propensity score, which is the estimated probability of having ES 
conditional on measured covariates, for each patient using a binary logistic 
regression model with ES as the dependent variable that included indicator variables 
for: gender, the unit in which the initial Genetics consult was performed, initial 
Genetics consult date (quartile of study period), age (days) at first genetics consult 
(quarter of year), and HPO terms. After predicting propensity score for each patient, 
each ES patient was matched to one most phenotypically similar No-ES patient from 
among all potential No-ES patients using a greedy matching algorithm based on the 
linear predictor of the propensity score. Compared to differences between ES 
patients and the entire group of No-ES patients prior to matching, the matching 
procedure successfully reduced differences in covariates between ES and No-ES 
patients in the final cohorts.  
 
Study Power 
Aim 1 
Not Applicable. 
 
 
Aims 2 and 3 
 
The sample size in this study was fixed and unknown prior to completion of 
the data collection process. The statistical power to detect a difference in outcomes 
between study arms was calculated prior to performing any data collection. The 
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most relevant information to calculate power was from a study of infants admitted to 
an ICU at TCH in the first 100 days of life who had ES.3 The 120-day mortality for 
patients in the sample was 81/272 (29.8%). The study does not provide any 
information on patients who did not have ES.  
The ability to detect a difference in effect between a diagnostic pathway that 
includes ES and a diagnostic pathway that does not include any form of ES is of 
interest. Because this study will utilize matched pairs and 120-day mortality is a 
dichotomous outcome, the power calculation is performed for a two-sample paired-
proportions test (McNemar’s). Assuming a 120-day mortality of 29.8%, sample size 
of 400 pairs, and sum of discordant proportions of 0.50, the power would be 77.7% 
to detect a 9.6% difference in 120-day mortality using a two-sided test and alpha of 
0.05. In the smallest expected study arm (trio ES), assuming a sample size of 50 
patients and all of the above conditions, the power would be 15.8%.  
The detectable effects size as an odds ratio at a desired power level of 0.80 
can also be calculated. With 400 matched sets of cases and controls and one 
matched control per case, assuming a 120-day mortality of 0.298 and a correlation 
coefficient for mortality between matched cases and controls of 0.50, and alpha of 
0.05, a true odds ratios for impact of ES in patients who died relative to patients who 
did not die of 0.576 or 1.615 would be detectable with a power of 0.80. Similarly, 
with 50 matched sets, true odds ratios for impact of trio ES of .139 or 3.519 would be 
detectable with power of 0.80.   
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Data Collection 
Aim 1 
Key pieces of information were collected from each included article. A data 
extraction form was developed and pilot tested, and then two refined versions were 
created based on the two types of analyses and reporting encountered. For the 
purpose of collecting and presenting results in this review, studies of five or fewer 
patients were considered “case reports” and studies of more than five patients were 
considered “aggregate analyses.” The cutoff number of five was determined based 
on differences in article structure and information presentation according to the 
number of patients included. Thus, the data collection form used for each type of 
study reflected the way in which facts were reported.  
Data items selected for abstraction from articles were broadly based on 
parameters recommended for assessment in evaluation of genetic tests.88 The data 
collection form for aggregate analyses included the following items: study objective, 
country, type of CGS, comparator, clinical setting, study design, outcome measures, 
study population, inclusion criteria, exclusion criteria, average age at test, percent of 
probands younger than 19 years of age, percent of probands who were male, 
diagnostic laboratory, sequencing platform, whether a duo and/or trio approach was 
used, turnaround time, molecular diagnostic yield, number of probands with a 
change in medical management, discussion of insurance coverage, discussion of 
costs or cost-effectiveness, and average cost to diagnosis or cost of potentially 
replaced tests. For case reports, the above information was collected on the 
individual level as well as the gene implicated and diagnosis. For economic studies, 
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the perspective of the analysis, cost data source, and incremental cost per outcome 
measure were recorded. Data from all included studies was abstracted into a 
spreadsheet. Analysis was performed with Stata IC 13 (College Station, Texas). 
Variables to be measured are presented in Table 2. 
 
Table 2. Measurement Matrix for Aim 1 
Variable Definition Coding Scheme 
Publication Year Year article was published Numeric 
First Author Name of first author of article Text 
Title Title of Article Text 
First Author Geneticist 
Indicator of whether the first author was a 
geneticist 
1 = First author is a 
geneticist 
0 = Otherwise 
888 = Cannot determine 
Study Objective Stated objective of article Text 
Country of Origin Country of the clinical setting Text 
Study Location 
Name of hospital or clinic (or description if 
name not given) Text 
Study Dates 
Beginning and end date of study data 
collection period Text 
Center Single versus multicenter study 
1 = Single Center 
2 = Multi-center 
Type of NGS ES, WGS Text 
Comparator What NGS diagnostic tool is compared to Text 
Clinical Setting NICU, PICU, clinic, lab, etc. Text 
Study Design Description of study design Text 
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Table 2. Measurement Matrix for Aim 1 
Variable Definition Coding Scheme 
Outcome Measures Listed 
(explicitly as goal of 
study)* 
Whether outcome measures are listed in the 
text of the article 
1 = Yes 
0 = No 
Outcome Measures 
Defined* 
Whether an operational definition of outcome 
measures is provided in the text 
1 = Yes 
0 = No 
Outcome Measures Outcome measures reported Text 
Study Population Description of study population Text 
Inclusion Criteria Description of inclusion criteria Text 
Exclusion Criteria Description of exclusion criteria Text 
Sample Size Total sample size of individuals sequenced Numeric 
Number of Patients* Total number of patients included Numeric 
Number of Families* Total number of families included Numeric 
Age at Test 
Average age at test date (record in units 
given) 
Text (include unit in 
parentheses) 
% of Patients < 18 y.o.* 
Percent of patients less than 18 years of age 
at test date 
Numeric 
888 = Cannot determine 
999 = Not Given 
Sex (% Male) Percent of patients sampled who were male 
Numeric 
888 = Cannot determine 
999 = Not Given 
Lab 
Name of laboratory that performed NGS 
(may be more than one) 
Text (e.g., BG, Ambry, 
GeneDX) 
Multi-lab* 
Whether samples were sent to more than 
one lab 
1 = More than one lab used 
0 = All samples sent to 
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Table 2. Measurement Matrix for Aim 1 
Variable Definition Coding Scheme 
single lab 
Platform Sequencing platform used by the lab 
Text (e.g., Illumina HiSeq 
2500) 
Consensus review* 
Whether a clinical consensus review process 
for discussing laboratory results is described 
1 = Clinical team consensus 
review of results described 
0 = No clinical team 
consensus review of results 
described 
2 = review by ordering 
geneticist 
Use ACMG Variant 
Pathogenicity Category 
Whether ACMG variant pathogenicity 
categories are used to categorize findings 
1 = ACMG categories used 
0 = ACMG categories not 
used 
999 = Not Given 
Trio Approach 
Whether a trio approach was used to also 
sequence parents or siblings 
1 = Trio approach used in at 
least some cases 
0 = Trio approach never 
used 
Trio Preferred* 
Whether trio approach was 
preferred/recommended, as indicated by the 
authors 
1 = Trio approach 
preferred/recommended 
0 = Trio approach not 
preferred/recommended 
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Table 2. Measurement Matrix for Aim 1 
Variable Definition Coding Scheme 
Confirmation by Sanger 
Sequencing* 
Whether confirmation of variants by Sanger 
sequencing was performed 
1 = Confirmation by Sanger 
sequencing 
0 = No confirmation by 
Sanger sequencing 
999 = Not Given 
Turnaround time 
Average turnaround time of test (record in 
units given) Numeric 
Report Incidental Findings 
Whether "incidental" or "secondary" findings 
unrelated to clinical phenotype are reported 
1 = Reported 
0 = Not reported 
999 = Not Given 
Percent of Patients with 
Incidental Findings 
Percent of patients who had incidental 
findings returned Numeric 
Molecular diagnostic yield* Overall molecular diagnostic yield (%) 
Numeric 
888 = Cannot determine 
999 = Not Given 
Diagnostic‡ Diagnostic outcome of sequencing 
0 = Non-diagnostic 
1 = Diagnostic 
2 = Prompted candidate 
gene association studies 
3 = Most likely candidate for 
clinical presentation 
Phenotypic subgroups 
reported* 
Whether analysis is broken down into clinical 
phenotype subgroups 
1 = Yes 
0 = No 
Phenotype‡ Description of patient's phenotype Text 
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Table 2. Measurement Matrix for Aim 1 
Variable Definition Coding Scheme 
Neurologic phenotype (%)* 
Percent of patients classified as a neurologic 
phenotype 
Numeric 
999 = Not Given 
Neurologic phenotype 
diagnostic yield (%)* 
  Congenital structural 
anomaly (%)* 
Percent of patients with a congenital 
structural anomaly 
Numeric 
999 = Not Given 
Congenital structural 
anomaly diagnostic yield 
(%)* 
  
Change in Medical 
management* 
Percent of patients with a reported change in 
medical management following return of 
sequencing results 
Numeric 
999 = Not Given 
Change in Medical 
management description‡ 
Change in medical management for the 
proband described in the case Text 
Description of change in 
medical management* 
Ways in which authors report that medical 
management was changed following return 
of sequencing results Text 
Other health outcome 
measure* 
Health outcome metric other than those 
collected in this form Text 
Discussion of medical 
management change 
Authors discuss that sequencing results may 
impact medical management of the patient 
1 = Yes 
0 = No 
Discussion of economics 
Authors discuss economic notions related to 
sequencing 
1 = Yes 
0 = No 
Discussion of economic Authors discuss challenges related to health 1 = Yes 
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Table 2. Measurement Matrix for Aim 1 
Variable Definition Coding Scheme 
evaluation methodology 
challenges* 
economic evaluation of genetic sequencing 0 = No 
Average cost to diagnosis Average cost to diagnosis via sequencing 
Numeric 
. = Not Given 
Cost of potentially 
replaced tests 
Collective cost of potentially avoided 
diagnostic testing if sequencing used as a 
frist-line test 
Numeric 
. = Not Given 
Discussion of insurance 
coverage 
Authors discuss insurance coverage of 
clinical genomic sequencing 
1 = Yes 
0 = No 
Strength 
Study strengths from study design 
perspective Text 
Limitations 
Study limitations from study design 
perspective Text 
*Aggregate analyses only 
‡ Case Reports only 
 
 
Aims 2 and 3 
ES uptake and health outcomes were systematically assessed through 
retrospective EMR review. A data collection form was designed to collect key pieces 
of information from the TCH Epic EMR system. Each patient’s EMR was individually 
reviewed, and data were extracted and compiled in a spreadsheet with a single row 
of data for each patient that combined EMR and BG data. EMR review was 
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completed in August 2018 such that there is at least one year of clinical follow-up 
data on all patients. 
Variables relevant for matching were collected for all patients who met the 
inclusion criteria (cases and potential controls). To address heterogeneity of the 
patient population, subgroup analyses were performed. Clinically relevant features 
were used to define the strata. Patients were divided into subgroups intended to 
generate evidence to inform clinical decision-making and guideline development. We 
performed subgroup analyses for patients admitted in 2016 and 2017 after all three 
ES forms were available, patients who survived to 28 days of life, patients in the 
NICU during the genetics consultation, and patients in the ES-recommended group. 
Medical records were filtered for diagnostic-related activities performed during 
the patient’s ICU stay and over the year following the initial Genetics consultation 
and clinical notes originating from a member of the genetics service (inpatient) or 
genetics clinic (outpatient), including notes signed by geneticists, genetics trainees, 
and genetic counselors. 
Cost data was obtained from the hospital administrative cost reports. Patient-
level costs were reported for the index admission and over the year following the 
initial genetics consult order date. As there is no standard diagnostic pathway for this 
population of patients, we defined the diagnostic pathway as clinical tests performed 
for the purpose of making a diagnosis, rather than routine care or monitoring. An 
inclusion rule of “first,” “none,” or “all” was determined for each test on a list of all 
laboratory and radiology tests performed in our study sample. The rule was used to 
determine which, if any, instance of a specific test in a patient was counted as part of 
 
 
 
 
58 
the diagnostic pathway and applied to the cost data to sum the cost of diagnostic 
pathway investigations. Similarly, to determine the cost of genetic tests, we identified 
each genetic test in the list of laboratory tests. In each patient’s cost data, each line-
item for “miscellaneous referred test” was cross-referenced by service date to 
miscellaneous referred tests ordered in the EMR to determine whether it was a 
genetic test or not. All tests determined to be genetic tests were included in both the 
diagnostic pathway and genetic test cost categories. Genetic test and diagnostic 
pathway costs are not necessarily inclusive or exclusive of billing categories.  
Variables to be measured for Aim 2 and Aim 3 are presented in Table 3 and 
Table 4, respectively. 
 
Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Patient Characteristics 
ES Indicates whether patient had ES 
0 = Patient did not 
have ES 
1 = Patient had ES 
BG; TCH 
Administrative 
Records 
Last name Patient last name Text 
TCH 
Administrative 
Records 
Date of Birth Patient date of birth Date 
TCH 
Administrative 
Records 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
MRN Medical record number Numeric 
TCH 
Administrative 
Records 
First IP Genetics 
consult order date 
Date first order for genetics consult during 
ICU stay was placed in TCH EMR from 
TCH records Date 
TCH 
Administrative 
Records 
Ethnicity 
Ethnicity of patient as listed in 
Demographics tab in TCH EMR (or from 
H&P or genetics note if not listed in 
Demographics. If genetics note in conflict 
with demographics tab facesheet, 
deferred to genetics note) 
Hispanic 
Non-Hispanic 
unknown TCH EMR 
Race 
Race of patient as listed in Demographics 
tab in TCH EMR (or from H&P note if not 
listed in Demographics) 
American Indian 
and Alaska Native 
Asian 
Black/African-
American 
Native Hawaiian 
or Other Pacific 
Islander 
White/Caucasian 
unknown TCH EMR 
Sex Patient sex as listed in TCH EMR M = male TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
F = female 
U = ambiguous 
("none") 
Alive 
Indicator of whether a patient is alive as 
determined in TCH EMR through review 
of notes. Note that even if a patient is not 
marked as deceased in the TCH EMR 
system, documentation of communication 
of patient death was used to determine 
status. 
0 = Deceased 
1 = Alive TCH EMR 
Primary Language 
Primary language of family as listed in 
TCH EMR or as indicated in clinical notes 
was spoken with the family (or spoken 
through translator). If at least one member 
of the family could communicate with 
medical staff in English, and no translator 
used, recorded as English. 
English 
Spanish 
Other TCH EMR 
Zip code 
Patient zip code, identified from Detailed 
Report for admission from index 
admission Numeric TCH EMR 
Date of last follow-
up or death 
Date of last follow up or death as 
determined from encounter list in TCH 
EMR Date TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Date of Death 
Date of death as determined in TCH EMR 
from death summary note or other note Date TCH EMR 
Date ICU admit 
Date of index ICU admission (defined as 
admission during which initial inpatient 
genetics consult order was placed), 
identified from Detailed Report for 
admission Date TCH EMR 
Length of inpatient 
stay 
Length of inpatient stay in days for index 
ICU admission (defined as admission 
during which initial inpatient genetics 
consult order was placed), identified from 
Detailed Report for admission Numeric TCH EMR 
Date ICU 
discharge 
Date of discharge for index ICU 
admission (defined as admission during 
which initial inpatient genetics consult 
order was placed), identified from 
Detailed Report for admission Date TCH EMR 
Discharge to 
Place where patient was discharged to 
following index ICU admission, identified 
from Detailed Report for admission as 
"Disposition" 
Expired 
Home Health Care  
Home/Self Care 
Hospice 
Other facility TCH EMR 
Admit Service Service listed under admission Text TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
information, identified from Detailed 
Report for admission 
Principal problem 
Principal clinical problem for admission, 
identified from Detailed Report problem 
list as item with blue square Text TCH EMR 
Principal 
problem_ICD-10-
CM 
ICD-10-CM code for principal problem for 
admission, identified from Detailed Report 
problem list as item with blue square Text TCH EMR 
Reason for 
visit_DXcode1 
Dx code for Reason for Visit (coded), 
identified from Detailed Report for 
admission Text TCH EMR 
Reason for 
visit_DX1 
Diagnosis for Reason for Visit (coded), 
identified from Detailed Report for 
admission Text TCH EMR 
Reason for 
Admission - 
Primary 
Primary reason for admission identified 
from Detailed Report for admission Text TCH EMR 
Reason for 
admission - 
Primary_code 
ICD-9 (or ICD-10) code corresponding to 
the primary reason for admission 
identified from Detailed Report for 
admission Text TCH EMR 
Clinical setting 
(unit) 
Unit listed in Detailed Report for 
admission Text TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Insurance 
Payer_Epic 
(priority 1) 
Insurance carrier in TCH EMR (at time of 
admission) - priority 1 Text TCH EMR 
Insurance 
Payer_Epic 
(priority 2) 
Insurance carrier in TCH EMR (at time of 
admission) - priority 2 Text TCH EMR 
Point of Origin 
Place where patient was admitted from for 
index ICU admission, identified from 
Detailed Report for admission as "Point of 
Origin" 
Clinic or Physician 
Referral 
Newborn at TCH 
Self Referral/Non-
Health Care 
Facility 
Transfer Center TCH EMR 
Gestational age 
Gestational age at birth, identified from 
H&P, Genetics, or discharge note Numeric TCH EMR 
Age of mother 
(years) 
Age of mother at patient's birth, identified 
from H&P or Genetics note Numeric TCH EMR 
Mother Parity 
G&P status of mother prior to delivery of 
patinet, identified from H&P or Genetics 
note Text TCH EMR 
Primary Caregiver 
marital status 
Primary caregiver's marital status, 
identified from Social Work, H&P, or other 
notes 
Living with partner 
Engaged 
Married TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Separated 
Single 
Unknown 
Age of father 
(years) 
Age of father at patient's birth, identified 
from H&P or Genetics note Numeric TCH EMR 
Unit_Genetics 
consult note 
Unit listed on initial inpatient Genetics 
consult note Text TCH EMR 
Genetics Consult 
Note Chief 
Complaint 
Chief complaint listed on initial Genetics 
Consult Note Text TCH EMR 
Initial Genetics 
Consult Note 
Author 
Author of initial Genetics Consult Note 
(Fellow or Resident) Text TCH EMR 
Initial Genetics 
Consult Note 
Cosigner 
Cosigner of initial Genetics Consult Note 
(Attending) Text TCH EMR 
Date of initial 
Genetics Consult Date of initial inpatient Genetics Consult Date TCH EMR 
ES Genetics 
Consult/Physician 
Note Author 
Author of Genetics Consult Note 
describing ES order (inpatient only) 
(Fellow or Resident) Text TCH EMR 
ES Genetics 
Consult/Physician 
Cosigner of Genetics Consult Note 
describing ES order (inpatient only) Text TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Note Cosigner (Attending) 
Date of ES 
Genetics Consult 
Date of Genetics Consult that describes 
ES order (inpatient only) Date TCH EMR 
ES ordered during 
different admission 
than initial 
Genetics consult 
Whether ES was ordered during a 
different inpatient admission than the 
index admission (inpatient only;  
outpatient = 0) 
0 = No (ES 
ordered during 
index admission or 
outpatient) 
1 = Yes TCH EMR 
Principal Problem 
for admission 
during ES ordered 
if different 
Principal problem for admission during 
which ES was ordered if ordered during a 
different admission than the index 
admission Text TCH EMR 
Date of Admit for 
ES admission (if 
different from 
index) 
Date of admission for inpatient stay during 
which ES was ordered if different than 
index admission Date TCH EMR 
Date of Discharge 
for ES admission 
(if different from 
index) 
Discharge date for inpatient stay during 
which ES was ordered if different than 
index admission Date TCH EMR 
ES Test Code ES test code 
1500 = Proband 
1600 = Trio 
1722 = Critical BG 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Trio 
Date ES 
Ordered_Epic 
Date ES was ordered in TCH EMR, as 
listed on the order Date TCH EMR 
Date ES 
Resulted_Epic 
Date ES was resulted in TCH EMR, as 
listed on the order Date TCH EMR 
Date ES Results 
Reviewed_Epic 
Date ES results were viewed in TCH EMR 
the first time, as listed on the order 
Date 
"not listed" = no 
reviewer 
name/date TCH EMR 
Date ES Results 
Reviewed 2_Epic 
Date ES results were viewed in TCH EMR 
the second time, as listed on the order Date TCH EMR 
ES result 
addendum/Expand
ed report 
Whether there was an addendum, 
expanded report, or reanalysis document 
scanned into the ES order in TCH EMR 
0 = No 
1 = Yes 
 
ES result pending 
at discharge 
Whether ES results were pending at ICU 
discharge for admission during which 
initial Genetics consult was ordered. Note: 
always = 1 if ES was ordered after index 
admission. 
0 = Returned 
during inpatient 
admission during 
which first 
Genetics consult 
occurred 
1 = ES result not 
returned during 
admission during TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
which first 
Genetics consult 
was ordered 
ES Order Clinical 
Setting Clinical setting in which ES was ordered 
Inpatient 
Outpatient TCH EMR 
ES ordering 
physician if 
outpatient 
Name of physician who ordered ES if 
ordered outpatient Text TCH EMR 
Date ES 
recommended if 
outpatient 
Date that physician recommended ES if 
ordered outpatient. Note: sometimes a lag 
before order placed because of insurance 
authorization process Date TCH EMR 
Result Return 
Geneticist 
Name of Genetics Service provider who 
returned ES results to family Text TCH EMR 
Result Return 
Geneticist_Attendi
ng 
Name of Genetics Service provider who 
returned ES results to family - attending 
geneticist Text TCH EMR 
Result Return 
Geneticist_Fellow/
Resident 
Name of Genetics Service provider who 
returned ES results to family - genetics 
fellow or resident Text 
 
Result Return 
Other Provider 
Name of Genetics Service provider who 
returned ES results to family - specialty 
other than Genetics Text TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Result Return 
Counselor 
Name of Genetic Counselor who returned 
ES results to family Text TCH EMR 
ES Result Return 
mode Mode of delivery of ES results to family 
Telephone 
Inpatient 
Genetics Clinic 
Visit 
Neurology Clinic 
Visit 
Metabolic Clinic 
Visit 
Other TCH EMR 
ES Result 
communication 
(first contact) 
Date of first communication of ES results 
with patient's family Date TCH EMR 
ROR Notes 
Notes about how return of results was 
performed Text TCH EMR 
Genetic 
Counseling Notes 
Notes from genetic counseling result 
disclosure Text TCH EMR 
Follow Up in 
Genetics 
Clinic_date 
Date patient had in-person follow-up visit 
in the Genetics outpatient clinic Date TCH EMR 
Follow Up in 
Genetics 
Clinician who saw patient in Genetics 
outpatient clinic at follow-up Text TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Clinic_MD 
Control_ES noted 
recommended or 
reflex 
For control patients only; whether the 
Genetics consult note had clinician 
documentation in the plan that they would 
consider ES in the future or reflex to it 
1 = Yes 
. = No/not noted TCH EMR 
Parents decline 
ANY genetic 
testing 
For control patients only; whether the 
Genetics consult note had clinician 
documentation that the patient's parents 
declined having any genetic testing 
 
1 = Yes 
. = No/not noted TCH EMR 
MedicalRefNo_BG MRN from BG records Numeric BG 
TestCode_BG Test code from BG records 
1500 = Proband 
1600 = Trio 
1722 = Critical 
Trio BG 
MedicalPresentati
on_BG 
Medical presentation as described by the 
clinician and given to the lab Text BG 
SampleDate_BG ES sample date from BG records Date BG 
TestOrderDate_B
G ES order date from BG records Date BG 
Focused Report 
Date Date focused report was faxed from BG Date 
TCH EMR 
(retrieved from 
scans of BG 
reports in TCH 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
EMR) 
Last_FaxedDate_
BG 
ES result fax date from BG records. Date 
last report (expanded, addendum, 
reanalysis, etc.) was faxed. If no 
reanalysis, same as date of focused 
report.  Numeric BG 
TestTurnAround 
(days, FaxedDate 
- OrderDate)_BG ES turnaround time (days) 
 
BG 
ClinicalSummary_
BG Clinical summary from BG Text BG 
Interpretation_BG Interpretation of ES results from BG Text BG 
Clinician 
Interpretation of 
Results 
Interpretation of Geneticist who followed 
up with patient after ES results available 
from clinic notes 
Remarkable 
Unremarkable TCH EMR 
HPO 
terms_curated 
Curated list of HPO terms generated for 
the patients via natural language 
processor from genetics consultation, 
admission, and discharge notes Text TCH EMR 
Outcome Measures 
Molecular 
diagnostic result Molecular diagnosis Text TCH EMR 
Molecular Description of molecular diagnosis Text TCH EMR 
 
 
 
 
71 
Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
diagnosis 
description 
Molecular 
diagnostic tool 
Diagnostic test used to determine 
molecular diagnosis Text TCH EMR 
Parent Availability 
note 
Description of family members who 
submitted samples to the lab for testing 
 
BG 
Clinical Diagnosis 
Clinical diagnosis (may or may not be 
molecularly confirmed) Text TCH EMR 
CMA Completed 
Indicator of whether patient had 
chromosomal microarray (CMA), either at 
TCH or outside hospital (as documented 
in clinical note) 
0 = No CMA 
performed 
1 = CMA 
performed TCH EMR 
CMA Result Result of CMA 
Normal 
Gain 
Loss 
AOH (absence of 
heterozygosity) TCH EMR 
Other genetic tests 
List of other genetic tests performed, as 
collected from Results Review tab in EMR Text TCH EMR 
Change in 
counseling 
Whether there was a change in 
counseling following ES results 
0 = No change in 
counseling 
1 = Change in 
counseling TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Change in 
counseling notes Notes about change in counseling Text TCH EMR 
Sub-specialty 
consult 
Whether there was a sub-specialty 
consult initiated following ES results 
0 = No surgical 
intervention 
following 
molecular 
diagnosis from ES 
1 = Surgical 
intervention 
following 
molecular 
diagnosis from ES TCH EMR 
Sub-specialty 
consult notes Notes about sub-specialty consult Text TCH EMR 
Change in 
medication 
Whether there was a change in drug 
therapy initiated following ES results 
0 = No change in 
drug therapy 
(initiation or 
discontinuation) 
following 
molecular 
diagnosis from ES 
1 = Change in 
drug therapy  TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
(initiation or 
discontinuation) 
following 
molecular 
diagnosis from ES 
Change in 
medication notes Notes about change in drug therapy Text TCH EMR 
Surgery/Procedure 
Whether there was a surgery or 
procedure performed following ES results 
0 = No surgical 
intervention 
following 
molecular 
diagnosis from ES 
1 = Surgical 
intervention 
following 
molecular 
diagnosis from ES TCH EMR 
Surgery/Procedure 
notes Notes about surgery or procedure 
 
TCH EMR 
Change in 
screening 
Whether there was a change in screening 
following ES results Text TCH EMR 
Change in 
screening notes Notes about change in screening Text TCH EMR 
 
 
 
 
74 
Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Change in diet 
Whether there was a change in diet 
initiated following ES results 
0 = No change in 
diet 
1 = Change in diet TCH EMR 
Change in diet 
notes Notes about diet change Text TCH EMR 
Change in 
Prognosis 
Whether there was a change in prognosis 
based on ES results Text TCH EMR 
Change in 
Prognosis notes Notes about prognosis change Text TCH EMR 
Palliation 
Whether palliation was initiated following 
ES results 
0 = Palliation not 
initiated 
1 = Palliation 
initiated TCH EMR 
Palliation notes Notes about palliation Text TCH EMR 
BMT 
Whether there was a bone marrow 
transplant initiated following ES results 
0 = No BMT 
following 
molecular 
diagnosis from ES 
1 = BMT following 
molecular 
diagnosis from ES TCH EMR 
BMT notes Notes about BMT Text TCH EMR 
Surveillance Plan Whether there was a change in 0 = No change in TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
surveillance plan initiated following ES 
results 
surveillance plan 
1 = Change in 
surveillance plan 
Surveillance plan 
notes Notes about surveillance plan Text TCH EMR 
Inheritance pattern 
Whether there was a change in thinking 
about inheritance pattern of disease 
following ES result return 
0 = No change in 
inheritance pattern 
thinking 
1 = Change in 
inheritance pattern 
thinking TCH EMR 
Inheritance pattern 
notes Notes about natural history Text TCH EMR 
Additional Genetic 
Testing of Proband 
Whether additional genetic testing of 
proband was recommended after ES 
results received 
0 = No additional 
genetic testing of 
proband 
recommended 
1 = Additional 
genetic testing of 
proband 
recommended TCH EMR 
Additional Genetic 
Testing of Proband 
Notes regarding additional genetic testing 
of proband recommended after ES results Text TCH EMR 
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Table 3. Measurement Matrix for Aim 2 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
notes received 
Family testing/ 
surveillance 
Whether ES results prompted a 
recommendation of genetic testing or 
medical surveillance in the proband's 
family members 
0 = No family 
testing/surveillanc
e 
1 = Family 
testing/surveillanc
e recommended TCH EMR 
Family testing/ 
surveillance notes Notes about family testing/surveillance Text TCH EMR 
Other clinical care 
effect 
Notes about other effects of ES on clinical 
care Text TCH EMR 
 
Table 4. Measurement Matrix for Aim 3 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Cost Categories 
Index admission 
total cost Total cost of index admission Continuous 
TCH 
Administrative 
Records 
Year post 
encounters 
Count of encounters over year following initial 
genetics consult Discrete 
TCH 
Administrative 
Records 
Year post total Total cost of one year following index admission Continuous TCH 
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Table 4. Measurement Matrix for Aim 3 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
cost Administrative 
Records 
Index and year 
encounters 
Count of index admission + encounters over year 
following initial genetics consult Continuous 
TCH 
Administrative 
Records 
Index and year 
total cost 
Total cost combined (index admission and one 
year following) Continuous 
TCH 
Administrative 
Records 
Day Surgery 
Count Post  
Number of post index admissions encounters - 
day surgery Discrete 
TCH 
Administrative 
Records 
Emergency 
Count Post 
Number of post index admissions encounters - 
emergency Discrete 
TCH 
Administrative 
Records 
Inpatient Count 
Post 
Number of post index admissions encounters - 
inpatient Discrete 
TCH 
Administrative 
Records 
Observation 
Count Post 
Number of post index admissions encounters - 
observation Discrete 
TCH 
Administrative 
Records 
Outpatient Count 
Post 
Number of post index admissions encounters - 
outpatient Discrete 
TCH 
Administrative 
Records 
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Table 4. Measurement Matrix for Aim 3 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Renal Series 
Count Post 
Number of post index admissions encounters - 
renal series Discrete 
TCH 
Administrative 
Records 
Series Count 
Post 
Number of post index admissions encounters - 
series Discrete 
TCH 
Administrative 
Records 
Specimen Count 
Post 
Number of post index admissions encounters - 
specimen Discrete 
TCH 
Administrative 
Records 
Clinic Index Cost 
Index admission cost by UB revenue code 
category - clinic Continuous 
TCH 
Administrative 
Records 
Diagnostic Index 
Cost 
Index admission cost by UB revenue code 
category - diagnostic Continuous 
TCH 
Administrative 
Records 
Emergency Care 
Index Cost 
Index admission cost by UB revenue code 
category - emergency care Continuous 
TCH 
Administrative 
Records 
Laboratory Index 
Cost 
Index admission cost by UB revenue code 
category - laboratory Continuous 
TCH 
Administrative 
Records 
Med/Surg 
Supplies Index 
Index admission cost by UB revenue code 
category - med/surg supplies Continuous 
TCH 
Administrative 
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Table 4. Measurement Matrix for Aim 3 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Cost Records 
Nursing Care 
Index Cost 
Index admission cost by UB revenue code 
category - nursing care Continuous 
TCH 
Administrative 
Records 
OR Periop Index 
Cost  
Index admission cost by UB revenue code 
category - OR periop services Continuous 
TCH 
Administrative 
Records 
Organ Acq Index 
Cost 
Index admission cost by UB revenue code 
category - organ aq Continuous 
TCH 
Administrative 
Records 
OT/PT Index 
Cost 
Index admission cost by UB revenue code 
category - OT/PT Continuous 
TCH 
Administrative 
Records 
Other Index Cost 
Index admission cost by UB revenue code 
category - other Continuous 
TCH 
Administrative 
Records 
Pharmacy Index 
Cost 
Index admission cost by UB revenue code 
category - Pharmacy Continuous 
TCH 
Administrative 
Records 
Radiology Index 
Cost 
Index admission cost by UB revenue code 
category - radiology Continuous 
TCH 
Administrative 
Records 
Therapeutic Index admission cost by UB revenue code Continuous TCH 
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Table 4. Measurement Matrix for Aim 3 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Index Cost category - therapeutic Administrative 
Records 
Transport Index 
Cost 
Index admission cost by UB revenue code 
category - transport Continuous 
TCH 
Administrative 
Records 
Clinic Post Cost 
Post-index admissions' cost by UB revenue code 
category - clinic Continuous 
TCH 
Administrative 
Records 
Diagnostic Post 
Cost 
Post-index admissions' cost by UB revenue code 
category diagnostic Continuous 
TCH 
Administrative 
Records 
Emergency  
Care Post Cost 
Post-index admissions' cost by UB revenue code 
category - emergency care Continuous 
TCH 
Administrative 
Records 
Laboratory Post 
Cost 
Post-index admissions' cost by UB revenue code 
category - laboratory Continuous 
TCH 
Administrative 
Records 
Med/Surg 
Supplies Post 
Cost 
Post-index admissions' cost by UB revenue code 
category - med/surg supplies Continuous 
TCH 
Administrative 
Records 
Nursing Care 
Post Cost 
Post-index admissions' cost by UB revenue code 
category - nursing care Continuous 
TCH 
Administrative 
Records 
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Table 4. Measurement Matrix for Aim 3 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
OR Periop 
Services Post 
Cost 
Post-index admissions' cost by UB revenue code 
category - OR periop services Continuous 
TCH 
Administrative 
Records 
Organ 
Acquisition Post 
Cost 
Post-index admissions' cost by UB revenue code 
category - organ acquisition Continuous 
TCH 
Administrative 
Records 
OT/PT Post Cost 
Post-index admissions' cost by UB revenue code 
category - OT/PT Continuous 
TCH 
Administrative 
Records 
Other Post Cost 
Post-index admissions' cost by UB revenue code 
category - other Continuous 
TCH 
Administrative 
Records 
Pharmacy Post 
Cost 
Post-index admissions' cost by UB revenue code 
category - pharmacy Continuous 
TCH 
Administrative 
Records 
Radiology Post 
Cost 
Post-index admissions' cost by UB revenue code 
category - radiology Continuous 
TCH 
Administrative 
Records 
Therapeutic Post 
Cost 
Post-index admissions' cost by UB revenue code 
category - therapeutic Continuous 
TCH 
Administrative 
Records 
Transport Post 
Cost 
Post-index admissions' cost by UB revenue code 
category - transport Continuous 
TCH 
Administrative 
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Table 4. Measurement Matrix for Aim 3 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Records 
Index admission 
diagnostics 
count 
Count of tests on the "diagnostic pathway" during 
the index admission Discrete 
TCH 
Administrative 
Records 
Index admission 
diagnostics total 
cost 
Total cost of diagnostic pathway (using "first" and 
"all" rules) for the index admission Continuous 
TCH 
Administrative 
Records 
Year diagnostics 
count 
Count of tests on the "diagnostic pathway" from 
the beginning of the index admission through 
one year after the initial genetics consult Discrete 
TCH 
Administrative 
Records 
Year diagnostics 
total cost 
Total cost of diagnostic pathway (using "first" and 
"all" rules) for the year Continuous 
TCH 
Administrative 
Records 
Index admission 
genetic test total 
cost 
Total cost of genetic tests during the index 
admission Continuous 
TCH 
Administrative 
Records 
Year genetic test 
total cost Total cost of genetic tests during the index year Continuous 
TCH 
Administrative 
Records 
Measured 
Variable Variable Description 
Variable 
Coding/Type 
Data Source for 
calculation 
Variables Used to Perform Subgroup analyses  
Patient Characteristics 
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Table 4. Measurement Matrix for Aim 3 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
Proband-only Patient had BG test code 1500 
Categorical 
(0/1) BG 
Trio ES Patient had BG test code 1600 
Categorical 
(0/1) BG 
Critical trio ES Patient had BG test code 1722 
Categorical 
(0/1) BG 
No ES 
Patient did not have ES as part of diagnostic 
pathway (No-ES Cohort) 
Categorical 
(0/1) TCH EMR 
NICU 
Patient had initial genetics consultation in the 
NICU 
Categorical 
(0/1) TCH EMR 
Survived to 28 
days Patient survived to 28 days of life 
Categorical 
(0/1) TCH EMR 
Survived to 1 
year of life Patient survived to 1 year of life 
Categorical 
(0/1) TCH EMR 
Admit year Year of admission date for index admission 
2011 
2012 
2013 
2014 
2015 
2016 
2017 TCH EMR 
Outcome Measures 
Molecular Whether a molecular diagnosis was made Categorical TCH EMR 
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Table 4. Measurement Matrix for Aim 3 
Measured 
Variable Variable Description 
Variable 
Coding/Type Data Source 
diagnosis (0/1) 
28-day survival Patient survived to 28 days of life 
Categorical 
(0/1) TCH EMR 
1-year survival Patient survived to 1 year of life 
Categorical 
(0/1) TCH EMR 
 
 
 
Data Analysis 
Aim 1 
  Because this scoping review included articles that employed multiple 
methodologies and studied diverse patient populations, results across studies were 
summarized and narratively described rather than combined statistically in a meta-
analysis. Descriptive statistics were calculated on the number of articles on each 
type of CGS, characteristics of patients and institutions, clinical scenarios, and 
reported outcome measures. Discussion of costs and economic evidence was also 
summarized. The Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) checklist was used to assess the quality of reporting in articles with an 
economic evaluation focus.89 Two authors assessed each article independently and 
arrived at a consensus score. 
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Aim 2 
Data management and descriptive analyses were performed using Stata/IC 
15 (StataCorp, College Station, TX). Detailed electronic medical record review was 
performed for all patients who met inclusion criteria. The index admission was 
defined as the admission during which the initial genetics consult was ordered and 
the index year as the year following the date of initial genetics consultation.  
To characterize patient phenotypes, relevant information was extracted from 
the initial Genetics consult note (which contains the most extensive and detailed 
assessment of the patient’s clinical features) and index admission discharge note. A 
natural language processor was used to generate human phenotype ontology (HPO) 
terms based on the clinical characteristics of the patients described in notes. Thus, 
the set of HPO terms generated for each patient was intended to capture clinical 
presentation at the time of the Genetics team’s assessment. Careful attention was 
given so as not to include “pertinent negatives,” information from birth or family 
history, or phenotypic hallmarks of differential diagnoses described within the note.  
 A binary variable was generated for each HPO ID number appearing in the 
data. HPO ID numbers were used to ensure synonymous terms did not appear as 
separate variables. Granularity was preserved; we did not use hierarchical 
processing to map to higher order terms (although in many cases, both were 
generated). HPO term variables with count fewer than 10 (i.e., terms that were 
observed in fewer than 10 patients) were dropped, leaving 340 term variables. On 
the basis of consensus among clinicians, another 33 term variables were dropped 
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because they related to transient clinical characteristics, such as fever or emesis, 
not relevant for making a diagnosis.  
 A propensity score was then calculated for each patient. The propensity score 
is the estimated probability of having ES conditional on measured covariates. It is 
used to represent multiple HPO terms and other relevant factors as a one-
dimensional score.87 Propensity scores may be used to adjust for confounding when 
assessing multiple outcomes.85,86 The propensity score was calculated using a 
binary logistic regression model that included indicator variables for: the department 
in which the initial Genetics consult was performed, quartiles of time since ES 
availability, age at first genetics consult by quarter of year, and patient gender. A 
backward automated variable selection process (p-value for removal = 0.1) was 
used for selection of HPO term variables. Patients who had ES were matched to 
phenotypically similar patients who did not have ES using a greedy matching 
algorithm based on the natural log of the propensity score. Compared to differences 
between ES patients and the entire group of No-ES patients prior to matching, the 
matching procedure successfully reduced differences in covariates between ES and 
No-ES patients in the final cohorts. 
We calculated descriptive statistics on demographics of patients and 
characteristics of the index admission. We produced Kaplan-Meier survival curves to 
analyze survival to 28 days, 1 year, and to the end of study. We used Cox 
regression models to analyze survival times and logistic regression models to 
analyze odds of molecular diagnosis.  
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Outcomes were analyzed using the appropriate statistical test for the nature 
of the data involved to test for a difference in outcome and costs between the study 
arms and for subgroup analyses (e.g., Student’s t-test, Chi-square test, Wilcoxon 
rank-sum and Kruskall-Wallis tests for differences in cost categories between 
cohorts and ES forms, respectively.)  
Effects were tallied from the clinical note at the time of ES return of results 
and follow-up in the Genetics clinic. Establishment of a molecular diagnosis and 
survival were the primary outcomes of interest. Molecular diagnosis was defined as 
the identification of a specific genetic change, via analysis of chromosomes 
(karyotype, chromosomal microarray, FISH), sequencing of a single gene or a panel 
of multiple genes, deletion/duplication analysis, or methylation studies, interpreted 
as the cause or probable cause of the patient’s clinical presentation. All results of 
molecular diagnostic tests ordered in the year following the date of the initial 
Genetics consult were reviewed, and interpretation of findings was verified in clinical 
notes. ES cases reported by the laboratory as “solved” and “probably solved” were 
considered diagnosed. For ES patients, other changes in medical management were 
also tallied through analysis of the clinical note at the time of ES return of results and 
follow-up in the Genetics clinic. 
 
 
Aim 3 
Data management and descriptive analyses were performed using Stata/IC 
15 (StataCorp, College Station, TX). EMR data was merged with hospital cost data 
on MRN, and costs were analyzed using the hospital perspective. Costs and 
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outcomes were evaluated over the time horizon of the index admission and index 
year. 
Establishment of a molecular diagnosis and 1-year survival were the primary 
outcomes of interest. A comprehensive list of laboratory and radiology diagnostic 
investigations and associated costs and service dates for each patient over the year 
following the initial genetics consult order date was obtained from the hospital. 
Cost analyses considered costs of the index admission, index admission 
diagnostic pathway, index admission genetic tests, total cost of the index year, index 
year diagnostic pathway, and index year genetic tests. The total diagnostic cost 
included the cost of all activities performed with the goal of making a diagnosis, 
including ES, targeted genetic testing (single gene or gene panel), inborn error of 
metabolism screening, MRI, ultrasound, and EEG. Diagnostic cost excluded the cost 
of other tests performed for non-diagnostic related reasons, such as routine care, 
through the systematic application of rules for inclusion of the first instance, all 
instances, or no instances of each type of test. The total cost of the inpatient hospital 
stay was confined to costs accrued before discharge, even if the patient was 
discharged before ES results were returned.  
Neither costs nor effects were discounted because all costs and outcomes 
are modeled for one year, so there is no need to account for differences in time 
preference. All costs were adjusted to 2017 USD$ using the historical Consumer 
Price Index for All Urban Consumers (CPI-U): U.S. city average per year. 
We account for the skewed distribution of costs by using log transformations 
and non-parametric statistical tests. We used ordinary least squares (OLS) 
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regression on log transformed total cost of index admission to estimate the impact of 
patient characteristics on index admission cost. We employed Wilcoxon rank-sum 
and Kruskall-Wallis tests for differences in cost categories between cohorts and ES 
forms, respectively. Chi-square and Wilcoxon rank-sum tests were used for other 
comparisons as appropriate.  
We calculated the cost of the index admission and the diagnostic pathway per 
percent 1-year survival. We calculated incremental cost-effectiveness ratios 
(ICERs), the ratio of the difference in expected costs and expected outcomes 
between one diagnostic strategy and the next most effective is the incremental cost-
effectiveness.  
Cost-effectiveness of ES versus No-ES is presented in the form of an ICER 
calculated as: 
!"#$ = ! !"#$ ! !""#$%&'#(#))  
where ! !"#$ =  !"#$!" − !"#$!"!!" 
and ! !""#$%&'#(#)) =  !""#$%&'#(#))!" − !""#$%&'#(#))!"!!" 
 
We calculated ICERs for incremental index admission diagnostic pathways 
costs and incremental diagnoses, and for incremental index admission genetic test 
costs and incremental diagnoses. For each ICER, 95% confidence intervals were 
constructed from 1,000 bootstrap replicates. 
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Main Limitations 
The scoping literature review performed for Aim 1 was intended to include all 
relevant published studies. However, this analysis was limited in that it only included 
articles that were published in peer-reviewed academic journals. Descriptions of 
clinical experiences with genomic sequencing published in institutional reports or 
newsletters would not be detected by the search strategy. Additionally, because the 
review only considered English language articles, some relevant studies may not be 
included. However, only one relevant article was unavailable in English.  
The analysis performed in Aim 2 and 3 had several limitations. It was a 
retrospective analysis based on information available in medical records and 
administrative records, both of which can be incomplete or have other forms of error. 
Because of the retrospective nature of the study, patients were not randomly 
assigned to treatment or control group arms. However, this study improved upon 
previous research by matching patients who received ES to patients who did not on 
important clinical features in an attempt to control for confounding factors. Although 
many have called for prospective clinical trials in order to study the patient 
populations for which cGS is most effective,90 balancing cohorts by patient 
phenotype and other relevant clinical characteristics utilized in this study aimed to 
estimate the impact for specific types of patients while utilizing information available 
in patient charts.  
There were several potential confounding factors that may be important in the 
study of mortality, especially 1-year survival. This study was limited to data available 
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in the EMR and ES reports. Estimates of the impact of ES were interpreted based on 
documentations made in clinical notes, which may have been incomplete. It is 
possible that the death of some patients may have occurred outside of the hospital 
and not be documented in the EMR. Similarly, patients may have sought care 
outside of TCH, in which case costs and encounters would not be documented in the 
TCH EMR or cost data. 
This study used establishment of a molecular diagnosis as an outcome 
measure, which health economists traditionally consider an intermediate rather than 
a final health outcome measure. However, receipt of diagnosis is a relevant outcome 
in this case for both insurers and clinicians. Payers are highly interested in the cost-
effectiveness of using these tests to arrive at a diagnosis because it ends the 
diagnostic odyssey, which involves both diagnostic tests and various specialist visits. 
For clinicians, a molecular diagnosis can help direct medical management and also 
provide reassurance about treatment decisions or the decision to discontinue 
treatment. For both of these reasons, a diagnosis is a useful measure of health 
outcome in and of itself. 
The results of this study cannot be used to draw any conclusions about where 
in the diagnostic pathway ES should optimally be incorporated (i.e., as a first-line 
test or subsequent to other tests if they were unsuccessful in establishing a 
diagnosis). This analysis only looks at pathways with and without ES; it does not 
attempt to quantify cost-effectiveness for ES at a particular point in the diagnostic 
pathway (e.g., as a first-line test versus after other diagnostics have been 
performed). 
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To address the heterogeneity of the patient population, patients were 
matched on phenotypic and clinical characteristics. Even so, the underlying cause of 
disease remained diverse within patient groups because of the number of possible 
molecular findings associated with any categorization of patients. Unless each 
molecular diagnosis is modeled separately, which is not practical for sample size 
reasons, patient groupings will necessarily combine individuals with different genetic 
etiology. Heterogeneity presents challenges for modelling costs over a longer time 
horizon than the inpatient stay because each distinct molecular diagnosis will have 
different prognostic and treatment trajectories. As such, costs and outcomes are 
only modelled over the time horizon of the index admission and for one year. This 
allows time for ES to have an impact on care provision and costs, even if results are 
not returned before discharge from the index admission. As the cost of ES 
decreases, modelling over a shorter time horizon is more acceptable. Also, from a 
payer perspective, the shorter time horizon is more relevant than lifetime cost of care 
projections and may be more informative for coverage determination. 
 
 
Human Subjects Research: Ethical Considerations 
This study involves data that includes protected health information that was 
collected with patient identifiers. However, because it is a retrospective EMR review 
study, the only risk to the patient is the possibility of loss of confidentiality. All Excel 
spreadsheets were password encrypted, and data were stored on Box, the secure 
online cloud storage and file management service preferred by Baylor College of 
Medicine. There are potential benefits to future patients based on the findings of this 
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study, as results may influence patient access to cGS through informing the 
development of clinical and payer policy. The Baylor College of Medicine Institutional 
Review Board approved this research. A protocol was submitted for expedited 
review by The University of Texas Health Science Center (UTHSC) Committee for 
Protection of Human Subjects and approved.  
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ABSTRACT 
Purpose: Availability of clinical genomic sequencing (CGS) has generated 
questions about the value of whole genome and exome sequencing as a diagnostic 
tool. Analysis of reported CGS application can inform uptake and direct further 
research. This scoping literature review aims to synthesize evidence on the clinical 
and economic impact of CGS.  
Methods: PubMed, Embase, and Cochrane were searched for peer-reviewed 
articles published between 2009 and 2017 on diagnostic CGS for infant and 
pediatric patients. Articles were classified according to sample size and whether 
economic evaluation was a primary research objective. Data on patient 
characteristics, clinical setting, and outcomes were extracted and narratively 
synthesized.  
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Results: Of 171 included articles, 131 were case reports, 40 were aggregate 
analyses, and 4 had a primary economic evaluation aim. Diagnostic yield was the 
only consistently reported outcome. Median diagnostic yield in aggregate analyses 
was 33.2% but varied by broad clinical categories and test type.  
Conclusion: Reported CGS use has rapidly increased and spans diverse clinical 
settings and patient phenotypes. Economic evaluations support the cost-saving 
potential of diagnostic CGS. Multidisciplinary implementation research, including 
more robust outcome measurement and economic evaluations, are needed to 
demonstrate clinical utility and cost-effectiveness of CGS. 
 
Introduction 
Genome-scale next-generation sequencing (NGS) is increasingly applied in 
clinical settings as a diagnostic tool, indicative of the arrival of an era of medicine 
with the capacity to provide patient care guided by genetic makeup.1 Clinical 
genomic sequencing (CGS), which includes whole genome sequencing (WGS) and 
whole exome sequencing (WES), is unique in the realm of diagnostic tests for two 
primary reasons. First, results of a single test can both establish a molecular 
diagnosis and inform tailored medical management (i.e., precision medicine) where 
applicable. Second, the clinical utility of CGS increases with additional application. 
Uptake influences diagnostic effectiveness because as more patients are 
sequenced, detected variants are published in case reports and deposited into 
public databases, which increases the number of known disease genes and in turn 
impacts future diagnostic performance of the test. 
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The interplay of these two qualities is important as genetic research is 
translated into genomic medicine. Since WES became commercially available as a 
clinical test in 2011, uptake has been sufficient to generate real world evidence on 
the ability of CGS to provide a molecular diagnosis and impact patient care. 
Implementation research is suited to explore the context-dependent and dynamic 
nature of such evidence.2 In an analytical framework of technology translation, 
synthesis and analysis of reported findings from initial use in the clinic can inform 
evidence-based practice guidelines and future clinical application.3 Both case 
reports and larger-scale studies of institutional implementation are informative at the 
current stage of evaluation. Case reports demonstrate the breadth of clinical areas in 
which CGS has been successfully applied. Studies of larger numbers of patients 
provide aggregate data on diagnostic yield for different forms of the test (e.g., trio 
versus proband-only, rapid versus non-rapid), and patient subgroups according to 
phenotype or clinical setting.  
Diagnostic potential of CGS has been seen as particularly powerful for infant 
and pediatric patients because determination of molecular etiology early in life may 
enable more timely and specific intervention with a better chance of improving 
outcomes.4,5 Infants who are challenging to diagnose by other modalities because of 
incomplete, atypical, or blended phenotypes stand to benefit from the multiplex 
nature of CGS because it does not rely on clinical suspicion of the particular gene 
implicated. Avoidance of sequential single gene or gene panel testing can save time, 
which is valuable because time to diagnosis can impact the availability or 
effectiveness of clinical intervention.6  
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Establishment of clinical utility of CGS is a primary concern for clinical 
implementation and the interdependent development of health care payer policy. 
Careful evaluations of CGS utilization can inform optimal integration of genome-wide 
sequencing into diagnostic testing algorithms – where and how to best incorporate 
CGS into the diagnostic workup for which patients. This involves determining how 
CGS fits into the landscape of diagnostic decision-making that includes choices 
between forms of genetic investigation, including targeted genetic tests such as 
single gene and gene panel tests, complementary tests such as microarrays and 
copy number analysis, and CGS,7 which may be performed in addition to or in place 
of other non-genetic investigations. Although sequencing has typically been 
recommended for patients with nonspecific clinical features that may be associated 
with numerous underlying causes (even those which are not yet well established),7,8 
it may be possible to more precisely define types of patients who are the best 
candidates. Development of such guidelines requires assessment of patients’ clinical 
characteristics and effects of CGS on medical management to determine the types 
of patients most likely to benefit from CGS and its appropriate position in the 
sequence of diagnostics. 
Value assessment is an important component consistent with precision 
medicine’s goal of choosing the right diagnostic test for the right patient at the right 
time, especially as costly new diagnostics become available.9,10 Effectiveness data 
generated through clinical application studies are required for translational research 
and are an essential input in economic evaluations to determine the value of the 
test.3,11 While numerous methodological challenges exist for economic evaluations 
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of genomic sequencing tests,12 measurement of patient health outcomes is perhaps 
the largest. Difficulty of outcome measurement is not unique to CGS. It exists across 
all genetic medicine applications, including targeted and disease-specific genetic 
tests, and contributes to the lack of robust economic evidence on these 
applications.13 While diagnostic yield is an important outcome, it is only intermediate 
measure. More complete assessment of clinical utility would include measures of 
patients’ ultimate health outcome following clinical care provided in light of CGS 
results.14,15 Determination of CGS’s value for any specific clinically-defined group of 
patients is further complicated by to statistical uncertainty about outcomes (including 
diagnostic yield) due to small sample sizes, which can obstruct economic model 
development.16  
An understanding of how CGS has been applied in practice, its effects on 
physician decision-making and clinical care, and how outcomes have been reported 
is a necessary precursor to full economic evaluation. Technical and cost aspects of 
NGS compared to the gold standard dideoxy method have been explored.17 In 
contrast, evidence on patient outcomes following CGS application has not yet been 
systematically summarized, which this review seeks to address. 
The aim of this scoping review is to provide an overview of published peer-
reviewed articles on the application of CGS for diagnostic purposes in infant and 
pediatric patients. The research questions are: (1) what does the literature say about 
how diagnostic genome-scale sequencing has been applied in clinical settings for 
infant and pediatric patients; (2) how have results of these applications been 
reported; and (3) what was the clinical or economic impact? From studies that report 
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aggregate-level analyses, information on institutional features, patient population, 
reported outcome categories, and impact on those outcomes is summarized. From 
case reports, disease areas and the genetic spectrum in which diagnostic CGS has 
been applied are synthesized. For studies that aim to estimate the economic impact 
of CGS, key findings are outlined and the quality of economic evidence reporting is 
assessed. This review provides an overview of the landscape of CGS since 2009, 
when proof-of-concept for diagnostic WES was shown.18,19  
 
Materials and Methods 
Methods 
Scoping reviews are intended to provide an overview of the nature of 
literature on a topic via structured searches and identify gaps in knowledge. Fewer 
restrictions for inclusion are placed on patient population, intervention, outcome, and 
study design than in systematic reviews. This review was conducted according to 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines,20 adapted for use in a scoping review as appropriate. CGS is defined to 
include WGS and WES. Sequencing may have been performed for the proband (i.e., 
patient) only or alongside parents or other family members (duo or trio), in a non-
rapid or a rapid manner with reduced turnaround time. Sequencing was considered 
clinical rather than research for the purpose of this review if the report’s stated goal 
was to make a diagnosis or otherwise impact medical management of the patient(s). 
In contrast, if the objective was gene discovery or disease mechanism elucidation, 
the sequencing was considered research.  
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A search strategy was designed with the assistance of a librarian from the 
Texas Medical Center library. PubMed, Embase, and Cochrane Library were 
searched. The PubMed search included the following Medical Subject Headings 
(MeSH) terms: Genome; Exome; Sequence Analysis, DNA; Adolescent; Child; 
Infant; Diagnostic Techniques and Procedures; Clinical Decision-Making; Diagnosis, 
Differential. Items identified through database searches were imported into the web 
application Rayyan (Doha, Qatar) for title and abstract screening.21 Full search 
strategies are available online as Supplementary Materials and Methods. Two 
independent reviewers (HSS and SC) screened the title and abstract of each record, 
and conflicts were resolved through consensus. Citations selected for full-text review 
were imported into EndNote (Clarivate Analytics, Boston, Massachusetts), and full-
text articles were obtained. A full-text review form was completed for each article to 
determine whether inclusion/exclusion criteria were met. One author (HSS) reviewed 
each full-text article, and a second reviewer (SC) reviewed a randomly selected 10% 
of the full-text articles. 
Articles that met the following pre-determined criteria were included: (1) peer-
reviewed original research article; (2) published between January 2009 and June 
2017 (with an updated search performed in November 2017); (3) proband (if a case 
report) or the majority of probands (if more than 5 probands in study) less than 19 
years of age at the time of sequencing; (4) described/evaluated the clinical 
application of a CGS for diagnostic purposes. Studies of patients who had a clinical 
diagnosis of a condition with known genetic heterogeneity, and thereby not 
determined to have a “specific” diagnosis, were included. Studies of patients 
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enrolled in a research protocol performing CGS for a clinical purpose were included 
regardless of how costs of sequencing were covered, as the aim of sequencing was 
considered more important than the funding arrangement. No restrictions were 
placed on study design; clinical reports (individual cases and case series), 
intervention studies (any methodology), and economic evaluations (any 
methodology) were included. 
Publications with a primary aim of genetic research were excluded as were 
publications on population-based screening, tumor genotyping, mitochondrial 
genome sequencing only (without the nuclear genome), pharmacogenetic testing, 
disease carrier testing, prenatal genetic testing, and targeted exome sequencing 
(e.g., “clinical exome” or “Mendeliome”) panels of thousands genes known to be 
associated with single-gene disorders. While targeted exomes may be considered 
more similar to a whole exome than targeted panel, multiple permutations of such 
tests exist. Because there is inconsistency in covered genes, publications on 
targeted tests were excluded for comparability of results and feasibility of this review. 
Reports on patients who were sequenced post-mortem and those that indicated the 
initiation of sequencing but not results were also excluded.  
Because this scoping review included articles that employed multiple 
methodologies and studied diverse patient populations, results across studies were 
summarized and narratively described rather than combined statistically in a meta-
analysis. Descriptive statistics were calculated on the number of articles on each 
type of CGS, characteristics of patients and institutions, clinical scenarios, and 
reported outcome measures. Discussion of costs and economic evidence was also 
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summarized. The Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) checklist was used to assess the quality of reporting in articles with an 
economic evaluation focus.22 Two authors (HSS and HVR) assessed each article 
independently and arrived at a consensus score. 
 
Data Collection Process 
We developed and pilot tested a data extraction form, and then created two 
refined versions based on the two types of analyses and reporting encountered. For 
the purpose of collecting and presenting results in this review, studies of 5 or fewer 
patients were considered “case reports” and studies of more than five patients were 
considered “aggregate analyses.” The cutoff number of five was determined based 
on differences in article structure and information presentation according to the 
number of patients included. Thus, the data collection form used for each type of 
study reflected the way in which facts were reported.  
Data items selected for abstraction from articles were broadly based on 
parameters recommended for assessment in evaluation of genetic tests.23 The data 
collection form for aggregate analyses included the following items: study objective, 
country, type of CGS, comparator, clinical setting, study design, outcome measures, 
study population, inclusion criteria, exclusion criteria, average age at test, percent of 
probands younger than 19 years of age, percent of probands who were male, 
diagnostic laboratory, sequencing platform, whether a duo and/or trio approach was 
used, turnaround time, molecular diagnostic yield, number of probands with a 
change in medical management, discussion of insurance coverage, discussion of 
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costs or cost-effectiveness, and average cost to diagnosis or cost of potentially 
replaced tests. For case reports, the above information was collected on the 
individual level as well as the gene implicated and diagnosis. For economic studies, 
the perspective of the analysis, cost data source, and incremental cost per outcome 
measure were recorded. One author (HSS) abstracted data from all included studies 
into a spreadsheet. Analysis was performed with Stata IC 13 (College Station, 
Texas). 
 
Results 
Study Selection 
The study selection process is summarized as a PRISMA flow diagram in 
Figure 1. Database searches and a hand search yielded 3,039 records after 
duplicates were removed. After review of abstracts, 359 records were selected for 
full-text review. Following full-text review and resolution of discrepancies by 
consensus, 135 articles were included and 224 articles were excluded. The inter-
rater reliability was high (Cohen’s kappa = 0.81) for the 10% of articles receiving a 
full-text review by two investigators, suggesting good agreement on 
inclusion/exclusion decisions and unbiased selection of articles for inclusion in this 
review. The search was updated in November 2017, and an additional 36 articles 
were included. 
Study Characteristics 
Of the 171 total included articles, 131 (76%) were case reports19,24-153 and 40 
(24%) were aggregate analyses.5,6,154-191 Four studies had a primary objective of 
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economic evaluation and also reported primary effectiveness data.153,189-191 The 
number of included articles increased by publication year. One article each year was 
included from 2009-2011, 2 from 2012, 7 from 2013, 24 from 2014, 29 from 2015, 48 
from 2016, and 58 from 2017. Most studies were conducted in the USA (71) and the 
European Union (28), followed by Japan (14), Canada (12), China (7), Australia (6) 
and Korea (5). The first author (or co-first author) listed had a clinical or commercial 
genetics affiliation for 97 (57%) of articles. Out of 24 items on the CHEERS checklist 
recommended for reporting, the economic evaluation articles reported 7, 14, 18, and 
17 items.  
 
Syntheses of Results 
WES was used in 93% (159/171) of articles, WGS in 6% (10/171), and a 
combination of WES and WGS in 1% (2/171). Of the 98 studies that reported the 
sequencing platform used, 88% (86/98) were Illumina, 6% (6/98) were Life 
Technologies, and 3% (3/98) were Thermo Fisher. The majority (22/40) of aggregate 
analyses reported sequence analysis of proband-parent trios for at least some 
cases, 5 of which also reported a duo of the proband and mother (or another first-
degree relative) in some cases. Turnaround time from test order to result return was 
reported in 25% (10/40) of aggregate analyses and only 2 case reports. The 
commercial lab(s) in which sequence analysis was performed was stated in 19 
aggregate analyses and 24 case reports, while 16 aggregate analyses and 87 case 
reports stated that analysis was performed in-house (some of which were College of 
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American Pathologists-accredited and Clinical Laboratory Improvement 
Amendments-certified environments).  
The 40 aggregate analyses included an average of 225 patients (median = 
79; range: 6 – 2,000). Results from the 37 aggregate analyses that did not have a 
primary aim of economic analysis are summarized in Table 1. Clinical setting and 
patient population varied widely. Clinical settings included genetics referral centers 
and hospital specialty clinics (Genetics, Neurology, Epilepsy, Developmental, 
Dermatology, Mitochondrial Disorders, Hemophilia Treatment), pediatrics 
departments, and intensive care units. The most common setting was 
Genetics/Individualized Medicine/Developmental Clinic (12 articles), followed by 
non-specific children’s hospital/university medical center clinic (9 articles) and 
Pediatric Neurology/Epilepsy/Intellectual Disability Clinic (6 articles). Clinical 
laboratory (4 articles) and neonatal/pediatric intensive care unit (3 articles) were also 
reported settings. Most large sample studies (33/37) were retrospective medical 
record reviews to form a case series (12 of which were sequential) of patients that 
met specific inclusion criteria for CGS to be performed. All studies that used data 
from diagnostic laboratories reported information for consecutively obtained 
samples.  
Phenotypic characteristics were used to delineate the types of patients 
included in each study. All patients lacked a molecular diagnosis at the time CGS 
was performed by virtue of the inclusion criteria for this review. Phenotype 
categories were either determined by the study authors, such as organ system 
affected, severity of disease, or broad phenotypic class (18 articles), or according to 
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human phenotype ontology (HPO) terms (5 articles). Although the specific category 
definition varied by study, neurologic phenotypes including intellectual disability 
(ID)/developmental delay (DD) were a commonly reported phenotypic group (22/37 
articles). Diagnostic yield for neurologic phenotypes is presented in Table S1.  
Each aggregate analysis reported diagnostic yield, and it was the only 
consistently reported outcome measure. Where defined, diagnostic criteria were 
consistent with American College of Medical Genetics and Genomics (ACMG) 
guidelines.192 Patients were considered diagnosed if pathogenic or likely pathogenic 
variant was detected in a disease gene related to phenotype. Diagnostic yield varied 
by patient population and type of test. Trio sequencing had a higher yield than 
proband-only when the two were compared (Table 1). Overall diagnostic yield 
ranged from 8.4 – 100%, with a median of 33.2%. Other than 3 studies that reported 
100% yield, the highest yield was 68.3%.178 Beyond diagnostic yield, other health 
outcome measures of the downstream effect of sequencing on medical management 
were listed5,6,165,173-175,178,180,182 or presented in a table154,159,172 in 30% of large 
sample studies. Of the 12 studies that measured them, 8 studies5,6,172-175,178,182 
provided a definition of outcomes, including providing specific examples of the types 
of care changes included in each category. 
Aggregate analyses typically included a summary and discussion of 
molecular findings, and study authors chose clinically interesting examples to 
highlight. By nature of the report type, molecular findings dominated the discussion 
of outcomes in case reports. Table S2 presents implicated genes and the associated 
diagnoses made in case study patients. Among the case studies, 68% (89/131) 
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reported a diagnostic finding, 19% (25/131) reported a variant considered by the 
authors to be the most likely candidate for the patient’s clinical presentation, and 9% 
(11/131) reported a finding that prompted candidate gene association studies. Non-
diagnostic findings accompanied by a description of the clinical presentation were 
reported in 5% (6/131) of case studies. An expansion of the genetic spectrum or 
clinical phenotype associated with a particular condition was reported in 45% 
(59/131) case studies. 
Overall, 46% (78/171) of articles discussed implications of CGS results on the 
medical management of patients. Impact on clinical care was more frequently 
discussed in aggregate analyses (53%, 21/40) than in case reports (44%, 57/131). 
Likewise, a discussion of economic impact of CGS on the diagnostic workup was 
more frequently included in larger studies (70%, 28/40) than case reports (15%, 
19/131).  
 Even among the 37 aggregate analyses that did not have a primary objective 
of economic evaluation, 23 referred to the economic impact of CGS on the 
diagnostic workup. Several articles specifically stated the need for economic 
evaluation of such testing (5 articles),5,6,161,174,185 highlighted that CGS may shorten 
the time and cost involved in the diagnostic odyssey or sequential single gene 
testing (6 articles),5,156,159,162,168,170 or provided an illustrative example or summary 
statistics on the number or cost of negative diagnostic tests performed prior to CGS 
(10 articles)156,162,165,168,171,172,175,182,183,185 which could have been averted if CGS had 
been utilized as a first-line test. Table S3 summarizes findings from articles that 
included quantitative results related to economic impact of CGS but that did not have 
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a primary economic evaluation objective. Only 5 of 37 studies included a comparison 
group, which was standard diagnostic investigation.6,162,174,175,183 Insurance coverage 
of CGS was discussed in 8 large studies and 2 case reports. No formal health state, 
quality of life, utility values, or specific instruments to measure such outcomes were 
reported. 
Results from economic evaluation studies are presented in Table 2. Each 
analyzed single-study effectiveness data reported in the same publication. In 
general, the results suggest that WES can be cost-saving when performed as a first-
tier diagnostic test and thus replace serial performance of single gene, gene panel, 
and other tests. The incremental cost-effectiveness ratio may be considered within 
acceptable limits even if CGS is employed at later points in the diagnostic trajectory. 
For example, one prospective analysis in which standard diagnostics were 
performed in parallel with WES found that first-tier WES was associated with an 
incremental cost savings of US $1,702 per additional diagnosis, and when WES was 
performed after standard diagnostics, the incremental cost per additional diagnosis 
was US $6,327.190 Another study estimated incremental savings of US $6,840 per 
diagnosis when WES was performed at the initial tertiary clinical visit and 
incremental cost of US $4,371 when WES was used after standard diagnostic 
investigations.191 These results underline the role of timing and number of other non-
diagnostic investigations performed in whether incremental diagnoses via WES lead 
to savings or come at an additional cost. 
 
 
 
 
 
 
109 
Discussion 
In this examination of the published reports of CGS in the pediatric clinical 
setting, authors of included studies convey enthusiasm about the availability of 
sequencing technology in the clinic and its potential value as a diagnostic tool. 
Investigators highlight instances of success in particularly meaningful or puzzling 
clinical cases. Overall, the results show diagnostic CGS’s broad application across 
clinical settings, increased uptake since commercial availability as measured by the 
number of publications each year, and high success rates for identification of 
molecular cause of disease (Table 1). Proliferation of publications appears to reflect 
diffusion of this diagnostic technology across geographic areas and clinical 
specialties. Findings of economic evaluations suggest that the multiplex nature of 
CGS is important for generating value because CGS is capable of replacing other 
diagnostic tools. However, even if other non-diagnostic investigations are performed 
prior to CGS, the cost to diagnose an additional patient may still look favorable to 
decision makers. 
Reviewed publications are predominantly retrospective case reports or series 
across diverse clinical presentations. Among aggregate analyses, 85% employed a 
retrospective design. Reports to date can largely be classified as descriptive, 
although quantitative analysis has improved with time and sample size. While there 
is work to be done to improve the analytical rigor of analyses, particularly in terms of 
outcome measurement and economic evaluation, this is to be expected in the 
assessment of a test with paradigm-shifting diagnostic capability. Best practices 
should be established for measurement and reporting of outcomes subsequent to 
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sequencing. Standardization would allow more robust analyses to demonstrate 
clinical utility and cost-effectiveness of CGS. This review suggests multiple 
candidate categories of outcomes that could be quantified. For example, it may be 
possible to measure major procedures, imaging studies, or pharmacological 
intervention averted or initiated as a consequence of GCS results. A framework of 
standardized category definitions, including specification of procedures and imaging 
studies considered, and means by which changes are assessed would benefit future 
research.  
Diagnostic yield is the most commonly reported outcome and also the most 
feasible and straightforward to capture. Results across studies suggest that patient-
parent trio sequencing has a higher diagnostic yield than sequencing the proband 
only (Table 1). Investigators have begun to look at the downstream consequences 
on patient care; however, categories of clinical impact are not consistently defined or 
measured. Reported medical management outcomes fall into the following broadly 
defined categories: surveillance and testing, change in prognosis/impression, 
subspecialty consult, time to diagnosis, pharmacological intervention, procedure 
change, imaging change, diet change, palliative care initiation, facility transfer, 
clinical trial education, family planning, familial genetic testing initiation, genetic 
counseling, end of diagnostic workup, psychological, and personal/social. Specific 
wording of outcome categories was not consistent across studies, and details on 
how assessments were made were rarely provided. Lack of standardization makes 
comparison across articles difficult. The discussion of care impact in reviewed 
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articles largely centered on a selected few illustrative cases detailed by study 
authors. 
Follow-up time presents another impediment to outcome measurement. It 
may not be feasible to ascertain all effects of CGS within the study timeframe. The 
follow-up period in reported studies was not sufficient to measure potential impacts 
over the course of the patient’s lifetime such as access to school and social 
programs, disease surveillance, or reproductive decision-making of the proband. 
Widespread effects of CGS may extend many years after sequencing and to multiple 
members of the proband’s family. 
The retrospective nature of the majority of evaluations may introduce 
selection bias due to preferential reporting and patient inclusion criteria. For each 
article included in this review, results are specific to the particular clinical population 
studied. The majority of aggregate analyses employed specific inclusion criteria, 
sometimes determined by a clinical approval process for CGS specified by the 
institution. For example, patients may have been required to have already 
undergone a negative diagnostic workup or meet broadly defined clinical criteria, 
such as ID/DD, in order to be eligible for CGS. If clinicians selectively include 
patients whom they have determined CGS would be most likely to yield a diagnosis, 
the patient sample will not reflect the general patient population. However, the 
findings will reflect clinical practice and interpretation of results in light of the 
inclusion criteria may be informative for clinical or institutional policy-making. 
There is a risk of publication bias across studies, particularly for case reports 
and small case series. It is more likely that instances in which CGS was successful 
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in determining a diagnosis for the patient will be published in a case report. 
Nevertheless, looking across the clinical spectrum where CGS has been 
successfully applied can indicate the scope of sequencing as a diagnostic tool. It is 
possible that some patients reported in case studies may also be included in the 
cohort of patients reported by the treating institution, where both types of 
publications exist.  
Absence of uniformity in outcome categories and measurement across 
studies may lead to ascertainment bias, or systematic error based on how a 
particular researcher defines and records a change in medical management. 
Similarly, inconsistent methods for costs measurement and medical record data 
abstraction may impact results of studies that assess costs or the number of 
previous diagnostic tests performed for each patient. Degree of transparent reporting 
on cost collection and handling can reveal potential sources of bias, such as how 
missing data, statistical uncertainty, and currency conversion and indexing were 
handled. One indicator of this is the quality of reporting as measured by number of 
items on CHEERS checklist described in the text, which are intended to inform 
readers about important aspects of how the analysis was conducted. For studies 
that include an economic analysis, the level of reporting of economic evidence was 
low, as approximately half of recommended items on the CHEERS checklist were 
reported on average. Inconsistency impedes comparison across published studies 
and makes it difficult to draw conclusions. For example, the percentage of patients 
for whom CGS results affected medical management cannot be directly compared 
across studies because it depends upon the types of clinical changes considered 
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and reported in each specific article. At the outcome level, this review is limited by 
differences in how medical management change is defined by the authors of each 
study. 
Authors of reviewed studies note that the cost-effectiveness of CGS deserves 
further and more rigorous study and that economic evaluations are an important 
component of translation to the clinic (Table S3). Discussion of insurance coverage 
or economics may not have been considered relevant by authors if sequencing was 
performed under a research protocol. Very few studies have performed a thorough 
assessment of costs in more than a few example patients. More robust economic 
evaluation of CGS is needed to quantify the cost effectiveness of testing and to 
guide reimbursement policy. Of the 4 articles with a primary economic evaluation 
aim, each limited the cost comparison to the diagnostic odyssey. This may be 
because outcomes are not clearly defined or because asking what it costs to 
determine a diagnosis is the most appropriate question at the moment. However, 
there are numerous cost-related questions that should be explored in future 
research, such as the cost consequences of earlier diagnosis that may lead to 
earlier intervention or the decision to not perform medical interventions. 
Database searches for this review were limited to PubMed, Embase, and 
Cochrane. It is possible that additional publications exist outside this search. 
However, it would be unlikely that relevant studies would not be indexed, and hand 
searches of other resources supplemented the database searches. This review is 
limited to articles published in the English language. Inconsistent terminology is a 
hindrance to systematic searching. WES applied as a clinical diagnostic tool is 
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sometimes abbreviated clinical exome sequencing (CES) or diagnostic exome 
sequencing (DES). However, CES is also used to refer to targeted exome 
sequencing of known disease genes, rather than the entire exome. It was necessary 
to read details of how the analysis was performed to determine whether it covered 
the whole exome or only a portion. Additionally, the terms “proband-only” and 
“singleton” are used interchangeably to refer to sequencing only the patient, and 
tests with expedited turnaround time are referred to as both “rapid” and “critical.”  
 
Conclusions 
 This review is the first to compile evidence on clinical utility of diagnostic CGS 
for infant and pediatric patients. CGS uptake, as measured by the number of 
published reports, has substantially and steadily increased since its commercial 
debut in 2011. It has been applied in a diverse array of clinical settings and 
demonstrated ability to determine the molecular basis of disease, even in patients 
who had previously undergone numerous negative diagnostic investigations. 
Information on diagnostic yield alone may not be ideal to determine the value 
of WGS and WES as diagnostic tools. However, downstream outcomes were not 
consistently defined or reported. While commonly reported information on molecular 
findings, mode of inheritance, and zygosity are informative for medical geneticists, 
they do not capture key aspects of CGS relevant for implementation analysis and 
development of clinical guidelines. Reflecting the dearth of outcomes information, 
economic analyses have used diagnostic yield as the final health outcome. Lack of 
standardized outcomes is an obstacle for evaluation of CGS from a health services 
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research perspective, including determination of cost-effectiveness. Challenges for 
generating compelling real world evidence of CGS include determination of best 
practices for defining, measuring, and reporting patient health outcomes subsequent 
to sequencing. Future studies should aim to reach consensus among experts 
regarding which outcomes are important and best practices for measurement and 
reporting. Focus groups or other forms of structured deliberation among 
stakeholders are potential means to advance this discussion. 
As CGS moves toward standard-of-care, more robust evidence of clinical 
utility and economic and implementation research on CGS are needed. Consistency 
in outcome assessment is essential for economic analysis input and as part of the 
technology translation feedback loop. The power of CGS as a diagnostic tool derives 
from – and must be evaluated within – a dynamic environment that involves both 
basic science and application in the clinic. 
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Tables and Figures 
Figure 1. Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) flow diagram of study 
selection 
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Table 1. Summary of Large Sample Studies 
First Author (Year), 
Country 
Type of 
CGS Study Population 
Overall Diagnostic Yield (%); Sub-analysis by test type 
or comparator yield (%) 
Change in 
Mgmt (%)a 
Bick D (2017), USA154 WGS Suspected Mendelian disorder 3/22 (14); After reanalysis, 8/22 (36) 6/8 (75) 
Bowling KM (2017), 
USA155 
WES, 
WGS DD and/or ID 
100/371 (27); Trio: 90/309 (29), Duo: 8/42 (19), 
Proband: 3/20 (15)  
Farwell KD (2015), 
USA156 WES 
Consecutive samples sent to 
diagnostic lab 152/500 (30); Trio: 82/220 (37), Proband: 14/68 (21)  
Gauthier-Vasserot A 
(2017), France157 WES 
Syndromic congenital neutropenia 
with ID 4/10 (40)  
Helbig KL (2016), 
USA158 WES 
Consecutive samples sent to 
diagnostic lab 322/1131 (28)b   
Iglesias A (2014), 
USA159 WES 
Consecutive patients in genetics 
center 37/115 (32) 24/37 (65)b 
Lazaridis KN (2016), 
USA160 WES Diagnostic odyssey 15/51 (29)  
Lee H (2014), USA161 WES 
Consecutive patients referred to 
clinical lab 213/814 (26); Trio: 127/410 (31), Proband: 74/338 (22)  
Lionel AC (2017), WGS Suspected genetic etiology 42/103 (41); Conventional genetic testing: 25/103 (24)  
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Canada162 
Meng L (2017), USA5 WES 
Critically ill; suspected monogenetic 
disorder 
102/278 (37); Critical Trio: 32/63 (51), Trio: 13/39 (33), 
Proband: 57/176 (32) 53/102 (52) 
Nambot S (2017), 
France163 WES Consecutive CA and ID patients 
128/416 (31) over 3 years with 2 re-analyses; yield per 
year ranged 22 – 27% 9/128 (7) 
Need AC (2012), 
USA164 WES ID/DD, CA, or facial dysmorphisms 6/12 (50)  
Nolan D (2015), USA165 WES Neurology clinic  24/50 (48) 8/24 (33)b 
Ream MA (2014), 
USA166 WES  Drug-resistant epilepsy 1/6 (17) 0/6 (0) 
Romasko EJ (2017), 
USA167 WES 
Suspected inherited platelet 
disorder 5/21 (24) 1/5 (20) 
Rump P (2016), 
Netherlands168 WES ID and microcephaly 11/38 (29)  
Sawyer SL (2015), 
Canada169 WES Diagnostic odyssey 105/362 (29) families 
6/105 (6) 
families 
Shamriz O (2017), 
Israel170 WES Malignant infantile osteopetrosis 6/6 (100) 2/6 (33) 
Shashi V (2016), WES Outpatient pediatric genetics clinic  24/93 (26)c  
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USA171 
Soden SE (2014), 
USA172 
WES,  
rapid 
WGS Neurodevelopmental disorders 
53/119 (45) patients, 45/100 (45) families; NICU/PICU: 
11/15 (73) families by rapid WGS; Ambulatory: 34/85 
(40) families by WES (1 by WGS after negative WES) 
22/49 
families 
(45) 
Srivastava S (2014), 
USA173 WES Neurodevelopmental disorders 32/78 (41) 32/32 (100) 
Stark Z (2016), 
Australia174 WES Suspected monogenetic disorder 46/80 (58); Standard diagnostics: 11/80 (14) 15/46 (33) 
Stavropoulos DJ 
(2016), Canada175 WGS 
Referred for CMA by clinical 
geneticists 
34/100 (34) by WGS; CMA + targeted gene 
sequencing: 13/100 (13), CMA alone: 8/100 (8) 32/34 (94) 
Takeichi T (2013), 
Kuwait176 WES 
Pediatric dermatology genetics 
clinic 7/7 (100) 7/7 (100) 
Tammimies K (2015), 
Canada177 WES Developmental pediatrics clinics 8/95 (8); CMA: 24/258 (9)  
Tarailo-Graovac M 
(2016), Canada178 WES 
Potential ID with metabolic 
phenotype 28/41 (68) 18/41 (44) 
Taylor RW (2014), 
UK179 WES Suspected mitochondrial disease 28/53 (53) 0/28 (0) 
Thevenon J (2016), WES ID and/or epileptic encephalopathy 14/43 (33); Familial: 6/9 (67) 2/14 (14) 
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France180 
Trujillano D (2017), 
Germany181 WES Suspected Mendelian disorder 307/1000 (31)  
Valencia CA (2015), 
USA182 WES Diagnostic odyssey 12/40 (30) 12/12 (100) 
Vissers LE (2017), 
Netherlands183 WES 
Non-acute; neurological symptoms 
with suspected genetic etiology 44/150 (29); Standard diagnostics: 11/150 (7)  
Willig LK (2015), USA6 
Rapid 
WGS 
Critically ill; suspected monogenetic 
disorder 20/35 (57); Standard genetic testing: 3/32 (9) 13/20 (65) 
Wortmann SB (2015), 
Netherlands184 WES Suspected mitochondrial disease 
42/109 (39); MD gene "virtual panel": 21/42 (50), 
outside gene panel (WES): 28/42 (67)  
Yang Y (2013), USA185 WES 
Consecutive samples sent to 
diagnostic lab 62/250 (25)  
Yang Y (2014), USA186 WES 
Consecutive samples sent to 
diagnostic lab 504/2000 (25)  
Yavarna T (2015), 
Qatar187 WES Suspected Mendelian disease 89/149 (60)  
Zhang J (2016), 
Australia188 WES 
Hematological disorders with 
suspected genetic etiology 6/6 (100)  
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CGS, clinical genomic sequencing; WES, whole exome sequencing; WGS, whole genome sequencing; CMA, chromosomal microarray; ID, 
intellectual disability; DD, developmental delay; CA, congenital anomaly 
a Change in medical management overall (any change considered by the study’s authors). bAuthor’s calculation based on presented data. 
cAccording to diagnostic laboratory; clinician interpretation of definite or likely diagnosis in 22/93 (24) patients. 
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Table 2. Summary of Findings in Economic Evaluation Articles 
First Author (Year) 
Country/Perspective 
Type of 
economic 
evaluation; 
Type of CGS; 
Comparator 
Clinical 
Setting; 
Sample size 
Cost of Potentially Replaced Tests / 
Incremental cost per additional Dx by 
CGSa 
Joshi (2016)153 
USA / Hospital (not 
stated) 
Descriptive; Trio 
WES; Standard 
diagnostics 
Epilepsy 
center; n=4 
(including 2 
siblings) 
Total charges for standard diagnostics 
range $9,015 – $35,483; charge for trio 
WES $6,100 / Not Calculated 
Monroe (2016)189 
Netherlands / 
Hospital system 
Scenario 
analysis; Trio 
WES; Standard 
diagnostics 
Specialty 
center for 
intellectual 
disability;  
n=17 
Average diagnostic odyssey 6.6 years; 
average cost of traditional diagnostic 
pathway: $16,409. For patients who 
receive Dx, WES to replace genetic tests 
would save $4,986 and to replace 
metabolic tests would save $2,553, on 
average. For patients who did not receive 
Dx, WES to replace genetic tests would 
save $5,669 on average. / Not Calculated 
Stark (2017)190 
Australia / Hospital 
system 
CEA; Proband 
WES; Standard 
diagnostics 
NICU, PICU, 
other 
inpatient, and 
outpatient; 
n=40 
Avg. cost per Dx, traditional diagnostics: 
$21,099, WES: $3,937 / WES as a first-tier 
diagnostic test: savings of $1,702; WES to 
replace some diagnostic tests: $2,045; 
WES after all other diagnostic tests: 
$6,327 
Tan (2017)191 CEA; Proband Ambulatory Avg. diagnostic odyssey 6 years, 19 tests, 
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Australia / Health 
care system (not 
stated) 
WES; Standard 
diagnostics 
outpatient 
clinics; n=44 
cost of $7,509. Cost per patient of WES at 
initial Genetics appointment $3,933. / 
WES at initial tertiary clinical presentation: 
savings of $6,840; WES at initial Genetics 
consult: savings of $4,143; WES after 
standard diagnostics: $4,371 
CGS, clinical genomic sequencing; Dx, diagnosis; WES, whole exome sequencing; CEA, cost-
effectiveness analysis; NICU, neonatal intensive care unit; PICU, pediatric intensive care unit. aAll 
costs reported in USD. 
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Supplementary Appendices 
 
Supplementary Tables 
Table S1. Neurologic Phenotype Diagnostic Yield 
First Author (Year) Neurologic phenotype diagnostic yield (%)a 
Bowling KM (2017) Intellectual disability: 93/344 (27) b 
Farwell KD (2015) Neurologic organ system involvement: 99/324 (31) 
Helbig KL (2016) Epilepsy: 105/314 (33); Non-epilepsy: 212/817 (26) 
Iglesias A (2014) 
Autism, developmental delay/intellectual disability, 
neurological/neurodegenerative disorder, and seizures: 11/49 (22) b 
Lee H (2014) 
Global developmental delay in children < 5 years, trio: 45/109 (41); 
proband-only: 2/23 (9) 
Lionel AC (2017) Referred from Neurology clinic: 3/3 (100)  
Meng L (2017) Abnormality of the nervous system: 42/100 (42) 
Nambot S (2017) 
Congenital anomaly and intellectual disability: 128/416 (31) over 3 years 
with 2 re-analyses; yield per year ranged 22 – 27% 
Nolan D (2015) Neurodevelopmental symptoms: 21/53 (40) 
Sawyer SL (2015) Neurodevelopmental phenotype: 31/98 (32) 
Soden SE (2014) Neurodevelopmental disorders: 53/119 (45) children, 45/100 (45) families 
Srivastava S (2014) Neurodevelopmental disorders: 32/78 (41) 
Stark Z (2016) Neurometabolic disorder: 14/19 (74) 
Stavropoulos DJ (2016) Developmental delay: 22/57 (39) 
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Table S1. Neurologic Phenotype Diagnostic Yield 
First Author (Year) Neurologic phenotype diagnostic yield (%)a 
Tarailo-Graovac M 
(2016) Intellectual developmental disorder and metabolic phenotype: 28/41 (68) 
Thevenon J (2016) 
Intellectual disability and/or epileptic encephalopathy: 14/43 (33); Familial: 
6/9 (67) 
Trujillano D (2017) Abnormality of the nervous system 229/771 (30) 
Vissers (2017) 
Intellectual disability 78/150 (52); ID with epilepsy or ID with movement 
disorder 39/150 (26) 
Willig LK (2015) Neurological anomaly 4/7 (57) 
Yang Y (2013) 
Nonspecific neurologic disorder 20/60 (33); Specific neurologic disorder 
4/13 (31); non-neurologic 7/37 (19) 
Yang Y (2014) 
Neurological 143/526 (27.2); Neurological plus other organ systems 
282/1147 (25); Specific neurological 30/83 (36); non-neurological 49/244 
(20) 
a Neurologic diagnostic yield calculated as number of diagnostic cases out of total number of cases 
with the phenotype 
b Author’s calculation based on presented data 
 
Table S2. Genes and Associated Diagnoses Reported in Case Studies 
Year First Author Gene(s) Diagnosis 
2017 Aintablian HK ACAD9 
Acyl-CoA Dehydrogenase Family Member 9 (ACAD9) 
deficiency 
2017 Andreoletti G AMMECR1 Not stated 
2015 Arboleda VA KAT6A None 
2017 Ardicli D CD59 Inherited CD59 deficiency 
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Table S2. Genes and Associated Diagnoses Reported in Case Studies 
Year First Author Gene(s) Diagnosis 
2012 Bacino, CA WDR35 Sensenbrenner syndrome 
2017 Baertling F VARS2 Valyl-TRNA Synthetase 2 (VARS2) deficiency 
2017 
Balasubramaniam 
S MTP-ATP6 None 
2014 Balboa-Beltran E VEGFC Milroy-like disease 
2014 Bayer DK IL7R IL-7Rα deficient SCID 
2017 Bloom JL SLC29A3 H syndrome 
2017 Bochner R 
ABCA12, 
CAPN12 Likely explanation of clinical phenotype 
2017 Boczek NJ FAM58A STAR syndrome 
2016 Brion M TAZ Barth syndrome 
2017 Bruel AL MAB21L1 Likely explanation of clinical phenotype 
2016 Çağlayan AO FTO, CETP None 
2017 Çağlayan AO ALPK3 
ALPK3-associated dilated cardiomyopathy (DCM) that 
progressed to hypertrophic cardiomyopathy (HCM); Likely 
explanation of clinical phenotype 
2014 Chen M SBF2 
Charcot-Marie-Tooth disease type 4B2 with early onset 
glaucoma 
2017 Chen Q MMACHC Cobalamin C (cb1C) deficiency 
2015 Chetta M SMPD1 Niemann-Pick Type A 
2016 Chiplunkar S SLC33A1 Huppke-Brendel syndrome 
2016 Chiu ATG HRAS Costello syndrome 
2009 Choi M SLC26A3 Congenital chloride diarrhea 
2017 Choi R CPS1 Carbonyl-Phosphate Synthase 1 (CPS1) deficiency 
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Table S2. Genes and Associated Diagnoses Reported in Case Studies 
Year First Author Gene(s) Diagnosis 
2015 Choi R PMM2 Congenital disorder of glycosylation type Ia (CDG-Ia) 
2017 Coe RR CBL 
CBL syndrome, or Noonan syndrome-like disorder with or 
without juvenile myelomonocytic leukemia 
2014 Das AS RAPSN Congenital myasthenic syndrome 
2016 Demari J CLTC Likely explanation of clinical phenotype 
2013 Dhamija R SCN2A Likely explanation of clinical phenotype 
2013 Dinwiddie DL IL10RA Very early onset inflammatory bowel disease (VEO-IBD) 
2016 Dionisi-Vici C GPD1 Glycerol-3-phosphate dehydrogenase 1 (GPD1) deficiency 
2014 Dyment DA ASAH1 SMA-PME 
2016 Edvardson S ACER3 
Alkaline ceramidase deficiency (potentially a form of 
leukodystrophy) 
2017 Eskandrani A AFG3L2 Not stated 
2017 Fadus MC None None 
2014 Fraser JL TPK TPK deficiency (Leigh-like encephalopathy) 
2015 Gallagher JL CD40L X-linked hyper IgM syndrome (XHIGM) 
2015 Garg N AKT2 MORFAN syndrome with hypoinsulinemic hypoglycemia 
2017 Gerald B GNAO1 
Early infantile epileptic encephalopathy (EIEE); Likely 
explanation of clinical phenotype 
2015 Goldstein JHR SMC1A Cornelia de Lange syndrome (CdLS) 
2016 Goodwin G 
GATA3, 
STS 
Hypoparathyroidism and hearing loss (HDR syndrome) and 
X-linked ichthyosis 
2016 Guella I FGF12 Early-onset epileptic encephalopathy (EOEE) 
2017 Haberman Y SI Congenital sucrase-isomaltase deficiency (CSID) 
2015 Harel T RNF213 Moyamoya disease 
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Table S2. Genes and Associated Diagnoses Reported in Case Studies 
Year First Author Gene(s) Diagnosis 
2017 Hasosah MY NBAS Infantile liver failure syndrome type 2 (ILFS type 2) 
2017 He X WASP Wiskott-Aldrich syndrome 
2017 Hegde AU BRAT1 BRAT1-associated epileptic encephalopathy 
2017 Hildreth A NPC1 Niemann-Pick disease type C 
2016 Hirabayashi S MED17 Likely explanation of clinical phenotype 
2016 Holzerova E TXN2 
Thioredoxin 2 (TXN2) deficiency; Likely explanation of 
clinical phenotype 
2017 Ichimura T 
RPL11, 
RPS19, 
RPS7 Diamond-Blackfan anemia (DBA) 
2017 Ikeda T TBCD 
Atypical spinal muscular atrophy (SMA) with progressive 
cerebral atrophy; Likely explanation of clinical phenotype 
2016 Inui T EEF1A2 
Epileptic encephalopathy with EEF1A2 mutation; Likely 
explanation of clinical phenotype 
2017 Jehee FS TCF4 Pitt-Hopkins syndrome 
2016 Jezela-Stanek A 
PGAP2; 
PIGN 
Inherited glycosylphosphatidylinositol (GPI)-anchor 
deficiency (IGD); Likely explanation of clinical phenotype 
2017 Johannsen J MTM1 X-linked centronuclear myopathy (CNMX) 
2016 Joshi C PIGA 
Phosphatidyl inositol glycan biosynthesis class A protein 
(PIGA) deficiency 
2016 Kansal R MLH3 None 
2013 Keller MD MTHFD1 Severe combined immunodeficiency (SCID) 
2016 Kettwig M PGAP1 
Glycosylphosphatidylinositol (GPI) anchor-related 
intellectual disability; Likely explanation of clinical 
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Table S2. Genes and Associated Diagnoses Reported in Case Studies 
Year First Author Gene(s) Diagnosis 
phenotype 
2015 Khromykh A HSD17B4 D-bifunctional protein deficiency 
2017 Kimizu T SLC35A2 
Early-onset epileptic encephalopathy (EOEE) related to 
uridine diphosphate (UDP)-galactose deficiency 
2015 Kohrogi K SLC19A3 Biotin-responsive basal ganglia disease 
2015 Kuloglu Z PEPD Prolidase deficiency (PD) 
2016 Kvarnung M FLVCR2 Fowler syndrome 
2016 Lange L HNRNPK 
Kabuki-like syndrome; Likely explanation of clinical 
phenotype 
2015 Law CY GNAO1 Infantile-onset epilepsy 
2017 Leduc MS HNRNPU 
HNRNPU-related disorder; Likely explanation of clinical 
phenotype 
2016 Lee JJY SIGMAR1 
SIGMAR1 deficiency; Likely explanation of clinical 
phenotype 
2015 Lee JS ATRX 
Alpha-thalassemia X-linked intellectual disability (ATRX) 
syndrome 
2016 Lee JS ST3GAL5 GM3 synthase deficiency 
2016 Li N CYP11B2 Aldosterone synthase deficiency (ASD) 
2014 Lim BC DKC1 Hoyeraal-Hreidarsson syndrome 
2017 Lines MA VAC14 Yunis-Varon syndrome (YVS) 
2014 Makrythanasis P FGFR3 None 
2016 Miyamichi D HPS6 Hermansky-Pudlak syndrome type 6 
2016 Mohammad S PPP1R15B PPP1R15B deficiency 
2015 Mroske C MTOR MTOR-related megalencephaly and cognitive impairment; 
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Table S2. Genes and Associated Diagnoses Reported in Case Studies 
Year First Author Gene(s) Diagnosis 
Likely explanation of clinical phenotype 
2017 Murray CR 
DYRK1A; 
KARS; 
KAT6A 
Developmental and cognitive delay; Likely explanation of 
clinical phenotype 
2017 Nafisinia M GARS Mitochondrial respiratory chain dysfunction 
2017 Nakamura Y SZT2 Early-onset epileptic encephalopathy 
2016 Naseer MI STAMBP Microcephaly-capillary malformation syndrome 
2014 Ohashi T SCN1A SCN1A-associated epileptic encephalopathy 
2017 Ozkinay F CENPF Stromme syndrome 
2017 Palagano E FERMT3 
FERMT3-associated malignant osteopetrosis; Likely 
explanation of clinical phenotype 
2015 Per H ABCA1 Tangier disease (TD) 
2017 Peragallo JH AARS2 
Alanyl-TRNA synthetase 2 (AARS2)-related disease; Likely 
explanation of clinical phenotype 
2016 
Piekutowska-
Abramczuk D ADAR Aicardi-Goutieres syndrome type 6 (ASG6) 
2011 Pierson TM AFG3L2 AFG3L2-related spastic ataxia 
2016 Pinto AM CHD2 CDH2-related neurodevelopmental disorder 
2014 Pizzino A TUBB4A TUBB4A-related hypomyelination 
2016 Popp B GABRA1 
Early onset epilepsy; Likely explanation of clinical 
phenotype 
2017 Porntaveetus T 
FGFR3; 
ALPL Hypochondroplasia (HCH) and hypophosphatasia (HPP) 
2017 Powis Z RBM10 TARP syndrome 
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Table S2. Genes and Associated Diagnoses Reported in Case Studies 
Year First Author Gene(s) Diagnosis 
2014 Priest JR KCNH2 Long QT syndrome (LQTS) 
2015 Prontera P IGF1R SHORT syndrome type 2 
2015 Punwani D MALT1 
Infantile combined immunodeficiency caused by MALT1 
deficiency 
2014 Purnell SM TUBB4A Hereditary dystonia type 4 (DYT4) 
2016 Ramakrishnan KA MTHFD1 MTHFD1 deficiency 
2017 Renkema GH PET117 Mitochondrial complex IV deficiency 
2014 Reuter MS  HIBCH 3-hyforxyisobutyryl-CoA hydrolase (HIBCH) deficiency 
2010 Rios J ABCG5 Sitosterolemia 
2016 Sangsin A COL2A1 Spondyloepiphyseal dysplasia congenita (SEDC) 
2016 Santra S PCK1 Phosphoenolpyruvate carboxykinase (PEPCK) deficiency 
2016 Seidahmed MZ ASNS Asparagine synthase deficiency (ASNSD) 
2014 Shimojima K TUBA1A Malfunction of cortical development (MCD) 
2015 Shiota M NRAS 
NRAS-related RAS-associated leukoproliferative disease 
(RALD) 
2017 Stanik J HNF4A Congenital hyperinsulinism (CHI) 
2015 Stiles AR HIBCH 3-Hydroxyisobutryl-CoA hydrolase (HIBCH) deficiency 
2017 Subramanian VS SLC5A6 
Human sodium-dependent multivitamin transporter 
(hSMVT) deficiency 
2017 Takeda R GORAB Geroderma osteodysplastica (GO) 
2015 Tamura S LIG4 DNA ligase 4 (LIG4) syndrome 
2015 Thiffault I POLE1 POLE1-deficiency 
2016 Topa A SBDS Shwachman–Diamond–Bodian syndrome (SDS) 
2017 Tosur M SLC16A1 Congenital hyperinsulinism; Likely explanation of clinical 
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Table S2. Genes and Associated Diagnoses Reported in Case Studies 
Year First Author Gene(s) Diagnosis 
phenotype 
2017 Tsabari R MYH2 
Myosin heavy chain 2 (MYH2) deficiency; Likely 
explanation of clinical phenotype 
2014 Vanderver A KCNT1 KCN1-related epilepsy 
2016 Vanstone JR DNM1L DNM1L-related disease 
2016 Varma H POLG2 POLG2-associated mtDNA depletion syndrome 
2017 Villeneuve N FHF1 FHF1-related early onset epileptic encephalopathy 
2016 Wang X RAF1 
RAF1-associated hypertrophic cardiomyopathy (HCM) 
without Noonan or LEOPARD syndrome 
2016 Wasserman H INS1 Antibody-negative diabetes 
2013 Wassner AJ PROP1 PROP1 deficiency; Likely explanation of clinical phenotype 
2015 Wentworth K GNAS Likely explanation of clinical phenotype 
2017 Wilbur C ATP1A2 
Alternating hemiplegia of childhood (AHC); Likely 
explanation of clinical phenotype 
2016 Williams HJ PRX Dejerine-Sottas syndrome 
2014 Xia F AHCD1 Likely explanation of clinical phenotype 
2017 Yamamoto T ASNS Asparagine synthetase (ASNS) deficiency 
2013 Yourshaw M PCSK1 Prohormone convertase 1/3 (PC1/3) deficiency 
2014 Yu HC KAT6B 
Blepharophimosis-ptosis-epicanthus inversus syndrome 
(BPES) 
2017 Zrhidri A SH3PXD2B Frank-Ter Haar syndrome (FTHS) 
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Table S3. Economic Impact Calculations from Large Sample Studies 
First Author 
(Year) 
Country Discussion of Economics Cost of Potentially Replaced Tests 
Lazaridis KN 
(2016) 
USA 
Average cost of WES 
service $8,000 
Of 43 patients who had other genetic tests prior to 
WES, 11 (26%) received diagnosis by WES, at an 
incremental cost per diagnosis of $27,000 (assuming 
WES cost $7,000) 
Lionel AC 
(2017) 
Canada 
Number and cost of 
negative genetic tests prior 
to WGS 
In 103 total patients, median of 3 conventional genetic 
tests; median of 19 genes sequenced; CMA in 44 
patients; WES in 9 patients; median cost of 
conventional genetic testing $5,173 (range $585 – 
$18,361) 
Need AC 
(2012) 
USA 
Cost and reimbursement 
concerns are a barrier to 
translation of WES to clinic 
One patient had $22,000 in lab tests prior to diagnosis 
by WES 
Nolan D 
(2015) 
USA 
Calculate the charge for 
prior non-diagnostic tests 
For patients who had WES, average charge for prior 
non-diagnostic single gene and gene panels was 
$2,465.62  
Rump P 
(2016) 
Netherlands 
WES may be more cost-
effective than sequential 
single gene testing 
Average of 2.8 genetic tests (range 0 – 9) performed 
per family prior to WES 
Shashi V 
(2016) 
USA 
Concerns about cost and 
insurance coverage can be 
a barrier to uptake in the 
clinic 
All 93 patients had undergone diagnostic testing (range 
1 – 28 tests) prior to WES  
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Table S3. Economic Impact Calculations from Large Sample Studies 
First Author 
(Year) 
Country Discussion of Economics Cost of Potentially Replaced Tests 
Soden SE 
(2014) 
USA 
Estimate the cost-
effectiveness of WES/rapid 
WGS, as determined by 
calculating the total cost of 
prior negative diagnostic 
tests for patients diagnosed 
by WES or rapid WGS 
For ambulatory care patients, average total charge per 
family for prior diagnostic testing was $19,100 (range 
$3,248 - $55,321) for average of 13.3 (range 4 – 36) 
tests; for NICU/PICU patients, average total charge per 
family for prior testing was $9,550 (range $3,873 – 
$14,605) for average of 7 (range 1 – 15) tests. Estimate 
that WES for ambulatory patients would be "cost-
effective," i.e., lower than the cost of non-diagnostic 
prior tests, at a cost of $7,640 per family. 
Stavropoulos 
DJ (2016) 
Canada 
Calculate cost of prior non-
diagnostic genetic tests for 
illustrative cases 
Average of 3 genetic tests (CMA and two targeted 
genetic tests) per patient in parallel with WGS; example 
cases had 3 – 6 tests with a range in total cost of 
$3,325 – $5,280 
Valencia CA 
(2015) 
USA 
Calculate cost of genetic 
testing prior to WES 
19/40 (48%) of patients had at least 4 genetic tests 
prior to WES, leading authors to conclude “the cost of 
genetic testing before WES is significant." 
Vissers LE 
(2017) 
Netherlands 
Assessment of WES to 
replace conventional 
diagnostic tests 
For patients with diagnostic WES, average cost of 
diagnosis DKK 4,349 (assuming all other genetic tests 
and standard investigations averted); for patients with 
non-diagnostic WES, costs would be DKK 10,035 
(assuming all other genetic tests averted) 
Yang Y Need future studies of cost- For one patient, total charges for prior non-diagnostic 
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Table S3. Economic Impact Calculations from Large Sample Studies 
First Author 
(Year) 
Country Discussion of Economics Cost of Potentially Replaced Tests 
(2013) 
USA 
effectiveness genetic testing were 3 times the current cost of WES 
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Genet A. 2014;164(4):950-957. 
170. Zhang J, Barbaro P, Guo Y, et al. Utility of next-generation sequencing 
technologies for the efficient genetic resolution of haematological disorders. Clin 
Genet. 2016;89(2):163-172. 
171. Zrhidri A, Jaouad IC, Lyahyai J, et al. Identification of two novel SH3PXD2B 
gene mutations in Frank-Ter Haar syndrome by exome sequencing: case report and 
review of the literature. Gene. 2017;628:190-193. 
 
 
Complete Database Search Strategies 
PubMed Search: 
((((((((((("in patient"[ot] OR "clinic"[ot] OR "clinics"[ot] OR "clinical setting"[ot] OR 
office[ot] OR hospital[ot] OR hospitals[ot] OR "NICU"[ot] OR "PICU"[ot])) OR ("in 
patient"[tiab] OR "clinic"[tiab] OR "clinics"[tiab] OR "clinical setting"[tiab] OR 
office[tiab] OR hospital[tiab] OR hospitals[tiab] OR "NICU"[tiab] OR "PICU"[tiab])) 
OR ("Hospitals"[Mesh] OR "Hospital Units"[Mesh] OR "Physicians' 
Offices"[Mesh]))))) AND (((((((genom*[ot] OR exome[ot] OR "gene panel"[ot] OR 
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"next generation sequencing"[ot])) OR ((genom*[tiab] OR exome[tiab] OR "gene 
panel"[tiab] OR "next generation sequencing"[tiab]))) OR ("Genome"[Mesh:NoExp] 
OR "Exome"[Mesh] OR "Genome, Mitochondrial"[Mesh] OR "Sequence Analysis, 
RNA"[Mesh] OR "Sequence Analysis, DNA"[Mesh]))) AND ((("Sequence 
Analysis"[Mesh]) OR (sequence[tiab] OR sequencing[tiab])) OR (sequence[ot] OR 
sequencing[ot])))))) AND (((((neonate[ot] OR neonates[ot] OR child[ot] OR 
children[ot] OR adolescent[ot] OR adolescents[ot])) OR (neonate[tiab] OR 
neonates[tiab] OR child[tiab] OR children[tiab] OR adolescent[tiab] OR 
adolescents[tiab])) OR ("Adolescent"[Mesh] OR "Child"[Mesh] OR 
"Infant"[Mesh])))))) AND ((((("Diagnostic Techniques and Procedures"[Mesh] OR 
"Clinical Decision-Making"[Mesh] OR "Diagnosis, Differential"[Mesh])) OR 
(diagnosis[tiab] OR diagnostic[tiab] "clinical decision"[tiab] OR "clinical decision"[tiab] 
OR "medical management"[tiab])) OR ("diagnosis"[ot] OR "diagnostic"[ot] OR 
"clinical decision"[ot] OR "clinical decision"[ot] OR "medical management"[ot]))) 
 
Embase Search:  
('genome'/exp/mj or 'exome'/exp/mj or 'whole exome sequence'/exp/mj or 'whole 
genome sequence'/exp/mj or 'genome':ab,ti or 'exome':ab,ti or 'whole genome 
sequence':ab,ti or 'whole exome sequence':ab,ti or 'next generation 
sequencing'/exp/mj) and ('clinical'/exp/mj or 'diagnosis'/exp/mj or 'diagnostic'/exp/mj 
or 'differential diagnosis'/exp/mj or 'clinical':ab,ti or 'diagnosis':ab,ti or 
'diagnostic':ab,ti) and ('newborn'/exp or 'infant'/exp or 'pediatric'/exp or 'newborn 
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intensive care'/exp or 'neonatal intensive care unit'/exp or 'pediatric intensive care 
unit'/exp or 'newborn':ab,ti or 'infant':ab,ti or 'adolescent':ab,ti) 
 
Cochrane Search:  
#1 [mh genome] 
#2 [mh exome] 
#3 “next generation sequencing” 
#4 whole genome sequencing 
#5 whole exome sequencing 
#6 gene panel* 
#7 #1 or #2 or #3 or #5 or #6 
#8 clinic 
#9 “diagnosis” 
#10 “diagnostic” 
#11 #8 or #9 or #10 
#12 “newborn” 
#13 “neonatal” 
#14 “pediatric” 
#15 #12 or #13 or #14 
#7 and #11 and #15  
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Exome Sequencing for Critically Ill Infants Compared to Standard Diagnostics: 
A Retrospective Analysis of Clinically Matched Cohorts 
 
Target Journal: Genetics in Medicine 
 
Abstract  
Purpose: To estimate the effectiveness of clinical exome sequencing (ES) for 
patients with a suspected genetic etiology admitted to intensive care within the first 
year of life.  
Methods: We analyze ES application at a large children’s hospital over 5 years 
using electronic medical record data. We examine uptake of ES forms among 
attending Geneticists. We compare outcomes between cohorts of clinically similar, 
critically ill newborns and infants with a suspected genetic etiology who had ES 
(n=368) and diagnostic workup without ES (n=368). Main outcomes are 
establishment of molecular diagnosis and survival over a one-year time horizon.  
Results: We found variability in ES ordering practice at the provider level. Molecular 
diagnostic yield (25.8% No-ES, 27.7% ES; p=0.56) and 1-year survival (84.8% No-
ES, 80.2% E; p=0.10) were similar for patients who had ES and patients who had 
standard-of-care diagnostic investigations other than ES.  
Conclusion: As clinically applied, ES is an important diagnostic tool, as are 
chromosomal microarray and targeted genetic testing, for diagnosing patients with a 
severe clinical presentation within the first year of life. Further work to define utility of 
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ES testing not captured by diagnostic yield is warranted to develop clinical 
guidelines for the appropriate application of ES. 
 
Introduction  
Clinical genomic sequencing (cGS) has increased capacity to make robust 
molecular diagnoses of genetic disorders, even those difficult or impossible to 
clinically diagnose.1,2 Exome sequencing (ES) has demonstrated ability to diagnose 
critically ill newborns and infants influence medical management, especially when 
results are returned in an expedited fashion.1-6 Robust evidence of ES clinical utility 
to aid clinical guideline development, however, is currently sparse but is an active 
area of investigation.7-9 Very little is known about the impact of ES compared to 
standard diagnostics in real-world clinical practice. 
Evaluation of patients with suspected genetic disorders is important to pediatric 
and neonatology practice due to incidence of genetic diseases that manifest at birth 
or soon after. A leading cause of mortality in infancy, genetic disorders afflict more 
than one quarter of patients admitted to a level IV neonatal intensive care unit 
(NICU) who die before age 5.10,11 Both chromosomal abnormalities and single-gene 
disorders contribute to this disease burden.12,13 Diagnostic workup for a suspected 
genetic condition is associated with longer NICU stay,11 and diagnoses of genetic-
based diseases are associated with longer, more costly pediatric inpatient stays.14,15 
Most prior studies of ES have been conducted within a research framework, with 
inclusion criteria such as clinician review and prior negative diagnostic testing, more 
appropriate to establish efficacy of ES to identify an accurate diagnosis, rather than 
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effectiveness. Moreover, most studies do not include a comparison group of patients 
who did not have ES,7 which prevents conclusions about relative effectiveness in a 
population. 
Identification of an appropriate patient population and measurement of outcomes 
are both key challenges for generating evidence of cGS effectiveness.8,16-18 
Selection of a comparator group of patients is necessary to quantify ES impact 
relative to usual care yet difficult in retrospective analyses and in prospective trials 
involving critically ill children for whom withholding of sequencing may generate 
ethical concerns.19  
Outcome measurement is uniquely challenging in evaluations of cGS. Because 
ES analyzes changes at a genome-wide scale, it is capable of diagnosing nearly any 
of the more than 5,000 different single-gene disorders with a known molecular 
basis,20 meaning there is no one natural history of disease which can be modeled. 
Further, there is no standardized position of ES in the diagnostic pathway, as the 
workup for a suspected genetic disorder is largely left to the discretion of clinical 
geneticists caring for a particular patient. Diagnostic yield has therefore most widely 
used as a summary measure of outcome,7 as many downstream clinical outcomes 
vary at the disease-level. Because many diseases diagnosed by ES are very rare 
individually, disease-specific outcomes are sparse.  
We aim to evaluate the impact of ES on outcomes compared to standard 
diagnostics, including other genetic tests, for critically ill newborns and infants with 
suspected genetic disease. We study uptake and use of ES over more than 5 years 
at a large children’s hospital, reflective of effectiveness as clinically applied. We 
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employ a historical cohort design to enable comparisons between clinically and 
phenotypically similar patients who did and did not have ES as part of a diagnostic 
workup in the first retrospective, comparative analysis of ES in a large patient 
population. In this paper, we (1) describe a population of infants in intensive care 
who had a suspected genetic etiology and underwent diagnostic testing; (2) describe 
uptake of ES in its various test forms; (3) examine health outcomes, including 
molecular diagnostic yield and survival, in critically ill patients who did and did not 
have ES in the first year of life.  
 
Patients and Methods 
 We analyzed ES application at a large children’s hospital during the initial 
uptake period of December 2011 through June 30, 2017. The study population is 
patients with a suspected genetic etiology who had an intensive care unit admission 
within the first year of life. Patients were admitted to Texas Children’s Hospital (TCH) 
in Houston, TX, a large children’s hospital with 33,000 total admissions in 2017 and 
the highest level of neonatal intensive care (Level IV).21 Documentation of an 
inpatient consult from the Genetics service indicated that the patient was suspected 
to have a genetic etiology. All TCH ES orders were sent to Baylor Genetics (BG) 
diagnostic laboratory. Electronic medical record (EMR) review was completed in 
August 2018 such that there is a minimum of one year of clinical follow-up data on 
all patients. Data analysis was performed using Stata 15 (StataCorp, College 
Station, TX). 
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Identification of Eligible Patients  
We employ a retrospective cohort study design with ES as the exposure 
factor. Two patient cohorts were defined; patients who had ES as part of a 
diagnostic workup (ES cohort) were matched, based on clinical characteristics and 
phenotypic presentation, to patients who did not (No-ES cohort).  
Two datasets were combined to define the patient population. The first 
dataset, obtained from the hospital, contained medical record numbers (MRNs) of all 
patients at TCH who (1) had an intensive care unit inpatient admission within the first 
year of life, and (2) had an order for inpatient consultation from the Genetics service. 
The second dataset, obtained from the diagnostic laboratory, contained ES report 
data for all patients who had ES (1) ordered from TCH, and (2) an ES order date 
less than 366 days from date of birth. Datasets were merged on MRN. Patients 
appearing in both datasets were preliminarily designated as the ES cohort; patients 
appearing only in the hospital data were preliminarily designated as the No-ES 
cohort.  
 EMR review was then performed for all patients. We define the index 
admission as the admission during which the initial genetics consult was ordered. A 
consult order and a note from a member of the genetics service constituted 
consultation. Data on admission characteristics, demographics, phenotypic 
presentation, clinical outcomes, ES order and result return, and ES uptake by 
attending clinician was collected from index admission administrative notes and 
genetics consult and follow-up notes. Ethnicity was recorded as listed in the EMR 
demographics tab; if unlisted or if information in the demographics tab was 
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contradictory information to the genetics note, ethnicity was recorded as listed in 
genetics note, which contained detailed information on family history and country of 
origin. 
Patients had one of 3 forms of ES: sequence analysis of only the patient 
(proband), a trio of patient and both parents (trio), or trio of patient and parents with 
expedited turnaround time (critical trio). Clinical ES became available in October 
2011 in proband form. The trio test was introduced in October 2014 and critical trio 
in April 2015. Details of the matching procedure used to select No-ES cohort 
patients are given in Supplementary Materials and Methods. 
   
Measurement and Comparison of Outcomes 
ES uptake and health outcomes were systematically assessed through EMR 
review. Because a key assumption in our identification strategy is that clinically 
similar patients may have had ES or not based on variability in ordering practice at 
the provider-level, we analyzed the pattern of uptake among different attending 
Geneticists as different forms of ES (i.e., proband, trio, rapid trio) became available. 
We extracted the names of signers (trainees) and cosigners (faculty) of the initial 
Genetics consult note and the Genetics consult note during which ES was ordered. 
Establishment of a molecular diagnosis and survival were the primary 
outcomes of interest. Molecular diagnosis was defined as the identification of a 
specific genetic change, via analysis of chromosomes (karyotype, chromosomal 
microarray, FISH), sequencing of a single gene or a panel of multiple genes, 
deletion/duplication analysis, or methylation studies, interpreted as the cause or 
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probable cause of the patient’s clinical presentation. All results of molecular 
diagnostic tests ordered in the year following the date of the initial Genetics consult 
were reviewed, and interpretation of findings was verified in clinical notes. ES cases 
reported by the laboratory as solved and probably solved were considered 
diagnosed. For ES patients, other changes in medical management were also tallied 
through analysis of the clinical note at the time of ES return of results and follow-up 
in the Genetics clinic. A comprehensive list of diagnostic-related investigations 
performed for each patient over the year following the initial Genetics consult order 
date was obtained from the hospital.  
We calculated descriptive statistics on demographics of patients and 
characteristics of the index admission. We produced Kaplan-Meier survival curves to 
analyze survival time, including survival to 28 days, 1 year, and end of study. We 
used Cox regression models to analyze survival times and logistic regression 
models to analyze odds of molecular diagnosis. 
 
Results 
A total of 368 patients who had ES comprised the ES cohort, and the 368 
patients who comprised the No-ES cohort were selected via the matching process 
from among 936 patients meeting study criteria who did not have ES (Figure 1). 
Patients represented a diverse population with home addresses in 361 unique zip 
codes from across the US. 
Patient characteristics were well balanced between cohorts after matching 
(Table 1). More patients were male, Non-Hispanic, and white. Although race, 
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ethnicity, preferred language, gestational age at birth, and parental age at birth were 
not included in the propensity score, they are balanced between cohorts with no 
significant differences in any of these characteristics. The majority of patients were 
in the NICU during the initial Genetics consultation, most of which took place within 
the first quarter of a year of life.  
Characteristics of the index admission are presented in Table 2. Most patients 
were admitted from transfer centers, but admission and Genetics consultation took 
place soon after birth, a median of 11 and 13 days of life for the No-ES cohort and 
ES cohort, respectively. Length of stay was longer and distributed differently for ES 
patients than no-ES patients (Figure 2).  
 
Exome Sequencing Cohort 
Form of ES was proband for 227 (61.7%) patients, trio for 54 (14.7%) 
patients, and critical trio for 87 patients (23.6%) (Table S2). Median turnaround time 
was 13 days for critical trio ES and 87 days for the non-rapid versions (95 days for 
proband and 50 days for trio). Critical trio ES was recommended and ordered sooner 
after admission (median 9 days) than orders for trio and proband ES (median 25 
days, p<0.01).  
In addition to clinical acuity, availability of biological parents to submit a DNA 
sample was a factor in form of ES order. Two parents submitted DNA samples in 
271 cases (73.6%), one parent in 46 (12.5%), and no parents in 51 (13.86%). In 16 
cases (4.3%), the lab received parental samples after the initial ES report and issued 
an addendum that included interpretation in light of parental sample information. For 
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the 203 tests performed after critical trio was available, proband still accounted for 
31.0% (63/203) of all tests and was ordered in 16.2% (27/167) of cases with a DNA 
sample able to be obtained from two parents. 
ES was ordered at the initial Genetics consult for 205 patients (55.7%), a 
follow-up Genetics consult during the index admission for 115 (31.3%) patients, 
during a subsequent inpatient admission for 25 (6.8%) patients, and during a 
subsequent outpatient clinic visit for 23 (6.3%) patients. Among ES orders entered 
during the index admission, orders were placed median 24 days before discharge, 
which is shorter than the median turnaround time for non-rapid tests.  
ES resulted before discharge from the index admission for 106 (28.8%) 
patients. A higher proportion of patients who had critical trio were diagnosed before 
discharge (24.1%) than patients who had proband or trio tests (5.7%, p<0.01). 
After 6 months of uptake (June 2012), mean 6 ES tests of any form were 
ordered per month over the study period (Figure S1). Proband ES orders averaged 4 
per month prior to availability of trio forms, after which the average total number of 
tests ordered per month increased to 7, driven by uptake of trio and critical trio forms 
(p<0.001) as proband orders decreased to 3 per month. There were 19 attending 
geneticists who rotated on service and authored consult notes over the study period. 
Total consults, ES order consults, and molecular diagnostic yield by attending 
geneticist are presented in Figure S2, and ES orders by attending geneticist and 
form are presented in Figure S3. 
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Molecular Diagnostic Yield 
Overall, 205 (27.9%) of patients received a molecular diagnosis (Table 3). 
There was no difference in molecular diagnostic yield between the cohorts. A 
genetic change determined to be causal or probably causal of the patient’s clinical 
condition was identified in 95 (25.8%) No-ES cohort patients by genetic tests other 
than ES and 102 (27.7%) ES cohort patients by ES. In addition, 8 patients in the ES 
cohort were diagnosed by chromosomal microarray (CMA) which are not included in 
the ES diagnostic yield calculation. Genetic diagnoses and diagnostic tools with 
which they were identified in the No-ES cohort and ES cohort is given in Table S4 
and Table S5, respectively. There was no difference in outcomes within the ES 
cohort between patients who had different forms of ES (Table S6.) In addition to 
diagnostic yield, we assessed changes in management in the ES cohort in the 
following categories: subspecialty referral, medication change, screening 
recommendation, diet change, redirection of care to comfort care, and surveillance 
recommendation (Table S7). A Geneticist recommended at least one management 
change in light of ES results for 81 patients, 49 diagnosed and 32 undiagnosed by 
ES. In undiagnosed patients, subspecialist referrals and screening 
recommendations accounted for most management changes, as inconclusive ES 
results may not definitively rule out the need for clinical monitoring.  
Molecular diagnosis odds ratios are presented in Table 4. Overall, Hispanic 
patients had significantly lower odds of receiving a diagnosis, compared to Non-
Hispanic patients, holding other factors constant (model 1, p=0.002). In the ES 
cohort, Hispanic patients had half the odds of diagnosis of Non-Hispanic patients 
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(model 4, p=0.007). The odds of diagnosis for patients in the progressive care unit 
were approximately 3 times that of patients in the NICU (model 1, p=0.004). Patients 
who were referred for admission by a physician had 2.5 times odds of diagnosis for 
inborn patients (model 1, p=0.009). ES-by-admission year interaction effect was not 
significant and not included in the final model. 
 
Survival 
A total of 50 (6.79%) patients expired before 28 days of life, 129 (17.53%) 
before 365 days of life, and 166 (22.55%) before the end of the study period. Among 
patients who expired, patients in the No-ES cohort expired sooner after birth than ES 
cohort patients. Table 3 shows 28-day survival of 91.6% of patients in the No-ES 
cohort and 94.8% in the ES cohort. One-year survival was 84.8% in the No-ES 
cohort and 80.2% in the ES cohort. At the end of the study period, 80.4% of patients 
in the No-ES cohort were alive, whereas 74.5% of patients in the ES cohort were 
alive. 
Although there was no difference in age of death between cohorts (Table 3), 
the pattern of survival shows that a larger proportion of the patients who expired 
before 28 days of life were in the No-ES cohort, while the proportion that expired at 
later time points was greater in the ES cohort, which is illustrated by the converging 
survival curves for the ES and No-ES cohorts (Figure 3). Convergence of the 
survival curves indicates violation of the proportional hazards assumption and 
prevents statistical comparison of the cohorts’ survival distributions with the log-rank 
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test. However, inspection of the Kaplan-Meier curve suggests no meaningful 
difference between the curves.  
Survival analysis results from Cox regression models are presented in Table 
5. When hazard ratios are calculated within hospital unit, the proportional hazards 
assumption is satisfied (Table 5, models 4-6). Figure 4 shows Kaplan-Meier survival 
curves for all patients by unit. Patients who received a diagnosis had 58% higher 
hazard of death than undiagnosed patients (Table 5, model 4, p=0.007). Within the 
ES cohort, the hazard for diagnosed patients was 92% higher (model 6, p=0.004). 
Figure 5 shows survival curves by cohort and diagnosis category, with lowest 28-day 
survival in diagnosed No-ES patients and lowest 1-year survival in diagnosed ES 
patients. Older age at the initial Genetics consultation was associated with a 
significantly lower hazard rate (Table 5). 
 
Discussion 
We estimate the effect of ES for newborns and infants with suspected genetic 
disease. This is the first analysis, to our knowledge, to compare a group of patients 
who had ES to phenotypically matched controls in order to do so, and the sample 
size and comparator group are strengths of the study. Retrospective matching 
enables us to study the large number of patients who had ES over more than 5 
years while also identifying clinically similar patients who received standard-of-care 
diagnostic workup in order to compare outcomes. Although propensity score 
matching has been previously suggested as a way to address difficulties in 
identification of an appropriate comparator group for ES evaluations,22 we are the 
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first to apply this approach to identify counterfactual patients and estimate ES effect. 
Matching on phenotype instead of ultimate diagnosis is advantageous from both a 
clinical decision-making and study design perspective. The clinical decision point 
regarding ES order is prior to establishment of a diagnosis, not after, and decisions 
about diagnostic investigations are based upon the patient’s clinical presentation. 
Moreover, rarity of most conditions diagnosed by ES limits the possible sample size 
of cases matched on diagnosis.  
We find evidence of diagnostic utility of genetic testing overall in newborns 
and infants with suspected genetic disease, with a molecular etiology identified in 
27.9% of patients. We find no difference in diagnostic yield between the cohort of 
patients who had ES and the cohort of patients who had a standard genetic workup 
not including ES. These results suggest that CMA and other targeted forms of 
genetic testing remain important diagnostic tools. CMA has been suggested as the 
appropriate comparator by which to measure the value of ES.23 While CMA is first-
tier diagnostic standard care, and is therefore an appropriate comparator to evaluate 
ES against the status quo, ES and CMA detect different types of genetic changes 
(sequence variants and chromosomal abnormalities, respectively). An astute 
Geneticist may be able to suspect which type of change a patient has, and therefore 
the most appropriate test, based on clinical exam.  
This analysis examines the effectiveness of ES for patients with suspected 
genetic disease overall. We do not define requirements for sequential order of 
testing, diagnostic yield of ES is likely to be higher in the subset of patients with non-
diagnostic CMA than we report. While ES is a complementary test to CMA rather 
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than a substitute for it, genome sequencing (GS) can potentially replace CMA and 
ES. GS is capable of detecting structural changes and identifying diagnoses not 
detectable by ES.24 As such, CMA may be a more appropriate comparator for 
genome sequencing (GS) than for ES. Further work should be directed toward 
defining a more rigorous way of categorizing patients according to likely clinical 
impact of ES to develop clinical guidelines for appropriate use of ES. 
Our results highlight several other areas for further investigation. In the ES 
cohort, Hispanic patients had half the odds of diagnosis of Non-Hispanic patients. 
This finding speaks to the need for diversity in databases used for variant curation in 
order to better interpret findings in this group of patients and increase the likelihood 
of diagnosis.25 That we find no effect of ES-by-admission year interaction on 
molecular diagnosis suggests that the rate of molecular diagnosis did not change 
over time. In other words, neither experiential learning in terms of ES orders on the 
part of the clinician nor increased genetic knowledge in the field overall appear to 
have significantly impacted results over our study period.  
Our finding of no difference in survival can be interpreted in two ways. First, it 
may be due to study design and indicate successful matching of patients on severity. 
Neither cohort was more severely ill, in a broad sense, than the other. Second, it 
may indicate that ES is not effective at increasing survival compared to standard 
diagnostics. This finding is not altogether surprising due to rarity of diseases 
detected by ES for which a treatment may not be available.  
Our findings regarding timing of death, however, are somewhat unexpected. 
No-ES cohort patients expired sooner after birth, yet cGS has been predicted to 
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increase 28-day mortality driven by redirection to comfort-care only following 
confirmation of severe, untreatable disease.26 Our result is better understood in light 
of the diagnoses in the No-ES cohort, including severe chromosomal abnormalities 
not compatible with survival, such as trisomy 13, trisomy 18, and other large 
unbalanced chromosomal rearrangements, that likely drive the higher death rate in 
the early time period.  
The hazard rate for diagnosed patients was significantly higher than that for 
patients without a molecular diagnosis, driven by results in the ES group. Lower 
survival for diagnosed patients, compared to patients who did not receive a 
molecular diagnosis is consistent with other studies of genomic sequencing in the 
NICU.9 This indicates the severity of diagnoses identified through ES. Similarly, 
older age at the initial Genetics consultation was associated with a significantly lower 
hazard rate; this implies that the most severely ill patients likely to expire within a 
short time after birth are receiving attention from the Genetics team sooner than 
patients afflicted with less life-limiting conditions. 
We use summary outcome measures of diagnostic yield and survival to 
describe a heterogeneous population of patients. However, the myriad nuances of 
outcomes important to determine the effectiveness of ES are not captured in the 
commonly reported summary measure of diagnostic yield, and this is an active area 
of exploration. Need for development of a new approach to outcomes measurement 
and evidence generation for precision medicine applications such as ES has been 
identified as a top priority by the National Academy of Medicine.27 Definition and 
standardization of outcome measures has been recognized by researchers 
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attempting these evaluations in practice.28,29 The fact that ES is applicable as a 
diagnostic tool for theoretically any patient with suspected monogenetic disease, but 
without prior knowledge of which specific disease or implicated gene, makes it both 
potentially more effective and more difficult to evaluate at the population level. We 
have defined boundaries that allow meaningful analysis while preserving the 
features that make ES unique and useful. Our patient sample is diverse and 
heterogeneous yet defined by features that stakeholders can use to determine 
clinical and coverage policy for a distinguishable group of patients. 
Real world effectiveness of ES will likely differ by institution. Upon availability 
as a commercial clinical test, without data on clinical care impact, the technological 
imperative may have influenced uptake of genomic sequencing of infants.30 Uptake 
of genetic testing is influenced by institutional-level factors31 and other elements 
which we are not able to systematically study here but should be explored in the 
future.  
We recognize several limitations related to reliance on EMR and 
administrative data. Objectivity and scalability for a large patient population are 
advantages of outcome measurement through EMR review, yet potential for 
incomplete documentation and difficulty in identification of changes in management 
as a result of ES results are disadvantages.  We only measured changes where 
there was explicit documentation in the note related to the results of ES, whether 
diagnostic or non-diagnostic, although not all changes may be documented this way. 
Some ways in which ES results may influence clinical care, such as prognostication, 
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are especially hard to measure objectively and retrospectively and without the 
involvement of the treating clinician.  
Relatedly, HPO term generation depended upon the information in clinical 
notes. Clinicians may differ in meticulousness, extent, and quality of phenotypic 
description, which would, in turn, impact the HPO terms generated from the note. 
Moreover, HPO terms assessed individually do not capture syndromic patterns of 
features. Although syndromic features may be caused by both monogenic and 
chromosomal abnormalities, some patterns may indicate hallmark features of 
chromosomal abnormalities to clinically indicate CMA instead of ES.  
We do not consider non-health outcomes or impacts of ES not documented in 
the EMR which would require further data collection from patients, families, and 
clinicians. Empirical data suggest the potential value to families of information, even 
without possibility of treatment.32,33 Parents perceive information from ES to have 
benefits beyond direct clinical usefulness, such as reassurance regarding a 
transition to comfort care-only measures, help with coping, knowing risk for other 
family members, and reproductive planning.18,33-39 Incorporation of family 
preferences along with objective outcomes can help move toward a more holistic 
valuation of the cGS and methodological work is needed in this area.32,40 Moreover, 
results of cGS may impact clinical management decisions whether or not a definitive 
diagnosis is established.41 Valuation of non-health outcomes should be explored for 
patients, families, and clinicians should be further explored to complement this work. 
As clinically applied, ES is an important diagnostic tool, as are chromosomal 
microarray and targeted genetic testing, for diagnosing patients with a severe clinical 
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presentation within the first year of life. Combined, nearly 30% of newborns and 
infants in our study received a genetic explanation of the cause of their clinical 
features. While this percent may not define the complete spectrum of utility of ES 
testing, it represents the importance of various diagnostic tools for patients with 
various genetic disease etiologies. 
 
References 
 
1. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare 
disease in children. Nature Reviews Genetics. 2018. 
2. Rehm HL. Evolving health care through personal genomics. Nature Reviews 
Genetics. 2017;18(4):259. 
3. van Diemen CC, Kerstjens-Frederikse WS, Bergman KA, et al. Rapid 
Targeted Genomics in Critically Ill Newborns. Pediatrics. 2017;140(4). 
4. Meng L, Pammi M, Saronwala A, et al. Use of Exome Sequencing for Infants 
in Intensive Care Units: Ascertainment of Severe Single-Gene Disorders and 
Effect on Medical Management. JAMA Pediatr. 2017;171(12):e173438. 
5. Stark Z, Lunke S, Brett GR, et al. Meeting the challenges of implementing 
rapid genomic testing in acute pediatric care. Genetics In Medicine. 2018. 
6. Soden SE, Saunders CJ, Willig LK, et al. Effectiveness of exome and genome 
sequencing guided by acuity of illness for diagnosis of neurodevelopmental 
disorders. Sci Transl Med. 2014;6(265):265ra168. 
 
 
206 
 
7. Smith HS, Swint JM, Lalani SR, et al. Clinical Application of Genome and 
Exome Sequencing as a Diagnostic Tool for Pediatric Patients: a Scoping 
Review of the Literature. Genet Med. 2019;21(1):3-16. 
8. Phillips KA, Deverka PA, Marshall DA, et al. Methodological Issues in 
Assessing the Economic Value of Next-Generation Sequencing Tests: Many 
Challenges and Not Enough Solutions. Value in Health. 2018;21(9):1033-
1042. 
9. Willig LK, Petrikin JE, Smith LD, et al. Whole-genome sequencing for 
identification of Mendelian disorders in critically ill infants: a retrospective 
analysis of diagnostic and clinical findings. The Lancet Respiratory Medicine. 
2015;3(5):377-387. 
10. Xu J, Murphy SL, Kochanek KD, Bastian B, Arias E. Deaths: final data for 
2016. 2018. 
11. Wojcik MH, Schwartz TS, Yamin I, et al. Genetic disorders and mortality in 
infancy and early childhood: delayed diagnoses and missed opportunities. 
Genetics In Medicine. 2018. 
12. Lu X-Y, Phung MT, Shaw CA, et al. Genomic Imbalances in Neonates With 
Birth Defects: High Detection Rates by Using Chromosomal Microarray 
Analysis. Pediatrics. 2008;122(6):1310-1318. 
13. Daoud H, Luco SM, Li R, et al. Next-generation sequencing for diagnosis of 
rare diseases in the neonatal intensive care unit. CMAJ. 2016:cmaj. 150823. 
 
 
207 
 
14. McCandless SE, Brunger JW, Cassidy SB. The Burden of Genetic Disease 
on Inpatient Care in a Children's Hospital. The American Journal of Human 
Genetics. 2004;74(1):121-127. 
15. Gonzaludo N, Belmont JW, Gainullin VG, Taft RJ. Estimating the burden and 
economic impact of pediatric genetic disease. Genetics in Medicine. 2018. 
16. Buchanan J, Wordsworth S, Schuh A. Issues surrounding the health 
economic evaluation of genomic technologies. Pharmacogenomics. 
2013;14(15):1833-1847. 
17. Feero WGW, Catherine; Veenstra, David L. The Economics of Genomic 
Medicine: Insights From the IOM Roundtable on Translating Genomic-Based 
Research for Health. Journal of the American Medical Association. 
2013;309(12):1235-1236. 
18. Botkin JR, Teutsch SM, Kaye CI, et al. Outcomes of interest in evidence-
based evaluations of genetic tests. Genet Med. 2010;12(4):228-235. 
19. Petrikin JE, Cakici JA, Clark MM, et al. The NSIGHT1-randomized controlled 
trial: rapid whole-genome sequencing for accelerated etiologic diagnosis in 
critically ill infants. npj Genomic Medicine. 2018;3(1):6. 
20. OMIM. OMIM Entry Statistics: Number of Entries in OMIM. 2019; 
http://omim.org/statistics/entry. Accessed 2019/01/19. 
21. TCH. 2017 Annual Report. 2017; 
http://texaschildrensannualreport.org/index.html. 
 
 
208 
 
22. Wordsworth S, Doble B, Payne K, et al. Using “Big Data” in the Cost-
Effectiveness Analysis of Next-Generation Sequencing Technologies: 
Challenges and Potential Solutions. Value in Health. 2018;21(9):1048-1053. 
23. Friedman JM, Bombard Y, Cornel MC, et al. Genome-wide sequencing in 
acutely ill infants: genomic medicine’s critical application? Genet Med. 2018. 
24. Lionel AC, Costain G, Monfared N, et al. Improved diagnostic yield compared 
with targeted gene sequencing panels suggests a role for whole-genome 
sequencing as a first-tier genetic test. Genetics In Medicine. 2017;20:435. 
25. Landry LG, Ali N, Williams DR, Rehm HL, Bonham VL. Lack of diversity in 
genomic databases is a barrier to translating precision medicine research into 
practice. Health Affairs. 2018;37(5):780-785. 
26. Petrikin JE, Willig LK, Smith LD, Kingsmore SF. Rapid whole genome 
sequencing and precision neonatology. Seminars in perinatology. 
2015;39(8):623-631. 
27. Dzau VJ, Ginsburg GS. Realizing the full potential of precision medicine in 
health and health care. JAMA. 2016;316(16):1659-1660. 
28. Stark Z, Schofield D, Martyn M, et al. Does genomic sequencing early in the 
diagnostic trajectory make a difference? A follow-up study of clinical 
outcomes and cost-effectiveness. Genetics in Medicine. 2019;21(1):173-180. 
29. Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of 
Genomic Sequencing: Lessons Learned from the MedSeq Project. Value in 
Health. 2018;21(9):1054-1061. 
 
 
209 
 
30. Pereira S, Clayton EW. Commercial Interests, the Technological Imperative, 
and Advocates: Three Forces Driving Genomic Sequencing in Newborns. 
Hastings Center Report. 2018;48:S43-S44. 
31. Hamilton AB, Oishi S, Yano EM, Gammage CE, Marshall NJ, Scheuner MT. 
Factors influencing organizational adoption and implementation of clinical 
genetic services. Genetics in Medicine. 2014;16(3):238. 
32. Regier DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S. Valuation 
of Health and Nonhealth Outcomes from Next-Generation Sequencing: 
Approaches, Challenges, and Solutions. Value in Health. 2018;21(9):1043-
1047. 
33. Pereira S, Robinson JO, Gutierrez AM, et al. Perceived Benefits, Risks, and 
Utility of Newborn Genomic Sequencing in the BabySeq Project. Pediatrics. 
2019;143(Supplement 1):S6-S13. 
34. Makela NL, Birch PH, Friedman JM, Marra CA. Parental perceived value of a 
diagnosis for intellectual disability (ID): a qualitative comparison of families 
with and without a diagnosis for their child's ID. Am J Med Genet A. 
2009;149A(11):2393-2402. 
35. Carmichael N, Tsipis J, Windmueller G, Mandel L, Estrella E. “Is it Going to 
Hurt?”: The Impact of the Diagnostic Odyssey on Children and Their Families. 
Journal of Genetic Counseling. 2015;24(2):325-335. 
36. Srivastava S, Cohen JS, Vernon H, et al. Clinical whole exome sequencing in 
child neurology practice. Ann Neurol. 2014;76(4):473-483. 
 
 
210 
 
37. Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? Genetics 
in Medicine. 2006;8(7):448-450. 
38. Tarini BA, Singer D, Clark SJ, Davis MM. Parents' Interest in Predictive 
Genetic Testing for Their Children When a Disease Has No Treatment. 
Pediatrics. 2009;124(3):e432-e438. 
39. Vadeboncoeur C, McHardy M. Benefits of Early Referral to Pediatric Palliative 
Care for a Child With a Rare Disease. Pediatrics. 2018;141(6). 
40. Feero WG, Wicklund C, Veenstra DL. The economics of genomic medicine: 
insights from the IOM Roundtable on Translating Genomic-Based Research 
for Health. JAMA. 2013;309(12):1235-1236. 
41. Smith HS, Russell HV, Lee BH, Morain SR. Advancing Value Assessment in 
Pediatric Clinical Exome Sequencing: A Delphi Study of Clinicians’ Perceived 
Importance of Results. Manuscript submitted for publication. 2019. 
42. Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing 
propensity scores. Health services research. 2014;49(5):1701-1720. 
43. Wyss R, Girman CJ, LoCasale RJ, Alan Brookhart M, Stürmer T. Variable 
selection for propensity score models when estimating treatment effects on 
multiple outcomes: a simulation study. Pharmacoepidemiology and drug 
safety. 2013;22(1):77-85. 
44. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate 
matched sampling methods that incorporate the propensity score. The 
American Statistician. 1985;39(1):33-38. 
  
 
 
211 
 
Tables and Figures 
 
Figure 1. Study flow diagram 
 
DOL, days of life; ES, exome sequencing; IP, inpatient; ICU, intensive care unit 
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Table 1. Patient Characteristics 
 No-ES Cohort ES Cohort p-valuea 
Sex, n (%)    
Male 203 (55.16) 217 (58.97)  
Female 165 (44.84) 151 (41.03) 0.297 
    
Race, n (%)    
White/Caucasian 277 (75.27) 289 (78.53)  
Black/African-American 58 (15.76) 58 (15.76)  
Asian 22 (5.98) 17 (4.62)  
American Indian and Alaska Native 1 (0.27) 1 (0.27)  
Unknown 8 (2.17) 3 (0.82) 0.396 
    
Ethnicity, n (%)    
Non-Hispanic 200 (54.35) 190 (51.63)  
Hispanic 162 (44.02) 174 (47.28)  
Unknown 6 (1.63) 4 (1.09) 0.581 
    
Preferred Language, n (%)    
English 312 (84.78) 294 (79.89)  
Spanish 52 (14.13) 69 (18.75)  
Other 4 (1.09) 5 (1.36) 0.219 
    
Unit of Genetics Consult, n (%)    
NICU 245 (66.58) 222 (60.33) 0.078 
CVICU 62 (16.85) 70 (19.02) 0.442 
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Other 36 (9.78) 36 (9.78) 1.00 
PCU 17 (4.62) 25 (6.79) 0.204 
PICU 8 (2.17) 15 (4.08) 0.138 
    
Age at Genetics Consult (quartile of year), n (%)    
First 302 (82.07) 297 (80.71) 0.636 
Second 43 (11.68) 49 (13.32) 0.504 
Third 13 (3.53) 12 (3.26) 0.839 
Fourth 10 (2.72) 10 (2.72) 1.00 
    
Genetics Consult Date (quartile of study period), n 
(%) 
   
First 92 (25.00) 92 (25.00) 1.00 
Second 105 (28.53) 79 (21.47) 0.027 
Third 90 (24.46) 95 (25.82) 0.671 
Fourth 81 (22.01) 102 (27.72) 0.073 
    
Gestational Age at Birth, weeks, mean (median) 36.40 (37.29) 37.00 (38.00) 0.0711b 
    
Mother’s Age at Birth, years, mean (sd) 28.93  (6.27)d 28.39 (6.33)e 0.251c 
    
Father’s Age at Birth, years, mean (sd) 31.60 (7.55)f 31 (7.78)g 0.357c 
ES, exome sequencing; NICU, neonatal intensive care unit; CVICU, cardiovascular intensive care 
unit; PCU, progressive care unit; PICU, pediatric intensive care unit 
a All p-values from chi-square tests unless otherwise noted; b Wilcoxon rank-sum test  c Student’s t-
test; c n = 360; d n = 362; e n = 312; f n = 316 
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Table 2. Index Admission Characteristics 
 No-ES Cohort ES Cohort p-valuea 
Age at admission, days, median 
(IQR), mean 1 (0–36), 35.18 2 (0 – 44), 38.30 0.430b 
    
Age at initial genetics consult, days, 
median (IQR), mean 
10.5 (2–54.5), 
44.92 
13 (2 -57.5), 
47.30 0.515b 
    
Point of Origin, n (%)    
Transfer Center 167 (45.38) 160 (43.48)  
Newborn at TCH 128 (34.78) 136 (36.96)  
Self Referral/Non-Health Care Facility 42 (11.41) 40 (10.87)  
Clinic or Physician Referral 31 (8.42) 32 (8.70) 0.928 
    
Length of stay, days, median (IQR), 
mean 
27.5 (10–56), 
50.57 
39 (17–83.5), 
66.86 <0.001 b 
    
Discharge Place, n (%)    
Home 294 (79.89) 287 (77.99)  
Expired 51 (13.86) 60 (16.30)  
Other Facility 12 (3.26) 15 (4.08)  
Home Health Care Service 3 (0.82) 3 (0.82)  
Hospice 8 (2.17) 3 (0.82) 0.490 
    
Insurance Payer, n (%)    
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Public (Medicaid and Tricare) 194 (52.72) 224 (60.87)  
Commercial 172 (46.74) 142 (38.59)  
None 2 (0.54) 2 (0.54) 0.058c 
Second Insurance (public or 
commercial) 52 (14.13) 67 (18.12) 0.133 
ES, exome sequencing; IQR, interquartile range 
a All p-values from chi-square tests unless otherwise noted;  b Wilcoxon rank-sum test; c Fisher’s exact 
test 
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Figure 2. Index admission length of stay (days) for patients who did and did not have ES 
 
ES, exome sequencing 
p<0.001 
 
  
 
 
217 
 
 
Table 3. Outcomes 
 All Patients  
(n = 736) 
No-ES Cohort 
(n = 368) 
ES Cohort 
(n = 368) 
p-
valuea 
Diagnostic yield, n (%) 205 (27.85)b 95 (25.82) 102 (27.72) 0.560 
Survival to 28 days, n 
(%) 686 (93.21) 337 (91.58) 349 (94.84) 0.079 
Survival to 1 year, n (%) 607 (82.47) 312 (84.78) 295 (80.16) 0.099 
Alive at end of study 
period, n (%) 570 (77.45) 296 (80.43) 274 (74.46) 0.052 
Age at death, days, 
median (IQR), mean 
69.5 (18–335), 
240.90 
44.5, (7.5–
335), 247.29 
121.5 (40–
335), 236 0.136c 
ES, exome sequencing; IQR, interquartile range 
a All p-values from chi-square tests unless otherwise noted 
b Additional 8 diagnoses made by chromosomal microarray in ES cohort not included 
in ES diagnostic yield 
c Wilcoxon rank-sum test 
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Table 4. Molecular Diagnosis 
 (1) (2) (3) (4) 
 All Patients All Patients No-ES 
Cohort 
ES Cohort 
Molecular Diagnosis OR OR OR OR 
     
Exome Sequencing 1.145    
 (0.201)    
Female 1.000 0.997 1.183 0.841 
 (0.178) (0.177) (0.313) (0.216) 
Hispanic 0.576*** 0.579*** 0.670 0.499*** 
 (0.103) (0.104) (0.175) (0.129) 
DOL Genetics consult 0.998 0.998 0.996* 1.001 
 (0.002) (0.002) (0.003) (0.002) 
Unita     
CVICU 0.978 0.986 1.574 0.520* 
 (0.240) (0.242) (0.544) (0.200) 
PICU 2.047 2.108 2.404 1.943 
 (0.992) (1.017) (2.255) (1.157) 
PCU 2.925*** 2.983*** 2.717* 3.159** 
 (1.091) (1.111) (1.639) (1.546) 
Other Unit 1.322 1.333 0.991 1.398 
 (0.472) (0.476) (0.567) (0.691) 
Point of Originb     
Transfer Center 1.244 1.237 1.028 1.643 
 (0.258) (0.256) (0.307) (0.502) 
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Self Referral 1.217 1.206 0.995 1.495 
 (0.404) (0.400) (0.473) (0.724) 
Clinic or Physician Referral 2.488*** 2.465*** 2.329 3.264** 
 (0.859) (0.850) (1.208) (1.608) 
Admission Yearc **     
2012 1.186 1.157 0.834 2.444 
 (1.171) (1.136) (1.253) (3.458) 
2013 0.504 0.499 0.293 1.436 
 (0.497) (0.490) (0.442) (2.005) 
2014 0.474 0.466 0.276 1.214 
 (0.465) (0.454) (0.412) (1.692) 
2015 0.662 0.648 0.448 1.271 
 (0.647) (0.630) (0.667) (1.766) 
2016 0.412 0.406 0.178 1.223 
 (0.403) (0.395) (0.266) (1.698) 
2017 0.471 0.473 0.139 1.590 
 (0.469) (0.469) (0.219) (2.224) 
Constant 0.605 0.658 1.119 0.250 
 (0.601) (0.646) (1.687) (0.348) 
n 726 726 362 364 
ES, exome sequencing; OR, odds ratio; DOL, days of life; NICU, neonatal intensive care unit; CVICU, 
cardiovascular intensive care unit; PCU, progressive care unit; PICU, pediatric intensive care unit  
a NICU base category; b Inborn base category; c 2011 base category 
**Year variables jointly significant at the 5% level in Model 1 
Standard errors in parentheses  
*** p<0.01, ** p<0.05, * p<0.1 
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Figure 3. Survival by ES cohort 
 
ES, exome sequencing 
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Table 5. Cox proportional hazards regression model 
 (1) (2) (3) (4) (5) (6) 
Survival All 
Patientsa 
All 
Patients, 
28-day 
Survival 
All 
Patients, 
365-day 
Survival 
All 
Patients, 
Unit 
Strataa 
No-ES 
Cohort, 
Unit 
Strataa 
ES Cohort, 
Unit 
Strataa 
 HR HR HR HR HR HR 
       
Exome 
Sequencing 
1.280 0.608 1.202 1.353*   
 (0.207) (0.191) (0.221) (0.222)   
Molecular 
Diagnosis 
1.535** 1.153 1.371 1.577*** 1.186 1.918*** 
 (0.260) (0.378) (0.268) (0.267) (0.318) (0.431) 
Female 1.181 1.460 1.101 1.184 1.307 0.957 
 (0.189) (0.440) (0.201) (0.192) (0.333) (0.207) 
Hispanic 1.125 1.420 1.048 1.098 1.342 1.080 
 (0.185) (0.431) (0.197) (0.182) (0.338) (0.243) 
PICUb 7.006*** 20.304** 7.613*** 1.000 1.000 1.000 
 (2.141) (24.296) (2.506) (0.000) (0.000) (0.000) 
CVICUb 1.369 1.898* 1.473* 1.000 1.000 1.000 
 (0.285) (0.640) (0.339) (0.000) (0.000) (0.000) 
PCUb 1.038 0.000 0.691 1.000 1.000 1.000 
 (0.383) (0.000) (0.365) (0.000) (0.000) (0.000) 
Other Unitb 0.696 0.000 0.354* 1.000 1.000 1.000 
 (0.265) (0.000) (0.217) (0.000) (0.000) (0.000) 
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DOL Genetics 
consult 
0.997** 0.861*** 0.995*** 0.996*** 0.996* 0.995** 
 (0.001) (0.035) (0.002) (0.001) (0.002) (0.002) 
Medicaid 1.367* 1.242 1.360 1.434** 1.272 1.430 
 (0.233) (0.387) (0.262) (0.247) (0.329) (0.339) 
       
n 724 724 724 724 361 363 
       
ES, exome sequencing; HR, hazard ratio; CVICU, cardiovascular intensive care unit; PCU, 
progressive care unit; PICU, pediatric intensive care unit; DOL, days of life 
a Survival to end of study period, unless otherwise noted.  
b NICU, neonatal intensive care unit base category 
Standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
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Figure 4. Survival by hospital unit, all patients 
 
ES, exome sequencing; NICU, neonatal intensive care unit; CVICU, cardiovascular intensive care 
unit; PCU, progressive care unit; PICU, pediatric intensive care unit 
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Figure 5. Survival by diagnosis category and cohort 
 
ES, exome sequencing 
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Exome Sequencing for Critically Ill Infants Compared to Standard Diagnostics: 
A Retrospective Analysis of Clinically Matched Cohorts 
 
Supplementary Appendices 
 
Supplementary Materials and Methods 
Phenotypic Characterization of Patients 
To generate standardized information on phenotypic characteristics across 
patients, we extracted details about clinical presentation from the initial Genetics 
consult note (which contains the most extensive and detailed assessment of the 
patient’s clinical features) and index admission discharge note. Relevant information 
was entered into a natural language processing application that generated a set of 
human phenotype ontology (HPO) terms for each patient, intended to capture 
clinical presentation at the time of the Genetics team’s assessment. Careful attention 
was given to avoid inclusion of “pertinent negatives,” information from birth or family 
history, or phenotypic hallmarks of differential diagnoses contained within the note, 
and the HPO terms for each patient were curated by hand for accurate 
representation of the note.  
 
Selection of Matched Controls 
 To determine comparable cohorts of patients who did and did not have ES, 
we calculated a propensity score for each patient. This method allows adjustment for 
confounding when assessing multiple outcomes.42,43 The propensity score was used 
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to represent multiple HPO terms and other relevant factors as a one-dimensional 
score.44 We generated a binary variable for each HPO identification (ID) number 
appearing in the data. HPO ID numbers were used instead of terms themselves to 
ensure synonymous terms did not appear as separate variables. Granularity was 
preserved; we did not use hierarchical processing to map to higher order terms 
(although in many cases, multiple levels of terms were generated). HPO term 
variables with count fewer than 10, meaning that the term was observed in fewer 
than 10 patients, were dropped, leaving 340 term variables. Based on clinician 
consensus, another 33 term variables were dropped because they related to 
transient clinical characteristics, such as fever or emesis, not relevant for making a 
diagnosis. HPO terms were selected for inclusion in the propensity score model 
using a backward automated variable selection process (p-value for removal = 0.1). 
We calculated a propensity score, which is the estimated probability of having 
ES conditional on measured covariates, for each patient using a binary logistic 
regression model with ES as the dependent variable that included indicator variables 
for: gender, the unit in which the initial Genetics consult was performed, initial 
Genetics consult date (quartile of study period), age (days) at first genetics consult 
(quarter of year), and HPO terms. After predicting propensity score for each patient, 
each ES patient was matched to one most phenotypically similar No-ES patient from 
among all potential No-ES patients using a greedy matching algorithm based on the 
linear predictor of the propensity score. Compared to differences between ES 
patients and the entire group of No-ES patients prior to matching, the matching 
 
 
227 
 
procedure successfully reduced differences in covariates between ES and No-ES 
patients in the final cohorts. 
 
Supplementary Tables and Figures 
 
Figure S1. Uptake by exome sequencing test form 
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Figure S2. Consults and diagnostic yield by attending geneticist 
 
Initial genetics consult note: percent of initial genetics consult notes among included patients listed as author 
ES order consult note: percent of exome sequencing (ES) order consult notes among ES order consult notes listed as author 
Molecular diagnosis: percent of patients for whom performed initial genetics consult that received molecular diagnosis by genetic test other 
than ES 
ES diagnosis: percent of patients for whom ES consult note author who received a diagnosis by ES 
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Figure S3. Form of exome sequencing orders by attending geneticist 
 
ES, exome sequencing 
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Table S4. Genetic diagnoses and the diagnostic tool with which they were identified in the 
No-ES cohort 
 Frequency Percent 
Molecular Diagnosisa   
17q25.3 deletion 1 1.05 
1p36 deletion 1 1.05 
30 Mb duplication seen on 15q11.1q21.2 1 1.05 
6q deletion 1 1.05 
Aicardi-Goutierres syndrome 1 1.05 
Apert syndrome 1 1.05 
Autosomal recessive polycystic kidney disease 1 1.05 
Biotinidase deficiency 1 1.05 
Cat eye syndrome 2 2.11 
CHARGE syndrome 4 4.21 
Chromosome 1 duplication 1 1.05 
Chromosome 1 unbalanced rearrangement 1 1.05 
Classic Galactosemia 1 1.05 
Cobalamin C deficiency 1 1.05 
Complex rearrangement of chromosome 8p 1 1.05 
Congenital adrenal hyperplasia 1 1.05 
Congenital Central Hypoventilation Syndrome (CCHS) 1 1.05 
Congenital Tufting Enteropathy 1 1.05 
Copy number gain of chromosome bands 18q11.1 to q11.2 1 1.05 
Copy number loss of chromosome band 6q26q27 of 1 1.05 
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approximately 6.907 Mb 
Cornelia de Lange syndrome 1 1.05 
Cystic fibrosis 1 1.05 
De novo 2.4 megabase duplication on chromosome 13q14.11 1 1.05 
De novo 52 Mb gain on 3q24q29 due to unbalanced 3q;15p 
translocation 1 1.05 
De novo copy number LOSS within chromosome bands 
19q13.42q13.43 1 1.05 
De novo gain of chromosome band 5q23.1q23.2 spanning 
approximately 1.714 Mb 1 1.05 
De novo loss on 4q21 1 1.05 
DiGeorge/Velocardiofacial syndrome 8 8.42 
DMD duplication 1 1.05 
Gaucher disease 1 1.05 
Hereditary folate malabsorption 1 1.05 
Kleefstra syndrome 1 1.05 
Large 11Mb deletion of chromosome 1q4.42.34 1 1.05 
LOSS of  5q15q23.2 involving the APC gene 1 1.05 
Loss on chromosome 17q12 1 1.05 
Maternally inherited UPD 14 1 1.05 
Microvillus inclusion disease 1 1.05 
Miller-Dieker syndrome 1 1.05 
Mosaic Trisomy 8 1 1.05 
Mosaicism for partial trisomy/tetrasomy of distal chromosome13q 1 1.05 
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(13q32.3q34) 
Mosaicism for trisomy 18 1 1.05 
Multiple congenital anomalies-hypotonia-seizures syndrome 
(MCAHS1) 1 1.05 
Multiple copy number GAINS within chromosome band Xq28, 
suggestive of a complex rearrangement 1 1.05 
Mutation seen in individuals with the clinical diagnosis of Pfeiffer 
syndrome (severe), Crouzon syndrome (severe), and Antley-
Bixler syndrome 1 1.05 
Neurofibromatosis-Noonan syndrome 1 1.05 
Noonan Syndrome 2 2.11 
Pallister-Killian syndrome 1 1.05 
Partial trisomy 18 (~35 Mb) 1 1.05 
Rhizomelic condrodysplasia punctata (RCDP) 1 1.05 
Russell Silver syndrome 1 1.05 
Spinal muscular atrophy 2 2.11 
Stickler syndrome 2 2.11 
Tetrasomy/AOH of chromosome 9 1 1.05 
Duplication of part of CALM2 1 1.05 
Trisomy 13 4 4.21 
Trisomy 18 3 3.16 
Trisomy 21 12 12.63 
Trisomy 22 2 2.11 
Turner syndrome 1 1.05 
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Unbalanced translocation 2 2.11 
Walker-Warburg syndrome 1 1.05 
Williams syndrome 1 1.05 
Williams syndrome spectrum 1 1.05 
Total 95 100 
   
Molecular Diagnostic Tool   
CMA/FISH/karyotype 68 71.58 
Gene panel 9 9.47 
Single gene sequencing; deletion/duplication analysis 18 18.95 
Total 95 100 
 
ES, exome sequencing; CMA, chromosomal microarray; FISH, fluorescence in situ 
hybridization 
a solved or probably solved/causal or probably causal 
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Table S5. Genetic diagnoses and the diagnostic tool with which they were identified in the ES 
cohort 
 
Frequency Percent 
Molecular Diagnosis by ESa 
  ABL1-associated syndrome characterized by congenital heart 
defects and skeletal malformations 1 0.9 
Aromatic L-amino acid decarboxylase deficiency (AADCD) 1 0.9 
arthrogryposis, renal dysfunction and cholestasis syndrome 1 
(ARCS1) 1 0.9 
autosomal dominant profound neonatal hypotonia, seizures and 
encephalopathy 1 0.9 
Bardet-Biedl syndrome 1 (BBS1) 1 0.9 
cardiomyopathy, dilated, 1FF 1 0.9 
cardiomyopathy, familial hypertrophic 2 (CMH2) 1 0.9 
CFAP52-related disorder 1 0.9 
CHARGE syndrome 2 1.8 
Coffin-Siris syndrome 4 1 0.9 
COL12A1 related disorder 1 0.9 
Combined oxidative phosphorylation deficiency 12 (COXPD12) 1 0.9 
congenital disorder of glycosylation 1 0.9 
Costello syndrome 1 0.9 
Culler-Jones Syndrome (GLI2) 1 0.9 
D-bifunctional protein deficiency 1 0.9 
de novo likely pathogenic variant in SHANK3 1 0.9 
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de novo missense variant in CTCF 1 0.9 
de novo novel variant in BCAP31 1 0.9 
Denys-Drash syndrome 1 0.9 
epileptic encephalopathy early infantile 4 3.6 
Familial Hemophagocytic Lymphohistiocytosis type 2 1 0.9 
Fanconi anemia 1 0.9 
Fanconi anemia complementation group D1 (FANCD1) 1 0.9 
Gaucher disease type 2 1 0.9 
generalized arterial calcification of infancy 1 0.9 
Glycogen storage disease type Ia 1 0.9 
glycogen storage disease type IV (GSD IV) 1 0.9 
granulomatous disease, chronic, X-linked (CGD) 1 0.9 
hepatic venoocclusive disease with immunodeficiency (VODI) 1 0.9 
insulin-like growth factor 1 resistance (IGF1RES) 1 0.9 
intellectual developmental disorder with dysmorphic facies, 
seizures, and distal limb anomalies 1 0.9 
Jeune syndrome 1 0.9 
Joubert syndrome 2 1.8 
Kabuki syndrome 5 4.5 
LAS1L-related intellectual disability 1 0.9 
left ventricular noncompaction 1 0.9 
lipoyltransferase 1 deficiency 1 0.9 
Lowe syndrome 1 0.9 
malignant migrating partial seizures of infancy 1 0.9 
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mandibulofacial dysostosis with microcephaly 1 0.9 
Marshall syndrome (MRSHS) 1 0.9 
MECP2 related disorder 2 1.8 
Megalencephaly-capillary malformation syndrome (MCAP) 1 0.9 
mental retardation, autosomal dominant 31 1 0.9 
mental retardation, X-linked 9 1 0.9 
microcephaly 5, primary, autosomal recessive (MCPH5) 1 0.9 
Microcephaly with Pontine and Cerebellar Hypoplasia 
(MICPCH) 1 0.9 
muscular dystrophy-dystroglycanopathy congenital with mental 
retardation B1 (MDDGB1) 1 0.9 
myopathy, centronuclear, 1 (CNM1)  2 1.8 
nemaline myopathy 2 1.8 
nephronophthisis 3 (NPHP3) 1 0.9 
Neurofibromatosis Type 1 and acamptomelic camptomelic 
dysplasia 1 0.9 
Noonan syndrome 9 8.11 
novel, de novo BICD2 VUS 1 0.9 
OFD1 mutation 1 0.9 
Ornithine transcarbamylase (OTC) deficiency 1 0.9 
Orofaciodigital syndrome 1 0.9 
pancreatic agenesis and congenital heart defects (PACHD) 1 0.9 
parietal foramina 2 with modulating effects from TWIST1 variant 1 0.9 
Pfeiffer syndrome (PS) type 1 1 0.9 
 237 
 
Pompe disease 3 2.7 
pyridoxine-dependent epilepsy (PDE) 1 0.9 
pyruvate decarboxylase E1 component deficiency (PDHE1 
deficiency) 2 1.8 
RARS-related leukodystrophy 1 0.9 
renal tubular dysgenesis (RTD) 1 0.9 
restrictive dermopathy 1 0.9 
Rett syndrome 1 0.9 
SCN1A-related seizure disorder 1 0.9 
short-rib thoracic dysplasia 3 with or without polydactyly 
(SRTD3) 1 0.9 
Smith-Kingsmore syndrome (SKS) 1 0.9 
split-hand/foot malformation 6 (SHFM6) 1 0.9 
titinopathy 1 0.9 
Townes-Brocks syndrome 1 0.9 
transient infantile liver failure (LFIT)  1 0.9 
transposition of the great arteries dextro-looped 3 (DTGA3) 1 0.9 
TRMU-associated transient infantile liver failure 1 0.9 
TTN compound heterozygous variants  1 0.9 
VUS in gene associated with lissencephaly 4 (with 
microcephaly) 1 0.9 
Walker-Warburg syndrome 1 0.9 
   
   
 238 
 
Molecular Diagnosis by CMA   
solved by CMA; 10 Mb loss in 15q11q13 1 0.9 
solved by CMA; 5.9 Mb deletion in chromosome 2q37.2q37.3 1 0.9 
solved by CMA; de novo, loss of 2p14p13.3 (B<P10) 1 0.9 
solved by CMA; loss 4q34.1q35.2 1 0.9 
solved by CMA; Trisomy 21 2 1.8 
solved by CMA; unbalanced translocation, 46,XY, 
der(6)t(X;6)(q26;q27) 1 0.9 
solved by CMA; Xp22.31p22.33 loss 1 0.9 
   Total 111 100 
ES, exome sequencing; CMA, chromosomal microarray; FISH, fluorescence in situ 
hybridization 
a solved or probably solved/causal or probably causal 
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Table S6. Outcomes by exome sequencing test form 
 
Proband ES  
(n = 227) 
Trio ES 
(n = 54) 
Critical Trio 
ES 
(n = 87) 
p-
valuea 
Diagnostic yield, n (%) 61 (26.87) 13 (24.07) 28 (32.18) 0.523 
Survival to 28 days, n (%) 213 (93.83) 52 (96.30) 84 (96.55) 0.544 
Survival to 1 year, n (%) 182 (80.18) 45 (83.33) 68 (78.16) 0.757 
Alive at end of study 
period, n (%) 163 (71.81) 44 (81.48) 67 (77.01) 0.283 
Age at death, days, 
median (IQR), mean 
133 (36.5–
399.5), 276.30b 
182.5 (29–
330), 188.40c 
92.5 (52–
181), 130.85d 0.151 
ES, exome sequencing  
a All p-values from one-way ANOVA;  b n = 64; c n = 10; d n = 20 
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Table S7. Medical management change, ES cohort 
Clinical Impact Category, n (%) 
All ES Patients 
(n = 368) 
ES Diagnosed 
(n = 102) 
ES 
Undiagnosed 
(n = 266) 
Subspecialist or Consult Referral 54 (14.67) 35 (34.31) 19 (7.14) 
Surveillance Plan 16 (4.35) 12 (11.76) 4 (1.50) 
Screening Recommendation 16 (4.35) 6 (5.88) 10 (3.76) 
Medication Change 11 (2.99) 8 (7.84) 3 (1.13) 
Redirection of Care 6 (1.63) 3 (2.94) 3 (1.13) 
Diet Prescription 5 (1.36) 3 (2.94) 2 (0.75) 
Total 81 (22.01) 49 (48.04) 32 (12.03) 
ES, exome sequencing  
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Cost-Effectiveness Analysis of Clinical Exome Sequencing Compared to 
Standard Diagnostics for Critically Ill Infants 
 
Target Journal: Genetics in Medicine 
 
Abstract  
Purpose: Estimate the cost-effectiveness of clinical whole exome sequencing (ES) 
as a diagnostic tool, compared to usual diagnostic care, for patients with a 
suspected genetic etiology admitted to intensive care within the first year of life. 
Methods: In this retrospective cohort study, we analyzed ES application at a 
children’s hospital December 2011 – June 2017. Diagnostic yield and survival were 
compared between cohorts of clinically similar patients who did (n=368) and did not 
(n=368) have ES in diagnostic workup, along with total and diagnostic-related costs 
of index admission and year.  
Results: Molecular diagnostic yield (25.8% No-ES, 27.7% ES; p=0.56) and 1-year 
survival (84.8% No-ES, 80.2% ES; p=0.10) were similar between cohorts, while ES 
patients had higher cost of admissions, diagnostic investigations, and genetic tests 
(all p<0.01). Incremental diagnostic pathway cost per additional diagnosis was 
$550,874 for ES patients, which was reduced to $46,489 when comparing ES cohort 
to patients for whom ES was recommended but not performed. 
Conclusion: ES is an important tool for diagnosing critically ill newborns and 
infants, as are chromosomal microarray and targeted genetic testing, yet it does not 
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appear cost-effective during initial clinical uptake. Further work is needed to develop 
clinical guidelines for appropriate application of ES. 
 
Introduction 
Evaluation of patients with suspected genetic disorders is important to 
pediatric and neonatology practice due to incidence of genetic diseases that 
manifest at birth or soon after. Neonatal intensive care has been upheld as the 
setting in which clinical genomic sequencing (cGS) has the most promise for both 
clinical and economic impact.1-3 Diagnostic workup for a suspected genetic condition 
is associated with longer, more costly neonatal intensive care unit (NICU) 
admissions, and diagnosis of genetic-based disease is associated with longer 
inpatient stays and higher cost of care compared to other pediatric chronic disease 
etiologies.4-6 Based on national estimates, up to 14% of inpatient pediatric 
admissions are associated with genetic disease, at a cost of up to $77,000 higher for 
neonatal admissions and up to $17,000 for pediatric admissions, compared to 
patients who did not have a genetic disease diagnosis.7 
Exome sequencing (ES) has demonstrated ability to identify diagnoses in 
critically ill newborns and infants, clinical uptake is increasing, and evidence of 
overall clinical utility is building.8-12 However, clinical guidelines for ES application 
are not yet developed. Compared to the current standard genetic diagnostic workup, 
including chromosomal microarray (CMA) and targeted gene sequencing,13,14 very 
little is known about the population-level impact of ES on health outcomes or cost of 
care. Cost-effectiveness evidence is severely lacking, especially within the US 
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health care system.12,15 Economic evaluation can inform appropriate clinical use and 
patient access to cGS. 
Among the few ES economic evaluations to date, the most robust have been 
based on data generated within a research framework on the efficacy of ES to make 
molecular diagnoses.16,17 Although the goal of cost-effectiveness analysis is to 
assess an intervention’s impact in practice rather than a trial environment,18,19 
conclusions of these modeling studies reflect study inclusion criteria, such as clinical 
presentation restrictions and requirement of previous non-diagnostic tests. 
Therefore, it may not be possible to extrapolate results to the real-world clinical 
setting. The impact of clinically applied ES on outcomes and costs compared to 
usual diagnostics in a large group of patients with suspected genetic disease has not 
yet been examined.  
The aim of this paper is to estimate the cost-effectiveness of ES as a 
diagnostic tool for infants less than 1 year of life with a suspected genetic etiology in 
intensive care settings. We study real-world ES application during the initial 5 years 
of uptake at a large children’s hospital by comparing clinically similar cohorts of 
patients who did and did not have ES as part of a diagnostic workup. We analyze 
and compare cost of care, diagnostic yield and survival outcomes for both cohorts, 
and estimate cost-effectiveness using electronic medical record and hospital cost 
data over the time horizon of the inpatient hospital stay and within one year of the 
initial Genetics service consultation. 
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Methods 
Study Design 
We analyzed ES application at a large children’s hospital located in an 
academic medical center from December 2011 through June 2017. The study 
population was undiagnosed patients with a suspected genetic etiology who had an 
intensive care unit (ICU) admission within the first year of life. Patients were 
admitted to Texas Children’s Hospital (TCH) in Houston, TX, a large children’s 
hospital with 33,000 total admissions in 2017 and the highest level (Level IV) of 
neonatal intensive care.20 All TCH ES orders were sent to Baylor Genetics (BG) 
diagnostic laboratory.  
Documentation of genetics consultation in the electronic medical record 
(EMR) indicated a suspected genetic etiology in the patient. The index admission 
was defined as the admission during which the initial genetics consult was ordered, 
and the index year was defined as the 365 days after the initial genetics consult took 
place. The 1-year time horizon allows estimation of ES impact on care provision and 
costs, even if results were not returned before index admission discharge.  
We employed a retrospective cohort study design in which ES was the 
exposure factor. Included patients met the following criteria: (1) ICU admission within 
the first year of life; (2) inpatient genetics consultation documented in the medical 
record; (3) inpatient stay and genetics consultation occurred between December 1, 
2011 and June 30, 2017. The ES cohort consisted of patients who met the following 
additional criteria: (1) received ES as part of the diagnostic pathway; (2) ES ordered 
within the first year of life.  
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Among included patients, patients who did not receive ES were evaluated for 
inclusion in the comparator cohort (No-ES). Methods for patient matching are 
detailed elsewhere.21 Briefly, patients included in the No-ES cohort were those 
propensity score-matched to ES cohort patients. The propensity score was 
calculated based on patient’s age at first genetics consult (by quarter of year), 
hospital unit in which the genetic consult occurred (NICU; pediatric intensive care 
unit, PICU; cardiovascular intensive care unit, CVICU; progressive care unit, PCU; 
other unit), consult date (by quarter of study period), sex, and phenotypic 
characteristics (Human Phenotype Ontology terms).  
Data on patient characteristics, genetics consultation, and clinical outcomes 
were collected through retrospective EMR review. ES order and report data were 
obtained from BG, and cost data were obtained from hospital administrative records. 
Data analysis was performed using Stata/IC 15.1 (StataCorp, College Station, TX). 
 
Interventions and Comparator 
Patients in the ES cohort had one of three ES forms: sequencing of the 
patient only (proband ES), sequencing of the patient and both parents (trio ES) and 
sequencing of the patient and both parents with a reduced turnaround time (critical 
trio ES). Patients in the No-ES cohort had a diagnostic workup that did not include 
ES but may have included other forms of genetic testing such as chromosomal 
microarray (CMA), fluorescence in situ hybridization (FISH), single gene or gene 
panel sequencing, deletion/duplication analysis, or methylation studies. A clinician 
may have ordered ES for patients in the No-ES cohort without it being performed for 
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reasons such as lack of parental consent or cancelation by lab due to insufficient 
blood sample; we refer to these patients as the ES-recommended group.  
 
Outcomes 
Main outcome measures considered in this study were establishment of a 
molecular diagnosis and 1-year survival. Molecular diagnosis was defined as the 
identification of a specific genetic change interpreted by a clinician as the cause or 
probable cause of the patient’s clinical presentation. Subgroup analyses were 
performed based on patient characteristics intended to generate evidence to inform 
clinical guideline development and decision-making. Subgroups were: patients 
admitted in 2016 and 2017 (after all three ES forms were available), patients who 
survived to 28 days of life, patients in the NICU during the genetics consultation, and 
patients in the ES-recommended group. 
 
Cost Analysis 
Costs were calculated using the hospital perspective. We analyzed total index 
admission and index year cost, cost by hospital billing category (UB revenue code), 
cost of the investigator-defined diagnostic pathway, and cost of genetic tests. To 
mitigate the influence of length of stay (LOS) on total index admission cost, we 
calculated the proportion of the total index admission cost accounted for by costs in 
each billing category, as well as the diagnostic pathway costs and genetic testing 
costs, at the patient level.  
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As there is no standard diagnostic pathway for the heterogeneous population 
of patients in this study, we defined the diagnostic pathway as clinical tests 
performed for the purpose of making a diagnosis rather than routine care or 
monitoring. An inclusion rule of “first,” “none,” or “all” was determined for each test 
on a list of all laboratory and radiology tests performed for study patients. The rule 
was used to determine which, if any, instance of a specific test on a patient was 
performed as part of the diagnostic pathway and applied to cost data to sum the cost 
of diagnostic pathway investigations. Similarly, we identified each genetic test in the 
list of laboratory tests and applied these rules to the cost data to determine the cost 
of genetic tests. In each patient’s cost data, each line-item labeled “miscellaneous 
referred test” was cross-referenced by service date to tests ordered in the EMR as 
miscellaneous referred tests to determine whether it was a genetic test or not. All 
tests determined to be genetic tests were included in both the diagnostic pathway 
and genetic test cost categories. Genetic test and diagnostic pathway costs are not 
necessarily inclusive or exclusive of the hospital administrative billing categories. 
For analysis of cost data, which has a skewed distribution, we used log 
transformations and non-parametric statistical tests. We used ordinary least squares 
(OLS) regression on logged total cost of index admission to estimate the impact of 
patient characteristics on index admission cost. We employed Wilcoxon rank-sum 
and Kruskall-Wallis tests to compare cost categories between cohorts and ES forms, 
respectively. Chi-square and Wilcoxon rank-sum tests were used for other 
comparisons as appropriate. Relevant cost analyses were performed for each 
subgroup of patients. 
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We describe cost of index admission, index year, and diagnostic pathway and 
genetic test during the index admission and the year. We calculated the cost of the 
index admission and the diagnostic pathway per diagnosis and percent 1-year 
survival. We calculated incremental cost-effectiveness ratios (ICERs) for incremental 
index admission diagnostic pathways costs and incremental diagnoses, and for 
incremental index admission genetic test costs and incremental diagnoses. For each 
ICER, 95% confidence intervals were constructed from 1,000 bootstrap replicates.22 
All costs were adjusted to 2017 USD$ using the historical Consumer Price Index for 
All Urban Consumers (CPI-U): U.S. city average per year. 
 
Results 
Outcomes 
The patient matching process successfully reduced variation in observable 
characteristics between patients in the No-ES and ES cohorts. Outcomes are 
reported elsewhere in more detail.21 Characteristics of the patient population are 
given in Table 1. Molecular diagnostic yield (25.8% No-ES, 27.7% ES; p=0.56) and 
1-year survival (84.8% No-ES, 80.2% ES; p=0.10) were similar for both cohorts 
(Table 2). In the ES cohort, 8 additional diagnoses were made with CMA not 
included in the ES diagnostic yield. Among patients admitted in 2016 and 2017, 
molecular diagnostic yield (p=0.02) was higher in the ES cohort than the No-ES 
cohort, as there was lower yield in the No-ES cohort over this period (Table 3).  
In the ES cohort, ES resulted before discharge from the index admission for 
106 (28.8%) patients. A significantly higher proportion of patients who had critical trio 
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were diagnosed before discharge (24.1%) than patients who had proband or trio 
tests (5.7%, p<0.01). Prior to the lab reporting results, 46 (12.5%) patients were 
deceased, and 11 patients who expired while in the hospital later had a diagnostic 
finding. For ES results communicated after patient discharge, results were returned 
121 days (median) after discharge.  
 
Costs 
Distributions of total cost of index admission and index year by cohort are 
presented in Figure 1 and Figure 2, respectively. Index admission total cost, 
diagnostic pathway cost, and genetic test cost were higher for ES patients than No-
ES patients (Table 2). Cost of the index admission diagnostic pathway per diagnosis 
were $24,763 [95% bootstrapped CI $19,956—$29,569] for the No-ES cohort and 
$60,869 [$49,749—$71,953] for the ES cohort. ES cohort Incremental index 
admission diagnostic pathway cost per additional diagnosis was $550,874. The 
incremental cost of index admission genetic tests per additional diagnosis was 
$410,614.  
Index year total cost, diagnostic pathway cost, and genetic test cost were also 
higher for the ES cohort. Controlling for length of stay and other features of 
hospitalization, ES was associated with approximately 17.7% higher total cost of 
index admission (p<0.01, Table S1). Within the ES cohort, genetic diagnosis was 
associated with higher index admission costs (p<0.01).  
Subgroup analyses showed similar results. Among patients admitted in 2016 
and 2017, costs in all categories (total, diagnostic pathway, and genetic tests) were 
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significantly higher in the ES cohort (Table 3). For patients who survived longer than 
28 days, costs were higher in the ES cohort in all categories (Table S2). Among 
patients with genetics consultation in the NICU, costs were significantly higher in the 
ES cohort (Table S3). Within the ES cohort, total cost of the index admission and 
index year were not significantly different between patients with each form of ES, but 
the cost of diagnostic pathway and genetic testing was significantly higher for 
patients with critical trio ES (Table S4).  
Within the No-ES cohort, there were 36 patients for whom ES was 
recommended but not performed. Table 4 compares costs for the ES-recommended 
group and ES cohort. Molecular diagnostic yield was significantly higher in the ES 
cohort (102, 27.7%) than the ES-recommended but not performed group (2, 5.6%). 
This difference in effectiveness results in a lower incremental cost per diagnosis. 
Therefore, even though costs were higher in the ES group, the incremental 
diagnostic pathway cost per additional diagnosis was lower for ES-recommended 
than for other comparator groups at $46,489. The incremental genetic test cost per 
additional diagnosis was $36,246.   
A comparison of cost components of the index admission is presented in 
Table 5 and Figure 3. As a proportion of the index admission total cost, cost of the 
diagnostic pathway was higher for the ES cohort (12.7%) than the No-ES cohort 
(7.9%, p<0.001). Similarly, genetic tests accounted for 8.4% of the index stay cost in 
the ES cohort and 3.7% in the No-ES cohort (p<0.001). By billing category, 
diagnostic UB revenue code cost was not different between cohorts, but laboratory 
cost made up a larger share of admission cost in the ES cohort (15.2%) than the No-
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ES cohort (9.9%, p<0.001). Nursing care accounted for the largest share of index 
admission total cost in both cohorts, although it represented a smaller share in the 
ES cohort (56.2%) than the No-ES cohort (60.7%, p<0.001). Pharmacy, radiology, 
and therapeutic billing categories made up similar shares of admission cost in both 
cohorts (all p>0.58).  
Diagnoses of 4 conditions were made in both cohorts: CHARGE syndrome, 
Noonan syndrome, Walker-Warburg syndrome, and Gaucher disease. Mean cost of 
the diagnostic pathway and genetic tests, as well as the total cost of the index 
admission and year, were higher for patients with the same ultimate diagnosis in the 
ES cohort for each diagnosis (Table S5; individual data not shown). Average length 
of index admission stay was longer for patients in the ES cohort than patients with 
the same diagnosis in the No-ES cohort for 3 of the 4 diagnoses.  
  
Discussion 
Our findings suggest that ES is not cost-effective, in terms of summary effect 
measures of diagnostic yield and percent survival, as applied during the initial 5 
years of clinical uptake at one large academic children’s hospital. ES patients had a 
longer and more costly index inpatient admission than clinically similar patients who 
did not have ES, on average. Our broad patient population of newborns and infants 
with suspected genetic disease allowed analysis of the real-world impact of ES on 
costs. Our findings suggest that ES is not cost-effective when applied generally to 
critically ill patients with suspected genetic disease presentations within the first year 
of life. Because the contribution of large chromosome structural rearrangements and 
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gene copy number variations present in this population, chromosomal analyses 
identified a diagnosis in a roughly equal proportion of patients and were associated 
with lower costs.  
Although the number of diagnoses out of the total number of patients in each 
cohort was similar, the diagnoses made in each cohort were qualitatively different 
based on the types of changes identifiable by tests used in each group (e.g., 
structural changes in the No-ES cohort versus single-gene sequence variants in the 
ES cohort). Some patients in the No-ES cohort may not have had ES because the 
clinician determined ES was not necessary or was the inappropriate genetic 
diagnostic tool to use. 
However, for some patients in the No-ES cohort, not having ES was the result 
of factors external to the clinical decision-making process, which makes these 
patients plausibly the best comparison group to ES patients. In these cases where 
ES was recommended but not performed, diagnostic yield was significantly lower 
than in the ES cohort. Among all of our subgroup analyses, the ICER for diagnosis is 
most favorable when comparing the ES cohort to the ES-recommended group of No-
ES cohort patients. Comparing diagnostic pathway cost in these two groups, an 
incremental cost of $46,489 per additional diagnosis may be deemed reasonable by 
decision makers, especially considering the backdrop of the high cost of admission 
for these patients. 
Our identifying assumption that a similar patient may have had ES or not 
depending upon who performed the consultation was supported by findings in prior 
work in which we find evidence of variability in ES uptake among attending 
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geneticists.21 However, we cannot rule out the potential, and results reported herein 
suggest, that ES was applied with bias toward more complex patients overall. In the 
absence of formal guidelines for ES use, it is difficult to map out details of the clinical 
decision-making process regarding ES order, yet it appears that clinicians have 
recommended ES in appropriate patients, all things considered. A formal 
characterization of this population from a phenotype and clinical presentation 
perspective, using more nuanced details than we were able to capture 
retrospectively through HPO terms, should be the subject of future work to develop 
guidelines for use in other institutions that may have less prior research-based 
familiarity with ES than academic physicians ordering ES in this study.  
Research that has found ES cost-effective has identified patient populations 
in which ES is the correct test by, for example, requiring clinician consensus, study 
enrollment, prerequisite non-diagnostic tests, and by using parallel, prospective 
study design to analyze the diagnostic pathway with and without cGS for the same 
patients.16,23 Results from a cost-effectiveness modeling study in an Australian infant 
cohort suggest that ES performed as a first-line test may be cost-saving.16 
Evaluating costs in such a setting is analogous to economic evaluation conducted 
alongside a randomized controlled trial in that there are threats to external validity 
because ES is applied as appropriately as possible. From a payer perspective, 
Sabatini and colleagues demonstrated that whether use of ES was cost-saving or 
cost-increasing depended upon clinical features of the patient population, the cost of 
the test and where it was incorporated in the diagnostic pathway.24 Other studies 
have summed costs of non-diagnostic workup prior to diagnostic ES,25-27 that can be 
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informative descriptions but lack a necessary comparator group for formal cost-
effectiveness analysis.  
We make a different contribution than studies of controlled ES application by 
evaluating impact for a broadly defined patient population. Our approach was 
optimal in order to utilize information on the large number of patients who had 
already had ES, ensure follow-up time of at least one year over which to measure 
outcomes, and enable comparison of multiple outcomes. The time frame of the study 
shows early adoption and implementation in the absence of clinical guidelines about 
application. Although uptake was variable during early stages of implementation, it is 
because of this property that we are able to construct a clinically similar comparison 
cohort that did not have ES before ES becomes standard-of-care. In the already 
high-cost setting of the NICU, availability of technology should not replace careful 
clinical assessment as to whether the patient is a good candidate for ES or not. CMA 
and other chromosomal tests remain important diagnostic tools for this patient 
population given the substantial burden of chromosomal abnormalities for children 
under one year of age in the United States.28,29  
Results from the ES-recommended group can support the hypothesis that ES 
might be most cost-effective when applied in patients that are difficult or impossible 
to diagnose with other modalities. This speaks to the original intended use of ES 
upon its availability as a clinical test for patients characterized as “hard to diagnose” 
and for whom other tests such as CMA are non-diagnostic. Clearer definition of how 
to identify such patients and quicker sequencing turnaround is needed to save cost. 
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Limitations 
Our study is limited by reliance on outcome data and clinical notation 
documented in the EMR, which may not be comprehensive. Administrative cost 
data, although reflective of the billing process, may not be entirely accurate or 
consistent. For example, there was variability in clinicians’ ES order entry in the 
EMR and how ES costs appeared in the cost data. This variability is a hurdle to 
performing a sensitivity analysis of the cost of care without ES in the ES cohort, and 
the degree to which higher costs for the ES cohort are attributable only to the cost of 
ES will be explored further. We are not able to account for care patients received at 
other institutions unrecorded in our EMR and administrative system. While this does 
not impact our ability to analyze the index admission, we may not capture all 
relevant costs over the index year.  
Results of this study cannot be used to draw conclusions about optimal 
placement of ES within the diagnostic pathway, such as use as a first-line test or 
subsequent other non-diagnostic investigations. This analysis only examines 
pathways with and without ES; it does not attempt to quantify cost-effectiveness for 
ES at a particular point in the diagnostic pathway. Lack of established practice 
guidelines on ES makes choice of comparators difficult because each provider may 
order sequencing based on different criteria or at a different point in the diagnostic 
pathway, and cost-effectiveness is always dependent upon the clinical context. 
The majority of ES patients did not have ES results returned during the index 
admission, meaning there was little potential for impact on care provision or the 
associated cost that would be captured in the cost of the index admission. Some of 
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the largest estimated cost savings as a result of neonatal cGS have come from 
saving inpatient days in hypothetical counterfactual cases when rapid sequencing 
results are returned while patients are admitted (median 23 days from order).30 
Because not all ES are ordered as a rapid test, we study the one-year follow-up 
period to allow return of results and potential for impact on care. For lengthy index 
admissions, the index admission almost entirely eclipses the index year. However, 
for patients with shorter, more frequent admissions and clinic visits, we are able to 
capture more of the ES impact. The higher costs for the index year ES group mirror 
the higher index admission costs. If return of ES results impacted care over the 
longer term, we would expect the cost of the index year to be proportionately higher 
than the index admission for the No-ES group. 
To address the heterogeneity of the patient population, patients were 
matched on phenotypic and clinical characteristics, which successfully reduced 
observable differences between the cohorts. Even so, the underlying cause of 
disease remained diverse within cohorts. Unless each molecular diagnosis is 
modeled separately, which is not practical for sample size reasons, patient 
groupings will necessarily combine individuals with different genetic etiology. 
Heterogeneity presents challenges for modeling costs over a longer time horizon 
than the inpatient stay because each distinct molecular diagnosis will have different 
prognostic and treatment trajectories. One interpretation of the insignificant 
difference in survival supports that the patients were well-matched in severity. 
However, more nuanced observations of diagnoses, costs, and clinical course (using 
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LOS as a proxy) suggests ES patients may still differ in some unexplained way from 
No-ES patients, on average, even for patients with the same ultimate diagnosis.  
While diagnostic yield was similar for ES and No-ES patients, we are not able 
to address differences in importance of availability of ES as a diagnostic tool with the 
ability to test for and detect rare disorders that it, among clinical tests, can uniquely 
identify. As highlighted by 2 recent systematic literature reviews of genomic 
sequencing, there is a need for more systematic outcomes measurement to enable 
health services research and economic evaluation of genomic sequencing.12,15 An 
important consideration is the potential utility of ES results – both diagnostic and 
non-diagnostic – and implications for the patient and patient’s family that may fall 
outside the realm of medical actionability. Number of diagnoses made does not 
necessarily convey the perceived utility of the results for either clinical decision-
making or the patient’s family. Clinicians may use ES results differently than results 
from other diagnostic tests, an unremarkable ES result that does not pinpoint a 
diagnosis may be more important than non-diagnostic results from other 
investigations, and clinicians may perceive outcomes outside of the traditional notion 
of medical management changes to be important results of ES.31 Moreover, families 
value genetic information for personal as well as medical purposes.32 Further 
development of methods to measure clinical utility, in a broader sense, of cGS is 
warranted. 
There are possible 5 channels to increase cost-effectiveness of ES. First, 
reduced turnaround time for results, which would allow greater potential for impact 
on LOS and medical management. Second, development of clinical guidelines to 
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rule out certain kinds of diagnoses first, such as a requirement of non-diagnostic 
CMA, prior to ES order. Third, reanalysis of genetic data and a longer time horizon 
over which to measure costs, which can lead to increased diagnostic yield upon 
reanalysis of the patient’s previously generated sequence information and potential 
impact on care.33,34 Fourth, reduction of ES cost, which may be possible with 
increased automation of result interpretation. Fifth, consideration of broader effects 
of ES which may flow from both diagnostic and non-diagnostic results. Systematic 
categorization and documentation of changes in medical management as a result of 
ES results to provide a robust description of utility would advance work in this area. 
Development of tools to measure utility to the patient and family should also be 
investigated. 
 
Conclusion 
ES demonstrated important diagnostic utility for patients with monogenic 
disease, yet other genetic tests, especially chromosomal microarray, remain 
important given the burden of chromosomal abnormalities in this population. As 
clinically applied over the first 5 years, ES does not appear cost-effective as a 
diagnostic tool for the broad population of newborns and infants with suspected 
genetic disease. Further work is needed to develop outcome measures to capture 
utility of both diagnostic ES results and non-diagnostic ES results for clinicians, 
patients, and patients’ families and to specify clinical guidelines for appropriate ES 
application.
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Tables and Figures 
Table 1. Patient Characteristics 
 No-ES 
Cohort 
ES Cohort p-valuea 
Sex, n (%)    
Male 203 (55.16) 217 (58.97)  
Female 165 (44.84) 151 (41.03) 0.297 
    
Race, n (%)    
White/Caucasian 277 (75.27) 289 (78.53)  
Black/African-American 58 (15.76) 58 (15.76)  
Asian 22 (5.98) 17 (4.62)  
American Indian and Alaska Native 1 (0.27) 1 (0.27)  
Unknown 8 (2.17) 3 (0.82) 0.396 
    
Ethnicity, n (%)    
Non-Hispanic 200 (54.35) 190 (51.63)  
Hispanic 162 (44.02) 174 (47.28)  
Unknown 6 (1.63) 4 (1.09) 0.581 
    
Preferred Language, n (%)    
English 312 (84.78) 294 (79.89)  
Spanish 52 (14.13) 69 (18.75)  
Other 4 (1.09) 5 (1.36) 0.219 
    
Unit of Genetics Consult, n (%)    
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NICU 245 (66.58) 222 (60.33) 0.078 
CVICU 62 (16.85) 70 (19.02) 0.442 
Other 36 (9.78) 36 (9.78) 1.00 
PCU 17 (4.62) 25 (6.79) 0.204 
PICU 8 (2.17) 15 (4.08) 0.138 
    
Age at Genetics Consult (quartile of year), n (%)    
First 302 (82.07) 297 (80.71) 0.636 
Second 43 (11.68) 49 (13.32) 0.504 
Third 13 (3.53) 12 (3.26) 0.839 
Fourth 10 (2.72) 10 (2.72) 1.00 
    
Genetics Consult Date (quartile of study period), n 
(%)    
First 92 (25.00) 92 (25.00) 1.00 
Second 105 (28.53) 79 (21.47) 0.027 
Third 90 (24.46) 95 (25.82) 0.671 
Fourth 81 (22.01) 102 (27.72) 0.073 
    
Gestational Age at Birth, weeks, mean (median) 36.40 (37.29) 37.00 (38.00) 0.0711b 
    
Mother’s Age at Birth, years, mean (sd) 28.93  (6.27)d 28.39 (6.33)e 0.251c 
    
Father’s Age at Birth, years, mean (sd) 31.60 (7.55)f 31 (7.78)g 0.357c 
    
ES, exome sequencing; NICU, neonatal intensive care unit; CVICU, cardiovascular intensive care 
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unit; PCU, progressive care unit; PICU, pediatric intensive care unit 
a All p-values from chi-square tests unless otherwise noted; b Wilcoxon rank-sum test  c Student’s t-
test; c n = 360; d n = 362; e n = 312; f n = 316 
 
Table 2. Costs by cohorta 
 All Patients  
(n = 736) 
No-ES Cohort 
(n = 368) 
ES Cohort 
(n = 368) p-value 
Molecular 
diagnosis, n (%) 205 (27.85)b 95 (25.82) 102 (27.72) 0.560c 
Survival to 28 
days, n (%) 686 (93.21) 337 (91.58) 349 (94.84) 0.079 
Survival to 1 year, 
n (%) 607 (82.47) 312 (84.78) 295 (80.16) 0.099 
Total cost of index 
admission, mean 
(sd) 272,600 (401,499) 218,503 (338,489) 326,698 (449,887) < 0.001d  
Total cost of index 
year, mean (sd) 338,179 (421,266) 266,768 (357,009) 409,591 (466,617) < 0.001d 
Total cost of index 
admission 
diagnostic 
pathway, mean 
(sd) 11,632 (9,429) 6,393 (5,243) 16,871 (9,773) < 0.001d 
Total cost of index 
year diagnostic 
pathway, mean 
(sd) 13,886 (10,398) 7,584 (6,018) 20,188 (10,034) < 0.001d 
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Total cost of index 
genetic tests, 
mean (sd) 6,322 (6,533) 2,417 (2,905) 10,227 (6,817) < 0.001d 
Total cost of index 
year genetic tests, 
mean (sd) 7,239 (7,265) 2,627 (3,633) 11,851 (7,061) < 0.001d 
Cost (index admission) per percent 1-
year survival [95% CI]e 
948,413  
[779,806—1117022] 
1,499,755 
[1,251,970— 
1,747,540]  
Cost (index year) per percent 1-year 
survival [95% CI]e 
1,157,910 
[9,77,368—
1,338,451] 
1,880,285 
[1,606,999—
2,153,570]  
Cost (index admission diagnostic 
pathway) per diagnosis, [95% CI]e 
24,763  
[19,956—29,569] 
60,869  
[49,784—71,953]  
Incremental cost-effectiveness ratio for 
index admission diagnostic pathway 
diagnoses [95% CI]e 
550,874  
[-5,651,018—6,752,766] 
Incremental cost-effectiveness ratio for 
index admission genetic testing 
diagnoses [95% CI]e 
410,614  
[-4,106,198—4,927,426] 
ES, exome sequencing 
a All costs reported in 2017 USD$ 
b Additional 8 diagnoses made by chromosomal microarray in ES cohort not included in ES diagnostic 
yield 
c chi-square test;  d Wilcoxon rank-sum test 
e 95% CI, confidence intervals constructed from 1,000 bootstrap replicates 
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Table 3. Costs, Patients admitted in 2016 and 2017a 
 All Patients  
(n = 257) 
No-ES Cohort 
(n = 119) 
ES Cohort 
(n = 138) p-value 
Molecular 
diagnosis, n (%) 
61 (23.74) b 19 (15.97) 39 (28.26) 0.019c 
Survival to 28 
days, n (%) 
233 (90.66) 102 (85.71) 131 (94.93) 0.011c 
Survival to 1 year, 
n (%) 
206 (80.16) 92 (77.31) 114 (82.61) 0.288c 
Total cost of index 
admission, mean 
(sd) 
280,491 
(370,566) 
217,571 
(273,630) 
334,747 
(430,933) 
0.003d 
Total cost of index 
year (mean) 
338,516 
(389,571) 
256,202 
(294,373) 
409,497 
(444,964) 
<0.001d 
Total cost of index 
admission 
diagnostic 
pathway, mean 
(sd) 
13,048 (8,389) 6,358 (4,249) 18,818 (6,599) <0.001d 
Total cost of index 
year diagnostic 
pathway, mean 
(sd) 
14,585 (8,912) 7,483 (5,107) 20,708 (6,661) <0.001d 
Total cost of index 
genetic tests, 
mean (sd) 
7,671 (5,850) 2,395 (2,206) 12,221 (3,838) <0.001d 
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Total cost of index 
year genetic tests, 
mean (sd) 
8,113 (5,921) 2,749 (2,831) 12,739 (3,472) <0.001d 
ES, exome sequencing 
a All costs reported in 2017 USD$ 
b Additional 2 diagnoses by chromosomal microarray in ES cohort not included in ES diagnostic yield 
c chi-square test 
d Wilcoxon rank-sum test 
 
 
 
 
Figure 1. Total cost of index admission by cohort 
 
ES, exome sequencing 
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Figure 2. Total cost of index year by cohort 
 
ES, exome sequencing 
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Table 4. Costs by ES recommended but not performeda 
 No-ES Cohort, ES 
recommended (n = 36) 
ES Cohort 
(n = 368) p-valueb 
Molecular diagnosis, n (%) 2 (5.56) 102 (27.72) 0.004c 
Survival to 28 days, n (%) 32 (88.89) 349 (94.84) 0.142 
Survival to 1 year, n (%) 28 (77.78) 295 (80.16) 0.733 
Length of stay, median 
(IQR), mean 
35.5, (9.5—58), 43.28 39 (17—83.5), 66.87 0.107 
Total cost of index 
admission, mean (sd) 
178,135 (172,766) 326,698 (449,887) 0.057 
Total cost of index year, 
mean (sd) 
246,097 (263,362) 409,591 (466,617) 0.008 
Total cost of index 
admission diagnostic 
pathway, mean (sd) 
6,568 (5,087) 16,871 (9,773) <0.001 
Total cost of index year 
diagnostic pathway, mean 
(sd) 
7,704 (5,147) 20,188 (10,034) <0.001 
Total cost of index genetic 
tests, mean (sd) 
2,194 (3,000) 10,227 (6,817) <0.001 
Total cost of index year 
genetic tests, mean (sd) 
2,450 (3,373) 11,851 (7,061) <0.001 
Incremental cost-effectiveness ratio for index 
admission diagnostic pathway diagnoses [95% CI]d 
46,489 [16,701—76,278] 
Incremental cost-effectiveness ratio for index 
admission genetic testing diagnoses [95% CI]d 
36,246 [14,578—57,915] 
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ES, exome sequencing; IQR, interquartile range 
a All costs reported in 2017 USD$ 
b Wilcoxon rank-sum test unless otherwise noted; c chi-square test 
d 95% CI, confidence intervals constructed from 1,000 bootstrap replicates 
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Table 5. Cost drivers, index admissiona 
Cost Categoryb 
Any 
cost, 
n 
All patients 
with any 
cost, mean 
(sd) 
All 
patients, 
mean (sd)  
(n = 736) 
Mean % 
admission 
cost, all 
Patients 
No-ES 
Cohort, 
mean (sd) 
(n = 368) 
Mean % 
admission 
cost, No 
ES Cohort 
ES 
Cohort, 
mean (sd)  
(n = 368) 
Mean % 
admission 
cost, ES 
Cohort 
p-
valuec 
Diagnostic Pathway 736 
11,632 
(9,429) 
11,632 
(9,429) 10.33 
7,584 
(6,018) 7.94 
20,188 
(10,034) 12.73 < 0.001 
Genetic Tests 736 6322 (6,534) 
6,322 
(6,534) 6.08 
2,417 
(2,905) 3.73 
10,227 
(6,817) 8.43 < 0.001 
Diagnostic 714 
4,703 
(6,475) 
4,562 
(6,428) 2.42 
3,647 
(5,691) 2.44 
5,477 
(6,976) 2.41 0.715 
 
Emergency Care 138 1,135 (365) 213 (4,70) 0.47 217 (481) 0.59 208 (460) 0.35 0.796 
Laboratory 736 
22,067 
(32,051) 
22,067 
(32,051) 12.55 
13,277 
(20,014) 9.88 
30,857 
(38,754) 15.21 < 0.001 
Medical/Surgical 
Supplies 709 
11,142 
(22,816) 
10,733 
(22,491) 3.22 
8,662 
(16,834) 3.27 
12,803 
(26,853) 3.16 0.285 
Nursing Care 736 
155,983 
(222,073) 
155,983 
(222,073) 58.43 
128,833 
(193,753) 60.65 
183,133 
(244,435) 56.20 < 0.001 
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Operating Room 
Perioperation 
Services 616 
14,360 
(23,061) 
12,019 
(21,752) 4.52 
9,557 
(15,620) 4.60 
14,480 
(26,296) 4.44 0.038 
Organ Acquisition 13 
133,468 
(20,665) 
2,357 
(17,790) 0.31 
1,326 
(12,848) 0.21 
3,389 
(21,601) 0.41 0.163 
Occupational/Physical 
Therapy 595 
4,982 
(6,419) 
4,027 
(6,095) 1.64 
3,222 
(4,938) 1.75 
4,832 
(6,980) 1.63 0.313 
Pharmacy 736 
34,916 
(94,333) 
34,916 
(94,333) 7.93 
29,143 
(93,880) 8.05 
40,688 
(94,560) 7.82 0.600 
Radiology 725 
5,180 
(6,094) 
5,103 
(6,081) 2.75 
4,088 
(5,012) 2.72 
6,118 
(6,847) 2.77 0.582 
Therapeutic 659 
18,744 
(44,974) 
16,783 
(42,939) 4.03 
13,481 
(33,989) 4.07 
20,085 
(50,154) 4.00 0.861 
Transport 3 
18,816 
(44,974) 77 (1,373) 0.06 77 (1,272) 0.05 77 (1,469) 0.07 0.565 
Other 700 
3,952 
(5,995) 
3,758 
(5,909) 1.66 
2,971 
(4,259) 1.82 
4,547 
(7,109) 1.50 0.553 
ES, exome sequencing; a All costs reported in 2017 USD$; b Cost categories other than Diagnostic Pathway and Genetic Test are by UB 
Revenue Code; c Wilcoxon rank-sum test 
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Figure 3. Mean index admission total cost by cost category and cohort 
(a) Dollar amount 
 
(b) Mean proportion of total index admission cost by cost category and cohort 
 
ES, exome sequencing 
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Table S1. Cost of Index Admission Regression Model 
 (1) (2) (3) 
ln(total cost index admission) 
All Patients 
No-ES 
Cohort ES Cohort 
    
Exome Sequencing 0.163***   
 (0.045)   
Length of Stay 0.020*** 0.022*** 0.022*** 
 (0.001) (0.001) (0.001) 
Length of Stay2 -0.00002*** -0.00002*** -0.00003*** 
 (0.000) (0.000) (0.000) 
Molecular Diagnosis -0.122** -0.094 -0.182*** 
 (0.051) (0.079) (0.059) 
DOL Genetics consult 0.0006 0.001 0.001 
 (0.000) (0.001) (0.000) 
Unita    
CVICU 0.545*** 0.599*** 0.454*** 
 (0.062) (0.096) (0.071) 
PICU 0.748*** 0.470 0.860*** 
 (0.145) (0.294) (0.141) 
PCU 0.230** 0.371** 0.240** 
 (0.108) (0.183) (0.117) 
Other Unit 0.055 0.035 -0.013 
 (0.092) (0.143) (0.108) 
Point of Originb    
Transfer Center 0.026 0.023 0.022 
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 (0.052) (0.080) (0.060) 
Self Referral -0.088 -0.111 -0.092 
 (0.086) (0.130) (0.102) 
Clinic or Physician Referral -0.407*** -0.628*** -0.203* 
 (0.096) (0.153) (0.109) 
Constant 10.647*** 10.555*** 10.806*** 
 (0.051) (0.073) (0.057) 
    
n 736 368 368 
R-squared 0.767 0.734 0.829 
RMSE 0.598 0.651 0.489 
a NICU base category; b Inborn base category 
Standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
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Table S2. Costs by 28-day survival 
 
Survived to 
28 days  
(n = 686) 
Did not 
survive to 
28 days (n 
= 50) p-valuea 
No-ES 
Cohort, 
Survived to 
28 days 
(n = 337) 
ES Cohort, 
Survived to 
28 days 
(n = 349) p-value 
Molecular 
diagnosis, n 
(%) 187 (27.26) b 16 (32.00) 0.387c 85 (25.22) 96 (27.51) 0.497 
Length of 
stay, 
median 
(IQR), 
mean 
36 (15–71), 
62.44 
6 (3–10), 
7.56 <0.001 
29 (12—
59), 54.49 
43 (19—
83), 70.13 <0.001 
Total cost of 
index 
admission, 
mean (sd) 
285,433 
(410,426) 
84,673 
(71,592) <0.001 
229,052 
(346,186) 
339,874 
(458,052) <0.001 
Total cost of 
index year, 
mean (sd) 
355,510 
(428,858) 
100,393 
(17,0197) <0.001 
281,397 
(364,304) 
427,076 
(472,681) <0.001 
Total cost of 
index 
admission 
diagnostic 
pathway, 
11,871 
(9,602) 
8,351 
(5,730) 0.026 
6,508 
(5,367) 
17,050 
(9,946) <0.001 
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mean (sd) 
Total cost of 
index year 
diagnostic 
pathway, 
mean (sd) 
14,289 
(10,548) 
8,351 
(5,730) <0.001 
7,808 
(6,156) 
20,547 
(10,123) <0.001 
Total cost of 
index 
genetic 
tests, mean 
(sd) 
6,397 
(6,639) 
5,291 
(4,807) 0.580 
2,416 
(2,935) 
10,240 
(6,948) <0.001 
Total cost of 
index year 
genetic 
tests, mean 
(sd) 
7,381 
(7,395) 
5,291 
(4,807) 0.132 
2,647 
(3,716) 
11,952 
(7,187) <0.001 
ES, exome sequencing; IQR, interquartile range 
a Wilcoxon rank-sum test unless otherwise noted;  
b Additional 6 diagnoses made by chromosomal microarray in ES cohort not included in ES diagnostic 
yield 
c chi-square test 
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Table S3. Costs, NICU patients onlya 
 All Patients  
(n = 467) 
No-ES Cohort 
(n = 245) 
ES Cohort 
(n = 180) p-value 
Molecular 
diagnosis, n (%) 120 (25.70)b 59 (24.08) 56 (25.23) 0.775 c 
Survival to 28 
days, n (%) 430 (92.08) 221 (90.20) 209 (94.14) 0.115 c 
Survival to 1 year, 
n (%) 387 (82.87) 207 (84.49) 180 (81.08) 0.329 
Total cost of index 
admission, mean 
(sd) 
214,503 
(290,247) 
176,466 
(254,405) 
256,480 
(320,630) <0.001 d 
Total cost of index 
year (mean) 
268,196 
(312,489) 
223,439 
(285,002) 
317,590 
(333,997) <0.001 d 
Total cost of index 
admission 
diagnostic 
pathway, mean 
(sd) 10,435 (9,133) 5,463 (3,919) 15,922 (10,064) <0.001 d 
Total cost of index 
year diagnostic 
pathway, mean 
(sd) 12,480 (10,047) 6,451 (4,480) 19,135 (10,292) <0.001 d 
Total cost of index 
genetic tests, 
mean (sd) 6,134 (6,607) 2,387 (2,800) 10,269 (7,117) <0.001 d 
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Total cost of index 
year genetic tests, 
mean (sd) 6,990 (7,219) 2,469 (2,930) 11,981 (7,262) <0.001 d 
a All costs reported in 2017 USD$ 
b Additional 5 diagnoses made by chromosomal microarray in ES cohort not included in ES diagnostic 
yield 
c chi-square test;  d Wilcoxon rank-sum test 
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Table S4. Costs by form of ESa 
 Proband ES  
(n = 227) 
Trio ES 
(n = 54) 
Critical Trio ES 
(n = 87) p-value 
Molecular 
diagnosis, n (%) 61 (26.87) 13 (24.07) 28 (32.18) 0.523b 
Survival to 28 
days, n (%) 213 (93.83) 52 (96.30) 84 (96.55) 0.079 
Survival to 1 
year, n (%) 182 (80.18) 45 (83.33) 68 (78.16) 0.727 b 
Total cost of index 
admission, mean 
(sd) 309,380 (455,314) 353,907 (450,153) 354,996 (438,161) 0.222c  
Total cost of index 
year (mean) 392,935 (471,912) 434,570 (471,404) 437,545 (452,828) 0.347c 
Total cost of index 
admission 
diagnostic 
pathway, mean 
(sd) 15,783 (10,630) 15,778 (6,538) 20,390 (8,241) < 0.001c 
Total cost of index 
year diagnostic 
pathway, mean 
(sd) 19,858 (11,147) 17,767 (6,245) 22,551 (8,336) < 0.001c 
Total cost of index 
genetic tests, 9,370 (7,781) 10,412 (3,821) 12,347 (4,868) < 0.001c 
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mean (sd) 
Total cost of index 
year genetic tests, 
mean (sd) 11,693 (8,348) 10,928 (3,317) 12,835 (4,614) < 0.001c 
a All costs reported in 2017 USD$ 
b One-way ANOVA;  c Kruskal-Wallis H test 
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Table S5. Costs by diagnosisa 
 No-ES Cohort ES Cohort 
CHARGE syndrome n=4 n=2 
Length of stay, index admission, mean (days) 91 84 
Survival to 1 year, n (%) 3 (75.0) 2 (100) 
Total cost of index admission, mean (sd) 431,360 (283,787) 317,590 (333,997) 
Total cost of index year (mean) 456,497 (290,059) 400,245 (266,596) 
Total cost of index admission diagnostic pathway, 
mean (sd) 8,142 (2,741) 15,266 (15,746) 
Total cost of index year diagnostic pathway, mean (sd) 8,778 (2,141) 20,951 (8,782) 
Total cost of index genetic tests, mean (sd) 2,983 (552) 7,739 (7,856) 
Total cost of index year genetic tests, mean (sd) 2,983 (552) 11,517 (2,512) 
   
Noonan syndromeb n=3 n=9 
Length of stay, index admission, mean (days) 27 54 
Survival to 1 year, n (%) 3 (100) 6 (66.7) 
Total cost of index admission, mean (sd) 102,819 (120,924) 212,770 (198,847) 
Total cost of index year (mean) 109,584 (121,021) 336,825 (301,821) 
Total cost of index admission diagnostic pathway, 
mean (sd) 5,511 (4,989) 9,931 (5,083) 
Total cost of index year diagnostic pathway, mean (sd) 5,568 (4.911) 16,276 (6,979) 
Total cost of index genetic tests, mean (sd) 2,894 (2,481) 5,496 (4,583) 
Total cost of index year genetic tests, mean (sd) 2,894 (2,481) 9,062 (4,890) 
   
Walker-Warburg syndrome n=1 n=1 
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Length of stay, index admission (days) 31 36 
   
Gaucher disease n=1 n=1 
Length of stay, index admission (days) 4 29 
ES, exome sequencing 
a All costs reported in 2017 USD$ 
b includes Neurofibramatosis-Noonan syndrome, and Noonan syndrome 1, 3, and 5 diagnoses 
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CONCLUSION  
This project presents evidence, both through literature review and analysis of 
a newly assembled dataset through systematic collection and merging of data, on 
the impact of clinical ES on the cost of care for infants undergoing a diagnostic 
workup for suspected genetic disease. Uptake of clinical genomic sequencing has 
occurred quickly and without robust, systematic evidence regarding either outcomes 
or costs from comparative studies to inform its application. In the patient population 
studied herein, ES demonstrated important diagnostic utility for patients with 
monogenic disease, yet other genetic tests, especially chromosomal microarray, 
remain important diagnostic tools given the burden of chromosomal abnormalities in 
this population. As clinically applied over the first 5 years, ES does not appear cost-
effective as a diagnostic tool for the broad population of newborns and infants with 
suspected genetic disease as compared to standard diagnostics. Further work is 
needed to develop outcome measures to capture utility of both diagnostic ES results 
and non-diagnostic ES results for clinicians, patients, and patients’ families and to 
specify clinical guidelines for appropriate ES application. 
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